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ABSTRACT 
FOOD PROTEIN-BASED CORE−SHELL NANOCARRIERS FOR ORAL DRUG 
DELIVERY APPLICATIONS: INFLUENCE OF SHELL COMPOSITION ON IN 
VITRO AND IN VIVO FUNCTIONAL PERFORMANCE OF ZEIN NANOCARRIERS 
MD SAIFUL ISLAM 
2017 
 
Oral delivery is the most preferred route for drug administration. Oral drug delivery 
is limited by poor physicochemical properties of drugs and physiological barriers in the 
gastrointestinal tract. To this end, there is a need for developing new carrier systems to 
enhance the oral bioavailability of poorly absorbed molecules. Food-grade biopolymers are 
attractive materials for developing drug delivery carriers’ due to their unique properties 
and proven safety. Six different core-shell nanocarriers were prepared using food-grade 
biopolymers including zein-casein (ZC) nanoparticles, zein-lactoferrin (ZLF) 
nanoparticles, zein-β-lactoglobulin (ZLG) nanoparticles, zein-whey protein isolate (ZWP) 
nanoparticles, zein-pluronic-lecithin (ZPL) nanoparticles and zein-PEG (ZPEG) micelles. 
The study was aimed at systematically investigating the influence of shell composition on 
the functional performance of core-shell nanocarriers for oral drug delivery applications.  
The first goal was to develop and study the structure-function relationship of core-
shell nanocarriers for oral drug delivery applications. Nile red (NR) and Cy 5.5 were used 
as model dyes for this study. The particle size of the nanocarriers ranged from 100 to 250 
nm, and the nanocarrier had a uniform size distribution as evidenced from the low PDI 
(0.08 to 0.3). The zeta potential values varied from -10 to 30 mV depending on the shell 
composition. The core-shell structure of the nanocarrier was confirmed by Transmission 
xxi 
 
Electron Microscopy (TEM). The nanocarriers sustained the release of NR in simulated 
gastric and intestinal fluids. NR release from the nanocarriers predominantly followed 
Peppas model which indicates the diffusion of NR from nanocarriers by polymer erosion 
by hydrolytic or enzymatic cleavage. NR release from ZPEG micelles followed first order 
release kinetics. The nanocarriers were taken up by endocytosis in Caco-2 cells, which is 
an established model for intestinal permeability studies. ZLG nanocarriers showed the 
highest permeability across Caco-2 cell monolayers, while ZC nanoparticles showed the 
lowest permeability among the six formulations. ZPEG micelles also showed P-gp 
inhibitory activity. All the nanocarriers were found to have bioadhesive properties. Among 
the six different nanocarriers, ZLG and ZWP nanocarriers showed significantly higher 
bioadhesive property. In-vivo biodistribution of the nanocarriers was studied using Cy 5.5, 
a near-IR dye and all the formulations showed longer retention in the rat gastrointestinal 
tract compared to the free dye. Among the formulations, ZLG and ZWP nanoparticles were 
retained longest in the rat gastrointestinal tract (≥24 hours). All the nanocarriers were found 
to be non-immunogenic on oral administration to mice.  
 
The second goal was to investigate the use of core-shell nanocarriers for oral 
delivery of a model antiretroviral drug, lopinavir (LPV). LPV is a first-line protease 
inhibitor used for the treatment of HIV infections, especially in children. The drug has poor 
oral bioavailability due to its poor water solubility, poor membrane permeability and first-
pass metabolism in the intestine. LPV is a substrate for the CYP3A4 enzyme and hence is 
used in combination with ritonavir (a CYP3A4 inhibitor) to boost the oral bioavailability 
of LPV. The current pediatric oral liquid formulation contains LPV and ritonavir (RTV) in 
xxii 
 
a mixture of high proportion of propylene glycol and alcohol.  The main goal was to test 
the feasibility of developing a water dispersible RTV free pediatric formulation of LPV 
using zein-based core-shell nanocarriers. The impact of shell composition on the functional 
properties of LPV loaded nanocarriers was evaluated in vitro and in vivo. The 
encapsulation efficiency for LPV was above 70% in all the nanocarriers, and ZPL 
nanoparticles showed the highest encapsulation efficiency (87.92±7.19%). The loading 
efficiency ranged from 2 to 5% based on the shell composition. The release of LPV was 
sustained both in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) for 24 
hours. To test the feasibility of developing a food sprinkle formulation, the compatibility 
of the nanoformulations with model food matrices were studied. The nanocarriers were 
stable when incubated in food matrices (milk and applesauce) and <30% of LPV was 
released within first 1 hour followed by sustained release in SGF and SIF for 24 hours. The 
nanocarriers increased the permeability coefficient (Papp) of LPV across the Caco-2 cell 
monolayers by two to four-fold. The Papp values of LPV loaded nanocarriers decreased in 
the following order ZPEG>ZC>ZLF>ZWP>ZLG>ZPL. In vivo pharmacokinetic study in 
rats showed that the oral bioavailability of LPV increased by 2-fold compared to marketed 
LPV/RTV liquid formulation (Kaletra®). The highest oral bioavailability was obtained 
with LPV loaded ZPEG micelles followed by ZWP and ZLG nanoparticles.  Highest 
plasma concentration (Cmax) of LPV was achieved with ZPEG micelles which was 
comparable to Kaletra® formulation. The extent of absorption (AUC) of LPV was in the 
following decreasing order of ZPEG>ZWP>ZLG>Kaletra®>free LPV. Multiple dose PK 
study further demonstrated that similar or higher steady-state plasma concentration can be 
obtained using ZPEG micelles compared to Kaletra®. Findings from this chapter 
xxiii 
 
concludes that zein-based nanocarriers can be used to develop ritonavir free LPV 
formulation which will ultimately reduce the total drug load and drug-drug interaction in 
the treatment of HIV infection.  
The last objective was to demonstrate the feasibility of using zein-based core-shell 
nanocarriers for oral delivery of fenretinide, an investigational anti-cancer molecule. 
Fenretinide has been found to be effective against several cancers including pediatric 
neuroblastoma, However, the clinical development of fenretinide is limited by its poor 
physicochemical properties. Fenretinide is a poorly soluble and poor permeable anti-cancer 
agent. Further, the compound has poor chemical stability. The encapsulation efficiency for 
fenretinide was above 70% in all the nanocarriers and zein-β-casein (ZC) nanoparticles 
showed the highest encapsulation efficiency (90±0.091%). The release of fenretinide was 
sustained both in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) for 24 
hours. The nanocarriers were stable when incubated in food matrices (milk and 
applesauce), and less than 30% of fenretinide was released after incubation for 1 hour in 
food matrices. About 60% of fenretinide was released over 24 hours when the nanocarriers 
was transferred from food matrices to SGF and SIF. The nanocarriers enhanced the 
permeability of fenretinide across the Caco-2 cell monolayers from 1x10-6 to 72.42x10-6 
cm/s. The order of permeability of fenretinide loaded nanocarriers was found to be in the 
following decreasing order ZPL>ZLG>ZC>ZWP>ZLF>ZPEG. Among others tested for 
single dose PK study of fenretinide, ZLG nanocarriers showed the highest oral 
bioavailability of fenretinide (6-fold) compared to free fenretinide suspension.  
Nanocarriers increased the elimination half-life (t1/2) by 2- to 4-fold. ZPL nanocarriers 
showed the highest Cmax (0.61 μg/mL) of fenretinide, while fenretinide loaded ZC 
xxiv 
 
nanocarriers showed the lowest Cmax (0.23 μg/mL). Nanocarriers showed the following 
decreasing rank order for relative oral bioavailability, ZWP>ZLG>ZPL>ZC, indicating 
that shell composition has a significant influence on the oral bioavailability. Further, 
multiple dose pharmacokinetic (PK) studies of fenretinide and fenretinide loaded zein-
pluronic-lecithin (ZPL) nanocarriers was performed. The pharmacokinetics of twice a day 
free fenretinide suspension was compared with once a fenretinide loaded ZPL nanocarriers. 
The steady state concentration of fenretinide and fenretinide loaded ZPL nanocarriers was 
achieved at around 50-hours. However, the steady-state plasma concentration of 
fenretinide from the ZPL nanocarriers was 5-fold higher compared to free fenretinide 
suspension.  
Overall, the outcomes from this study demonstrate the structure-function 
relationship of core-shell protein nanocarriers for oral drug delivery applications.  The 
findings from this study can be used to develop food protein based oral drug delivery 
systems with specific functional attributes for various oral drug delivery applications. 
 
 
 
 
1 
 
CHAPTER ONE: Introduction 
 
1.1. Oral drug delivery 
Oral drug delivery is the preferred route of drug administration due to the ease of 
drug administration, cost-effective, and ease of manufacturing. Additionally, oral drug 
administration has high patient compliance (Fix 1999). Therefore, 60% of the marketed 
formulations are for oral administration (Renukuntla et al. 2013).  
Despite the advantages for oral drug administration, the drug delivery by this route 
is associated with multiple challenges including varying pH, poor water solubility, poor 
membrane permeability, poor stability, and first-pass metabolism.  
 
1.2. Oral drug absorption 
1.2.1. Gastrointestinal anatomy and physiology 
 Human GIT is about 8.35 m long starting from the esophagus followed by the 
stomach, small intestine (duodenum, jejunum, and ileum) and large intestine (cecum, 
colon, and rectum) (Fig. 1A). Small intestine covers about 81% of the total length of the 
GIT and is the major site of drug absorption due to the large surface area (~100 m2) 
(DeSesso and Jacobson 2001). The presence of villi and microvilli contributes to the large 
surface area of small intestine (Fig. 1B) (Kararli 1995). There are numerous epithelial 
projections with lamina propria (villi) in the apical surface (Fig. 1B). Each villus is 
subdivided into microvilli and estimated to have 3000-7000 microvilli on each epithelial 
cell (Ritschel 1991). This anatomical feasure significantly increase the absorptive surface 
area of duodenum and jejunum than ileum in small intestine. Absorbing surface area 
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dramaticaly reduced in cecum (0.05 m2), colon (~0.25 m2) and rectum (0.015 m2) due 
reduced length and absence microvilli (Kararli 1995). 
The epithelial cells are connected to each other by zonula occludens or tight junctions in 
the mucosa side. Tight junctions allow only small hydrophilic molecules to through the 
aqueous channel (paracellular transport). In addition, the surface of the small intestine is 
covered with a thin aqueous mucus layer (around 25 μm thickness) which serves as a 
protective barrier against toxins and xenobiotics (Winne 1976; Strocchi et al. 1996). 
Various physiological factors including gastrointestinal transit time, variable pH, 
enzymatic activity, and metabolism can influence drug absorption from the GI tract. 
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Figure 1: Gastrointestinal anatomy showing major regions (A) and microanatomy of digestive tract (B). Reproduced from Remesz et 
al. (2004) and http://www.vivo.colostate.edu/hbooks/pathphys/digestion/basics/gi_microanatomy.html. 
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1.2.2. Mechanism of oral drug absorption 
 After oral administration, drug molecules can be transported from the absorption 
site to the blood by passive diffusion, facilitated transport, active transport, and 
endocytosis. Drug molecules can passively diffuse through the absorption membrane using 
transcellular and paracellular route. Facilitated transport is a carrier mediated transport 
which is mainly influenced by the concentration gradient. Transmembrane protein (e.g. 
vitamin B12 transporter, hexose transporter etc.) facilitates the entry and exit of molecules 
(Fig. 2). The active transport is an energy-dependent process and occur through 
transporters expressed on the epithelial cells, while vesicular transport (endocytosis) is 
dependent on the size (mainly particulates and macromolecules) (Thomas et al. 2006; Hurst 
et al. 2007; Varma et al. 2010). The absorption mechanisms are further described in more 
detail in subsequent sections. 
 
1.2.2.1. Passive diffusion 
 Passive diffusion of drug molecules is determined by the physicochemical 
properties of compounds such as molecular weight, lipophilicity, and capacity to form 
hydrogen bonds (Lipinski 2000; Avdeef 2001). Passive diffusion by transcellular pathway 
is limited to small molecules (<500 Da), and rate of absorption or flux (J) is described by 
the Fick’s law of diffusion,   
J = DS(Ko/w)(Cg.i.)
h
 
Where, D is the diffusion coefficient which is influenced by the molecular weight of drug 
and the membrane characteristics. 
‘S’ is the surface area of the membrane which is influenced by the location in the GI tract.  
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‘K’ is the octanol/water (o/w) partition coefficient which is influenced by the lipophilicity 
and ionization of drug molecules.  
‘C’ is the concentration of drug in the GI lumen which is dependent on the solubility and 
dosage form of drugs. 
‘h’ is the thickness of the diffusion membrane which varies in different section of GI tract. 
 
The intestinal epithelial layer serve as a protective barrier for the entry of pathogens, toxins, 
antigens, and foreign particles from the GI lumen to the systemic circulation (Lee 2015). 
The surface of the mucosal layer of the intestine is lined with epithelial cells connected to 
each other by the tight junction (Fig. 2). Tight junction is a multiprotein complex and pore 
diameter between cells is reported to be <10Å and is hence limited to small molecules 
(Takeuchi and Gonda 2004). Hydrophilic drugs and nutrients can be absorbed via an 
aqueous channel between the intercellular space of enterocytes (Lennernas 1995). Drug 
molecules with molecular weight <500 Da, have been found to be utilized this absorption 
pathway (Karlsson et al. 1999; Lee 2015; Turner 2006; Nusrat, Turner, and Madara 2000). 
The paracellular transport is also important for the absorption of drugs from GI tract. 
Hydrophilic molecules that are restricted to cross the lipid membrane of the epithelial cells 
usually absorb via paracellular pathway.  
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1.2.2.2. Transporter-mediated uptake and efflux 
Intestinal epithelial cells express multiple families of uptake and efflux transporters 
which is mainly divided into solute carrier (SLC) transporters and ATP-binding cassette 
(ABC) transporters (Fig. 3) (Leibach and Ganapathy 1996; Tamai 2012; Englund et al. 
2006; Roth, Obaidat, and Hagenbuch 2012). In general, ABC transporters use ATP as an 
energy source and play a major role in intestinal absorption, while SLC utilize H+, Na+, 
 
Figure 2: Various pathways of drug absorption from gastrointestinal lumen to blood 
stream. Reproduced from Agrawal et al. (2014). 
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Ca++ ion gradient created by Na+/K+-ATPase, or Na+/H+-ATPase (Tsuji and Tamai 1996; 
Ogihara, Tamai, and Tsuji 1998). 
ABC transporter includes P-glycoprotein (P-gp), breast cancer resistance protein 
(BCRP), and multidrug resistance proteins (MRP1-6) (Roth, Obaidat, and Hagenbuch 
2012). ABC transporters can be subdivided into uptake and efflux transporters. The uptake 
transporters play an important role in the absorption of nutrients such as glucose, amino 
acids, and small peptides, while the efflux transporters involve in the removal of absorbed 
foreign or toxic substances and return them to GI lumen. The apical membrane also 
expresses brush border enzymes for metabolizing macromolecules to small molecules to 
facilitate uptake by nutrient transporters (Hamman, Demana, and Olivier 2007). Drugs that 
have structural similarity with nutrients can bind with transporters and can be taken up by 
epithelial cells. In this regard, peptide transporters, amino acid transporters, and nucleoside 
transporters play a major role in the uptake of orally administered drugs (Hamman, 
Demana, and Olivier 2007). Peptide transporter 1 (PepT1) can bind and transport diverse 
compounds including antibiotics, antivirals, and peptidyl prodrugs (Smith, Clemencon, and 
Hediger 2013), while organic anion transporters can interact with statins, angiotensin-
converting enzyme inhibitors and other group of drugs (e.g., fexofenadine) (Kalliokoski 
and Niemi 2009). Taken together, all these transporters play a significant role in uptake or 
efflux, distribution, metabolism, and excretion of administered drugs.  
Drugs to overcome numerous barriers after oral administration to achieve 
therapeutic concentration in the blood. Figure 3 summarizes different factors that can 
influence drug absorption and bioavailability.   
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Figure 3: Schematic diagram of the steps and factors associated with oral drug absorption. 
Molecular weight (MW), Unstirred water layer (UWL), Cytochrome P450 (CYP), UDP-
glucuronosyltransferase (UGT), Glutathione S-transferase (GST), Sulfotransferase 
(SULT), apical sodium-dependent bile acid transporter (ASBT), Organic cation transporter 
(OCT), Concentrative nucleotide transporter (CNT), Electroneutral organic cation 
transporter (OCTN), Organic anion transporting polypeptide (OATP), Peptide transport 
protein (PEPT), P-glycoprotein (P-gp), Multidrug resistance protein (MDR), Multidrug 
resistance-associated protein (MRP), Breast cancer resistance protein (BCRP), 
Monocarboxylate transporter protein (MCT), equilibrative nucleoside transporter (ENT), 
(+) and (-) indicates an increase or a decrease in the rate and/or extent of drug absorption, 
respectively. Adapted from Huang, Lee, and Yu (2009). 
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1.2.2.3. Endocytosis 
     The uptake of macromolecules and particulate systems occurs by endocytosis. This is 
an energy-dependent process which can be divided into receptor-mediated or non-receptor 
mediated endocytosis. Vesicular transport mechanisms include clathrin-mediated 
endocytosis, caveolae-mediated endocytosis, and macropinocytosis (Fig. 4) (Lundquist 
and Artursson 2016). Clathrin-mediated endocytosis involves internalization by ligand-
bound receptors followed by transport to endosomes and fuse with lysosome for 
degradation or recycle back to the cell membrane (Yameen et al. 2014). Clathrin-coated pit 
(CCP) is a well-studied mechanism for receptor-mediated endocytosis. The process 
includes invagination of the cell membrane and formation of clathrin-coated vesicle 
(Somsel Rodman and Wandinger-Ness 2000; Roger et al. 2010; Ford et al. 2002). Clathrin-
independent process as shown in figure 4 does not require coat proteins for the formation 
vesicles. Instead of coat protein, actin and actin associated proteins is involved in clathrin-
independent endocytosis process (Robertson, Smythe, and Ayscough 2009). Clathrin-
independent pathway mediate uptake using glycolipids and glycoproteins and are 
insensitive to endocytosis inhibitors (Kirkham and Parton 2005). Uptake by clathrin 
mediated endocytosis mainly dependent on the size, shape and surface charge (Yameen et 
al. 2014). For example, particulate systems prepared using cationic polymers are 
predominantly taken up by clathrin-mediated endocytosis by electrostatic interaction with 
the negatively charged cell surface (Yameen et al. 2014). 
 Caveolae-mediated endocytosis process involves the formation of cavities which 
are transported to the nucleus by dynamin- and actin-mediated uptake (Lundquist and 
Artursson 2016). Caveolae-mediated endocytosis utilizes lipid-raft which is mainly 
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composed of cholesterol and sphingolipid for the formation of membrane microdomain 
(Conner and Schmid 2003). Caveolae-mediated endocytosis is characterized by the 
presence of caveolin protein which leads to the formation of caveosomes (Pelkmans, 
Kartenbeck, and Helenius 2001). Negatively charged polymers are generally found to be 
internalized via caveolae-mediated endocytosis (Sahay, Alakhova, and Kabanov 2010). 
Macropinocytosis also called as fluid-phase endocytosis is mainly dependent on the 
concentration of solute around the cells (Adler and Leong 2010). Macropinocytosis is an 
actin-driven endocytic process which usually takes up considerable volume of extracellular 
fluid into large vesicle known as macropinosomes (Falcone et al. 2006). Unlike the 
receptor-mediated endocytosis, the formation of macropinosomes is not activated by direct 
interaction of particulate systems (Fig. 4). Tyrosine kinase pathway is involved in the 
activation and polymerization of actin (Kerr and Teasdale 2009). Although micron size 
particles can be internalized via macropinocytosis, majority of macromolecules and 
particulate systems taken up by more than one endocytic process (Gratton et al. 2008; 
Zhang et al. 2014). 
The particle size of the drug carrier for oral delivery plays a significant role in the 
uptake by epithelial cells (Kulkarni and Feng 2013). Particle size of <50 nm diameter is 
shown to be transported via the paracellular pathway, while particles in the range of 100-
500 nm diameter are taken up by endocytosis (Desai et al. 1996). Particle size >1 µm to <5 
µm are usually taken up by M-cells in the Peyer’s patches (Desai et al. 1996). In general, 
particles around 100 nm diameter were observed to be taken up better by at intestinal 
mucosa (Desai et al. 1996; Agrawal et al. 2014). Further, Reineke et al. reported that wide 
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range of particles (500 nm to 5 µm) could be absorbed in small intestine via clathrin-
dependent endocytosis (Reineke, Cho, Dingle, Morello, et al. 2013). 
 
 
Figure 4: Illustration of internalization pathways (phagocytosis, macropinocytosis, 
clathrin-dependent endocytosis, clathrin-independent endocytosis, and caveolin-dependent 
endocytosis). The fate of internalized cargo and localization to subcellular compartments 
are also depicted. ER: endoplasmic reticulum, NLS: nuclear localization signal, NPC: 
nuclear pore complex, TPP: triphenylphosphonium cation. Reproduced from Yameen et 
al. (2014). 
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1.3. Oral drug delivery challenges 
 
Despite many advantages of oral drug delivery, there are several barriers for drugs 
absorption. Factors that influence the oral bioavailability of drugs include physiological, 
physicochemical, and biopharmaceutical factors (Sabnis 1999; Horter and Dressman 2001; 
Kramer and Wunderli-Allenspach 2001; Zhou 2003). 
 
1.3.1. Physiological barriers to oral drug delivery 
Multiple physiological factors including variable pH, digestive enzymes, efflux 
transporters, GI transit time, mucus layer, and first-pass metabolism influence oral drug 
absorption.  
 
1.3.1.1. Variable pH and digestive enzymes 
 One of the major barriers for oral drug delivery is the variable pH in the GI tract. 
The stomach pH ranges from 1.0 to 2.5 (Evans et al. 1988; O'Neill et al. 2011) and 
gradually increases to pH 6.6 and pH 7.5 in the proximal portion of intestine, then the pH 
decreases to 6.4 close to caecum, and again rises to pH 7.0 in the colon (Table 1). Majority 
of the drugs are either weak acid or weak base and the degree of ionization is dependent 
on the pKa of the drug molecule and pH of the biological fluid. For example, an acidic 
drug is predominantly ionized at a pH two units higher than pKa of the drug while the drug 
predominantly remains as unionized, if the pH is two units lower than the pKa (Roche 
2007). This is reverse for basic drugs. The unionized and soluble form of the drug is mainly 
absorbed by passive diffusion and drugs should remain as ionized to be soluble in GI fluid.  
Therefore, a drug which is not completely ionized or unionized at intestinal pH show good 
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absorption. (Chawla 2003). In addition to pH, the presence of numerous enzymes (pepsin, 
amylase, trypsin, lipases, pancreatin, peptidases, maltase etc.) can also pose an obstacle for 
oral delivery of drugs (Table 1).  
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Table 1: Anatomical and physiological features of human GI tract. Reproduced from Chawla et al. (2003). 
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1.3.1.2. GI transit time and mucus layer 
 GI transit time is another important factor that influence the drug absorption. GI 
transit time is influenced by the individual differences, meals, fluid intake, and disease state 
(Davis, Hardy, and Fara 1986; Dressman et al. 1992; Coupe, Davis, and Wilding 1991). 
Gastric emptying time for healthy individual varies from 25 minutes to 3 hours, while the 
intestinal residence time varies from ~3 to 4 hours. The residence time of drugs in upper 
intestine is lower than distal portion, and the movement of drugs gradually slow down 
when it reaches to the large intestine. The transit time for large intestine varies from 4 to 
20 hours (Table 1) (DeSesso and Jacobson 2001). 
Mucus layer in GI tract prevents damage to epithelial surfaces and can limit the oral 
drug absorption as the drug has to diffuse through the viscous mucus layer before reaching 
the epithelial cells (Ensign, Cone, and Hanes 2012). Mucus is a complex mixture of 
proteins (glycosaminoglycans), lipids, carbohydrates, salts, and unidentified materials 
(Larhed, Artursson, and Bjork 1998). GI mucus efficiently trap pathogens and foreign 
particles and continuous mucus turn-over clears the trapped bacteria and solid particles 
(Corfield et al. 2001). The mucus turn-over limits the residence time and prevents the 
penetration of particulate systems through the loosely adherent mucus layer (Ensign, Cone, 
and Hanes 2012). Drug delivery systems have been designed to enhance the penetration 
through loose mucus layer delay the GI transit time to enhance the absorption and oral 
bioavailability (Ch'ng et al. 1985; Longer, Ch'ng, and Robinson 1985; Lehr 1994, 2000; 
Vasir, Tambwekar, and Garg 2003). One of the commonly used approaches is to 
incorporate mucoadhesive materials to enhance residence time in GI tract (Ch'ng et al. 
1985; Shaikh et al. 2011). Polymers with high capacity of forming hydrogen, hydrophobic 
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or electrostatic interaction with mucus layer showed increased retention after oral delivery 
(Lai, Wang, and Hanes 2009; Date, Hanes, and Ensign 2016). Polymers can interact with 
the mucus layer by the following mechanisms: i) hydrogen bonding, ii) hydrophobic 
interaction, iii) anionic surface charge, and iv) polymer entanglement (Jimenez-Castellanos 
1993; Deraguin 1969; Gu, Robinson, and Leung 1988). Particles prepared from polymers 
such as poly(lactic acid) (PLA), poly(sebacic acid) (PSA), poly(lactic-co-glycolic acid) 
(PLGA) and poly(acrylic acid) (PAA) has been reported to interact with mucus through 
one or more of the above mentioned mechanisms (Lai, Wang, and Hanes 2009).  
 
1.3.1.3. GI metabolism and efflux pump 
Intestinal metabolic enzymes especially phase-I metabolic enzymes such as 
cytochrome P450 (CYP 450) are abundantly expressed in intestinal enterocytes (Chawla 
2003).  Many orally administered drugs interact with cytochrome P450 (CYP450) enzymes 
in the intestine (Watkins 1997). CYP3A is one of the main metabolic enzymes expressed 
in human intestine (Bezirtzoglou 2012; Thelen and Dressman 2009). CYP3A activity is 
higher in the small intestine and gradually decline in the ilium and colon (Chawla 2003). 
In addition to enzymes, efflux pumps can limit drug absorption. P-glycoprotein (P-
gp) is an ATP-dependent transmembrane protein expressed in columnar epithelial cells in 
the intestine (Loo and Clarke 2005). P-gp composed of 1280 amino acids (170 kDa) and 
contains a single chain of two homologous regions. Each region comprises six 
transmembrane domains connected by a flexible polypeptide linker (Fig. 5A). The ATP-
binding domains are positioned in cytosolic regions which are also known as nucleotide-
binding folds (NBFs). The NBFs are responsible for supplying energy for transporting 
substrate through the membrane. The Magnesium (Mg2+) ion is reported to play a role in 
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stabilizing the ATP-binding site (Tombline et al. 2004). P-gp translocate its substrate from 
cytosol of epithelial cells to intestinal lumen and thereby reduces the bioavailability 
(Chawla 2003). A wide range of drug molecules (mainly hydrophobic) can interact with P-
gp. These drugs include anticancer agents, immunosuppressants, steroid hormones, 
calcium channel blockers, beta-adrenoreceptor blockers, cardiac glycosides etc. (Sharom 
2011; Varma et al. 2003; Sharom et al. 2001). Most of these drugs are also substrate for 
CYP3A4 in the intestinal epithelial cells (Sharom 2011). The P-gp efflux pump along with 
CYP3A4 and can limit the oral absorption of these drugs. (Fig. 5B) (Li et al. 2016). 
Different classes of P-gp inhibitors have been investigated to overcome the P-gp efflux. 
These include small molecule P-gp inhibitors (e.g., Verapamil, Cyclosporin A), polymeric 
P-gp inhibitors (e.g. TPGS, pluronics), and natural P-gp inhibitors (e.g. Curcumin, 
Grapefruit) (Varma et al. 2003; Liscovitch and Lavie 2002; Kabanov, Batrakova, and 
Alakhov 2002; Zhou, Lim, and Chowbay 2004; Deferme, Van Gelder, and Augustijns 
2002; Cornaire et al. 2004). 
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Figure 5: Structure of P-gp efflux pump and mechanism of inhibition of drug 
absorption (A). Functional relationship between P-gp and CYP3A4 (B). Reproduced 
from Bansal et al. (2009) and Watkins (1997). 
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1.3.2. Influence of physicochemical and biopharmaceutical factors on oral drug 
delivery 
Oral bioavailability of drugs limited by the physicochemical properties of drugs. 
These includes poor solubility and permeability, poor chemical stability, and enzymatic 
metabolism in the GI tract (Prabhu, Ortega, and Ma 2005). The poor physicochemical 
properties of drug molecules lead to ~40% failure in drug development (Siew et al. 2012). 
Lipinski et al. developed ‘Rule of 5’ to guide oral drug development. According to 
this rule drugs with molecular weight >500 Da, log P >5, >5 H-bond donors, >10 H-bond 
acceptors are less likely to show good absorption after oral administration (Lipinski 2000; 
Wenlock et al. 2003). The rate of solubility in the intestinal fluid is one of the important 
factors that influence the drug absorption. Noyes-Whitney equation is used to describe the 
factors that influences the rate of drug dissolution (Healy 1984; Frenning and Stromme 
2003), 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑑𝑖𝑠𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 =
𝐴. 𝐷
ℎ
(𝐶𝑠 − 𝐶) 
Where A is the surface area, D is the diffusion coefficient, h is the thickness of the 
diffusion layer adjacent to the drug surface, Cs is the saturation solubility of the drug in the 
diffusion layer, and C is the concentration of drug in the bulk solution at any time. The 
above equation indicates that rate of drug dissolution increases with increase in drug 
surface area, which can be achieved by decreasing the particle size. Diffusion coefficient 
is dependent on the viscosity of the fluid (solvent) and rate of drug dissolution is inversely 
proportional to the viscosity of solvent. Saturation solubility (Cs) is dependent on the 
physicochemical characteristics of drug and nature of the fluid (solvent). Therefore, the 
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alteration of pH of the solvent can alter the degree of ionization of drug (discussed in 
section 1.3.1.1.) and thus can change the drug solubility. 
 Among all the factors, solubility and permeability are the primary determinants of 
oral bioavailability. This lead to the development of Biopharmaceutic Classification 
System (BCS) which classifies drugs based on its solubility and permeability (Fig. 6) 
(Amidon et al. 1995; Dahan, Miller, and Amidon 2009). According to BCS, a drug is 
considered as highly soluble if its highest dose is soluble in 250 mL water over the entire 
pH range of 1 to 7.5 (Yu et al. 2002). Similarly, a drug is regarded as highly permeable, if 
>90% of its administered dose is biologically available (Lennernas 2007). As shown in 
Figure 6, BCS class I drugs are highly soluble and highly permeable. BCS class I drugs 
are readily absorbed and are good candidates for oral delivery. BCS Class II drugs are 
poorly soluble and highly permeable, while BCS Class III drugs are highly soluble and 
poorly permeable. BCS Class IV drugs are poorly soluble and poorly permeable and 
require carriers or chemical modification to improve solubility and or permeability (Fig. 
6).  
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Figure 6: Biopharmaceutics Classification System (BCS). Reproduced from Dahan, 
Miller, and Amidon (2009). 
 
Benet et al. further modified BCS by including drug metabolism. This lead to the 
development of Biopharmaceutics Drug Disposition Classification System (BDDCS) (Fig. 
7) (Wu and Benet 2005). According to BDDCS, highly permeable drugs (class I and class 
II) are extensively metabolized, while the poorly permeable drugs (class III and class IV) 
are poorly metabolized. For class I and class II drugs, the prmary route of elimination is 
metabolism, while for class III and class IV drugs, the primary route of elimination is renal 
and biliary excretion (Fig. 7) (Benet et al. 2008; Wu and Benet 2005). In general, BDDCS 
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serve as basis for predicting the role of transporters in drug disposition and drug-drug 
interactions. 
 
 
 
Figure 7: Biopharmaceutic Drug Disposition Classification System (BDDCS). 
Reproduced from Wu and Benet (2005). 
 
 
 
 
 
23 
 
1.4. Different approaches for oral drug delivery 
Numerous approaches have been used to overcome oral drug delivery challenges. 
These can be divided mainly into two categories: i) physical or chemical modification of 
drug molecules, and ii) use of drug carriers (Bernkop-Schnurch 2013). The first strategy 
involves altering the physical or chemical form to improve the physicochemical 
characteristics of the drug. These include micronization, polymorphism, salt formation, 
pro-drug, and complexation. The second approach is to using drug carriers with different 
types of materials.  
 
1.4.1. Physical or chemical modification of drug molecules 
Various physical and chemical modification have been used to enhance aqueous 
solubility, intestinal permeability, and bioavailability of drug molecules (Savjani, Gajjar, 
and Savjani 2012).  
Micronization is one of the well-studied techniques to overcome the limitations 
associated with drug dissolution (Blagden et al. 2007). Reducing the particle size of drug 
crystals significantly increases the surface area, and rate of dissolution. For example, 
micronized formulation of poorly water-soluble glimepiride has been used to enhance the  
dissolution rate and to increase the oral bioavailability (Ning et al. 2011). Similarly, 
micronized megestrol acetate formulation show enhanced oral bioavailability (Farinha, 
Bica, and Tavares 2000). 
Drug crystallinity and polymorphisms can influence drug solubility and 
bioavailability (Singhal and Curatolo 2004). A drug that can crystallize in more than one 
crystal form and is known as polymorphism. Majority of drugs (50-70%) exhibit 
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polymorphism, which differ in the internal arrangement and conformations of the 
molecules in the crystal lattice (Higuchi et al. 1963; Podaralla 2008). The polymorphs have 
distinct chemical and physical properties such as difference in melting point, chemical 
reactivity, apparent solubility, dissolution rate, vapor pressure, density, optical and 
electrical properties. For example, HIV protease inhibitor ritonavir (Norvir®, Abbott 
Laboratories) exist as two polymorphs. Form I of ritonavir is more soluble than form II 
(Gardner, Walsh, and Almarsson 2004). An amorphous form of the drug does not have 
regular crystal lattice and has a higher solubility in comparison to crystalline form of the 
drug (Hancock 2000). Several reports have shown the improved solubility of amorphous 
form of the drug compared to the crystalline form (Imaizumi, Nambu, and Nagai 1980; al. 
1975). For example, aqueous solubility of amorphous celecoxib was found to be higher 
than its crystalline counterpart (Gupta, Chawla, and Bansal 2004). 
Salt formation is one of the most commonly used strategies to increase the solubility 
of ionic drugs (Berge, Bighley, and Monkhouse 1977; Chowhan 1978). The impact of salt 
formation on the rate of drug dissolution was first introduced by Nelson (1957) by 
comparing choline and isopropanolamine salts of theophylline with ethylenediamine salts. 
Approximately 70% drugs are ionizable and are weakly basic or weakly acidic (Kalepu 
and Nekkanti 2015). Therefore, the formation of an appropriate salt of drug molecules 
using oppositely charged counter-ions can alter the pH of the diffusion layer resulting 
improved solubility. Weakly acidic drugs form salt with strong base (e.g. Phenytoin 
sodium) while weakly basic drugs form salt with strong acids (e.g. Atropine sulfate). The 
salt formation is dependent on the relative pKa values of the drug and the salt forming 
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species (counter-ion). Table 2 lists commonly used counterions to form pharmaceutical 
salts. 
 
Table 2: Common pharmaceutical salts. 
Salts class Examples 
 
Inorganic acids 
Sulfonic acids 
Carboxylic acids 
Anionic amino acids 
Hydroxyacids 
Fatty acids 
Insoluble salts 
Anions 
Hydrochloride, hydrobromide, sulfate, nitrate, phosphate, 
mesylate, esylate, isethionate, tosylate, napsylate, besylate, 
acetate, propionate, maleate, benzoate, salicylate, fumarate, 
glutamate, aspartate, citrate, lactate, succinate, tartrate, glycolate, 
hexanoate, octanoate, decanoate, oleate, stearate, pamoate, 
polystyrene sulfonate (resinate) 
 
Organic amines 
Insoluble salts 
Metallic 
Cationic amino acids 
Cations 
Triethylamine, ethanolamine, triethanolamine, meglumine, 
ethylenediamine, choline procaine, benzathine, sodium, 
potassium, calcium, magnesium, zinc, arginine, lysine, histidine 
 
 
Prodrug approaches has been used to enhance aqueous solubility or permeability of 
drugs (Van Gelder et al. 2000). Chemical modification to create prodrug should be 
reversible and prodrug should be converted back into parent drug by an in vivo chemical 
and/or enzymatic reaction (van De Waterbeemd et al. 2001; Beaumont et al. 2003). For 
example, inactive sulindac prodrug derived from sulfinylindene which is 100-times more 
water soluble than sulindac drug. The prodrug is converted in vivo to an active sulfide 
compound by liver enzyme (Davies and Rampton 1991).  
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Complexation of drug molecules with hydrophilic polymers is another approach to 
enhance water solubility of lipophilic drugs (Loftsson 1998). Drug complexation with 
polymers like cyclodextrin (CD) improve both the pharmaceutical and biological 
properties of drug-CD complexes. Cyclodextrins are divided into α-, β-, and γ-
cyclodextrin-based into some D-glucopyranose units. Βeta-cyclodextrin is most commonly 
used to entrap and improve the solubility of lipophilic drugs (Fig. 8) (Shimpi, Chauhan, 
and Shimpi 2005). Complexation can also be used to increase the stability of compounds, 
mask the bitter taste of the drug, and control the drug release (Ranade 1991). Complexation 
of drug molecules with cyclodextrin has been used to enhance solubility and oral 
bioavailability of several drugs (Loftsson and Brewster 1996; Loftsson and Duchene 2007; 
Loftsson and Brewster 2010; Irie and Uekama 1997). For example, complexation of 
enalapril (antihypertensive) with beta-cyclodextrin enhanced the solubility, stability, and 
bioavailability of enalapril after oral administration (Fig. 8) (al. 2006). Other complexing 
agents such as sodium benzoate, caffeine, nicotinamide, and sodium salicylate have also 
been used to increase drug solubility.  
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Figure 8: Structure of beta-cyclodextrin-enalapril maleate complex. Reproduced from Ali 
et al. (2006). 
 
 
1.4.2. Drug carriers 
Several types of drug carriers have been used to improve the oral drug absorption.  
Drug carriers allow the delivery of poorly water-soluble drugs, target the drug release to 
specific site in the GI tract, sustain drug release, reduce drug efflux, and transport drugs 
through the GI membrane (Fig 9). Various types of drug carriers have been tested for oral 
drug delivery applications including micelles, nanospheres, liposomes, nanoemulsions, 
solid lipid nanoparticles, polymeric particles (nano and microparticles), and self-
emulsifying drug delivery systems (SEDDS) etc. (Fig. 10). Nanoparticles are defined by 
the diameter on the order of 100 nm which is comparable to many viral particles 
(Pridgen, Langer, and Farokhzad 2007).
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Figure 9: Application of nanocarriers in oral drug delivery applications. Reproduced from Agrawal et al. (2014). 
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Figure 10. Different nanocarrier systems investigated for oral drug delivery. Reproduced 
from Zhang, Wang, Zhang, et al. (2013). 
 
1.4.2.1. Lipid-based delivery systems 
1.4.2.1.1. Liposomes  
Liposomes are lipid vesicles with a hydrophilic core and a lipophilic bilayer. 
Liposomes can be used to entrap hydrophilic and/or hydrophobic molecules.    Traditional 
liposomes are composed of phospholipid and cholesterol. Liposomes are promising drug 
carrier. The composition of lipids in the liposomes can be varied to alter the surface charge 
and particle size (Wu, Lu, and Qi 2015). The size of liposomes can vary from very small 
(25 nm) to large (2.5 µm) vesicles and can be classified as unilamellar and multilamellar 
vesicles. In general, liposomes is prepared by dry-film-rehydration method where a thin 
lipid film is formed by evaporation of organic solvent followed by hydration of lipid film 
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using aqueous drug solution and sonication to encapsulate drug in the core of the liposome 
(Akbarzadeh et al. 2013). In this method, primarily form large multilamellar vesicles which 
require to either sonicate or extruded to produce small unilamellar vesicles. Alternatively, 
ethanol injection method is used prepare liposome. In this method, water injected into a 
concentrated lipid-ethanol solution followed by evaporation of ethanol (Maitani et al. 2007; 
Maitani et al. 2001; Pons 1993).   
Liposome based drug delivery is limited by i) low loading efficiency, ii) poor 
stability in GI media, and iii) leakage of entrapped drugs. Lipases can hydrolyze the 
liposomes within 2 hours of oral ingestion leading to disruption of bilayer (Liu et al. 2015). 
The integrity of liposomes can also be altered in the low gastric pH leading to burst release 
of drug in stomach. In this regard, polysaccharides and protein polymers have been used 
to improve the stability of liposomes (Manconi et al. 2013; Smistad et al. 2012). 
Polymerized liposomes showed enhanced stability in the GI tract and improved oral 
absorption. For example, incorporation of sodium glycocholate in liposomal composition 
resulted in increased resistance to peptic and tryptic digestion of encapsulated insulin (Niu 
et al. 2011). Thiolated chitosan-coated liposomes were found to be stable at low pH with 
mucoadhesive properties (Gradauer et al. 2013). Liposomes with multiple layers of 
polyelectrolyte have been prepared to achieve higher stability in GI fluid. The multilayer 
liposomes were reported to enhance the blood concentration of doxorubicin and paclitaxel 
(Thanki et al. 2013; Jain, Patil, et al. 2012; Jain, Kumar, et al. 2012). Lecithin vesicles 
achieved >98% encapsulation and enhanced the bioavailability of cyclosporine A 
compared to marketed Sandimmune® formulation (Guo, Ping, and Chen 2001; Chen et al. 
2003). Further, folic acid coupled phosphatidylcholine-based liposomes was used to 
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encapsulate cefotaxime to achieve receptor-mediated endocytosis and achieve higher oral 
bioavailability in rats (Ling et al. 2009). 
 
1.4.2.1.2. Solid lipid-based drug carriers  
Several solid lipid-based carriers have been investigated to overcome the 
limitations such as stability in low pH associated with liposome-based formulations. These 
includes solid lipid nanoparticles (SLNs), lipid-drug conjugate nanoparticles (LDC-NPs) 
and nanostructured lipid carriers (NLCs). SLNs are promising carriers for compounds with 
low water solubility and intestinal permeability (Attama 2011). SLNs are prepared from 
lipids with high melting points (Severino et al. 2012; Agrawal et al. 2014). The ease of 
scaling up using high-pressure homogenizer and the absence of organic solvents makes it 
an attractive drug delivery carrier. Small molecules and peptides have been encapsulated 
in SLNs and evaluated for oral delivery (Muller, Mader, and Gohla 2000). Insulin-loaded 
SLNs were found to increase their tolerance against peptic enzymes and enhanced the 
bioavailability in vivo compared to subcutaneous injection (Zhang et al. 2006). 
Incorporation of simvastatin (HMG-CoA reductase  and BCS II drug) in SLNs, consisting 
of glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate and PEG 
glyceride, and enhanced the oral bioavailability (Padhye and Nagarsenker 2013). NLCs are 
advantageous over other lipid-based systems in terms of high drug loading, longer shelf-
life, and feasibility of incorporating both hydrophilic and lipophilic drugs (Poonia et al. 
2016). However, SLNs suffer from low drug loading efficiency due to dense pack lipid 
molecules and can expel the loaded drug on storage (Muchow, Maincent, and Muller 2008; 
Poonia et al. 2016).  To address this issue, lipid-drug conjugate (LDCs) nanoparticles have 
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been developed. Lipid-drug conjugates are prepared by covalently conjugating drug 
molecules with lipids (Irby, Du, and Li 2017). For example, lipid-drug conjugate 
nanoparticles (LDC-NPs) of methotrexate (MTX) have been prepared to overcome low 
and variable oral bioavailability of this drug (Paliwal, Rai, and Vyas 2011). Nanostructured 
lipid carriers (NLCs) have also been tested for oral drug delivery (Poonia et al. 2016). For 
example, atorvastatin loaded NLCs demonstrated higher solubility and oral bioavailability 
compared to Lipitor® formulation (Elmowafy et al. 2017). NLCs are advantageous over 
other lipid-based systems in terms of high drug loading, longer shelf-life, and feasibility of 
incorporating both hydrophilic and lipophilic drugs (Poonia et al. 2016). Table 3 lists some 
representative examples of lipid nanoparticles used for oral drug delivery. 
 
1.4.2.1.3. Self-emulsifying drug delivery systems  
Self-emulsifying drug delivery systems (SEDDS) or self-micro emulsifying drug 
delivery systems (SMEDDS) is an isotropic mixture of solvents/co-solvents, lipids/oils, 
and surfactants designed to deliver compounds with poor solubility (Gursoy and Benita 
2004). Micro or nanoemulsions are thermodynamically stable, an isotropic mixture of oil, 
surfactant, water, and co-solvents.  Micro or nanoemulsion technology is used to address 
the challenges associated with the delivery of water-insoluble compounds.  
Micro/nanoemulsions are usually prepared using high-pressure homogenizer to reduce the 
droplet size in the range of 50-500 nm diameter (Table 3). The microemulsion have been 
reported to be effective in protecting the drug from enzymatic attack after oral delivery in 
the rabbits (Nicolaos et al. 2003). 
33 
 
SEDDS/SMEDDS can be placed in soft or hard gelatin capsules for oral 
administration and form stable oil-in-water emulsions in the presence of GI fluids (Shao et 
al. 2015; Pouton 2000). The lipid content in the formulation can also stimulate the biliary 
secretion from the gallbladder (Kalepu, Manthina, and Padavala 2013). In the presence of 
bile salts, lipid formulations (e.g., SEDDS or SMEDDS) can be digested leading to the 
formation of vesicles, micelles or mixed micelles (Fig. 9). Drug absorption efficiency is 
dictated by the physicochemical characteristics of SEDDS/SMEDDS formulations such as 
the ratio of oil and surfactant, the concentration of surfactant, polarity, droplet size and 
surface charge (Hauss 2007). Taken together, SEDDS/SMEDDS can improve the 
solubilization of drugs in the small intestine and enhance bioavailability after oral 
administration (McClements and Xiao 2014; Gursoy and Benita 2004). SEDDS have been 
efficiently used to enhance the oral bioavailability of BCS class III and class IV drugs.  
Currently, there are several SEDDS formulations are available in the market including 
Sandimmune®, Sandimmun Neoral® (Cyclosporin A), Norvir® (Ritonavir), and 
Fortovase® (Saquinavir).  
Lipid-based drug carriers have additional benefit that they mimic chylomicron 
pathway and target intestinal lymphatic system after oral delivery (Ahn and Park 2016). 
The lymphatic system plays an important role in the uptake and removal of toxins and 
foreign materials from the body (Longmire, Choyke, and Kobayashi 2008). Lymphatic 
systems are also responsible for maintaining the fluid balance in the body by removing 
interstitial fluid and return to blood after filtering damaged cells, cancer cells, bacteria, and 
viruses (Dixon 2010). Furthermore, lymphatic system plays an important role in the 
absorption and distribution of fat and fat-soluble vitamins from the GI tract (Dixon 2010). 
34 
 
Targeting lymphatic systems using lipid-based formulations (liposomes, SLNs, NLCs, 
SEDDS) is especially useful for treatment of diseases like lymphoma and HIV (Kalepu, 
Manthina, and Padavala 2013). Figure 11 shows the mechanism of drug absorption of drug 
from SEDDS formulation. The lipid-based drug delivery system can mimic the 
chylomicron pathway to improve the bioavailability and by-pass the first-pass metabolism 
(Chaudhary et al. 2014). Further, the lipid based delivery system can facilitate transcellular 
absorption due to increased membrane fluidity, allow paracellular transport by opening 
tight junctions, and increase epithelial cell uptake by inhibiting P-gp/CYP450 (Zeng et al. 
2012; O'Driscoll 2002; Frazer 1955). 
However, SEDDS formulations suffer from limitation such as i) migration of 
volatile co-solvents to capsule shell, ii) lack of good predictive in vitro models for 
assessment of formulations, and iii) high concentration of surfactants in SEDDS can be 
toxic to the epithelial membrane.  
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Table 3: Lipid nanoparticles used for oral drug delivery applications.  
Drug Excipients Type Outcome References 
Cefotaxime Unsaturated soybean 
phosphatidylcholine 
Liposomes At 90% confidence interval, the value for 
AUC0–∞ was 1.4–2-times higher and the value 
for Cmax was 1.2–1.8-times higher for the folic 
acid coupled liposomes compared with folic 
acid-free liposomes. 
Ling et al. (2009) 
Testosterone 
undecanoate 
Dynasan 118, stearic acid, 
Tween 80, carnauba wax 
NLC Facilitated administration of a single dose of 
testosterone undecanoate in a unit oral dosage 
form and reduced variation in bioavailability in 
the fed and fasted states 
Muchow et al. 
(2011) 
Pentoxifylline Lecithin, cetyl alcohol, 
Tween 20 
SLN SLN prepared by homogenization followed by 
sonication. The system enhanced the 
bioavailability of the drug (5.23-fold higher in 
comparison with the suspension) by avoidance 
of the first-pass metabolism 
Varshosaz, 
Minayian, and 
Moazen (2010) 
Crypto 
tanshinone 
Glyceryl monostearate, 
Compritol ATO, 
Tween 80, soy lecithin, 
sodium 
SLN Incorporation of the drug into a solid lipid 
matrix altered the in vivo metabolic behavior of 
the drug, thereby increasing the bioavailability. 
Incorporation of sodium dihydrofolate into 
Hu et al. (2010) 
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dihydrofolate SLNs significantly enhanced the oral 
bioavailability 
Buspirone  Poloxamer, soy lecithin, 
spermaceti, Polysorbate 80, 
cetyl alcohol 
SLN SLNs enhanced the bioavailability of the drug 
2.53-fold by avoiding the pre-systemic hepatic 
metabolism. 
Varshosaz, 
Tabbakhian, and 
Mohammadi (2010) 
Vinpocetine Compritol ATO, Solutol 
HS 15, Poloxamer, Miglyol 
812N, monostearate 
NLC Nanostructured lipid carriers showed sustained 
release of the drug, with a remarkable increment 
in bioavailability (322 %) in comparison to a 
drug suspension. Application of Solutol HS 15 
as a surfactant in the NLC altered the integrity 
of intestinal epithelial cells and increased the 
permeability. 
Zhuang et al. (2010) 
Lopinavir Stearic acid SLN The SLN showed a biphasic sustained drug 
release, which led to enhanced oral 
bioavailability (5- fold) and improved the 
distribution of the drug to HIV reservoirs. The 
report suggested this is a better an alternative to 
the marketed lopinavir/ritonavir co-
formulation. 
Ravi et al. (2014) 
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Saquinavir Dextran protamine, Precirol 
ATO15, Miglyol 812, 
Polysorbate 80, Poloxamer, 
protamine sulfate, dextran 
NLC The permeability of saquinavir loaded into 
dextran protamine-coated nanostructured lipid 
carriers was increased ninefold in comparison 
with uncoated NLC. 
Beloqui et al. (2014) 
Cyclosporin A Olive oil, polyglycolyzed 
glycerides, ethanol 
SEDDS Increased solubility and oral bioavailability of 
Cyclosporin A. 
Gursoy and Benita 
(2004) 
Ritonavir Oleic acid, Polyoxyl 35 
castor oil, ethanol 
SEDDS Improved oral bioavailability of ritonavir. FDA (2006) 
Paclitaxel dl-α-tocopherol, TPGS, 
Tyloxapol 
SMEDDS Enhanced solubility and oral bioavailability of 
paclitaxel.  
Gursoy and Benita 
(2004) 
Cefpodoxime 
proxetil 
Medium-chain 
triglycerides, Soybean 
Lecithin, Polysorbate 80, 
Microemulsion Enhancement of the absolute bioavailability of 
cefpodoxime proxetil. 
Nicolaos et al. 
(2003) 
HIV: human immunodeficiency virus, NLC: nanostructured lipidic carrier, SLN: solid lipid nanoparticle, AUC: Area under the plasma 
concentration-time curve, NLCs: Nanostructured lipid carriers, SLN: Solid lipid nanoparticles, SEDDS: Self-emulsifying drug 
delivery system, SMEDDS: Self-microemulsifying drug delivery system, Cmax: Maximum plasma drug concentration.  
Reproduced from Pathak and Raghuvanshi (2015) and Gursoy and Benita (2004).
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Figure 11: Schematic representation of mechanisms of intestinal drug transport from 
SEDDS formulations. Reproduced from Kalepu, Manthina, and Padavala (2013). 
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1.4.2.2. Polymeric nanocarriers 
Polymeric materials have been extensively investigated for the development of 
drug carriers (Galindo-Rodriguez et al. 2005; Pridgen, Alexis, and Farokhzad 2014, 2015). 
A variety of synthetic and natural polymers have been tested for their potential to overcome 
barriers associated with oral drug delivery (Table 4) (Agrawal et al. 2014). Drug molecules 
are encapsulated inside the polymeric matrix or dispersed, adsorbed, complexed within the 
polymeric matrix (Huang and Dai 2014). 
Various techniques have been used to prepare polymeric nanocarriers, which 
mainly fall into top-down and bottom-up processes (Fig. 10). The top-down method is 
based the reduction of particle size using various techniques such as ultrasonication, 
cavitation, homogenization, microfluidization, milling and spray drying (Reis et al. 2006). 
On the otherhand, the bottom-up technique is based on particle growth from individual 
particles such as phase separation method including controlled crystallization during 
freeze-drying or technologies that use supercritical fluid (de Waard, Frijlink, and Hinrichs 
2011). 
Polymeric microparticles exhibit higher stability in GI tract, encapsulate both 
hydrophilic and hydrophobic molecules (Vilos and Velasquez 2012). Different types of 
polymers have been used to prepare nanoparticles or microparticles (Table 5) (Chawla, 
Sharma, and Pawar 2012; Rahman et al. 2006; Hsu, Yu, and Huang 2013; Patel et al. 2016; 
Simonoska Crcarevska, Glavas Dodov, and Goracinova 2008). For example, alginate and 
chitosan are widely used natural polymers to develop nanoparticles and microparticles. 
These polymers found to reduce drug release in stomach, increase stability, and sustain 
drug release at higher pH  in intestine (Calija et al. 2013). 
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Nanoparticles are defined by the diameter on the order of 100 nm which is 
comparable to many viral particles (Pridgen, Langer, and Farokhzad 2007). Polymeric 
nanoparticles have also been studied for oral drug delivery applications and drug molecules 
can be entrapped in the core of the nanoparticles during the preparation (Mo et al. 2014; 
Galindo-Rodriguez et al. 2005). The surface of polymeric nanoparticles can be modulated 
by utilizing the polymeric end groups or by conjugating another polymer to the surface of 
nanoparticles (Valencia et al. 2013).  
Polymeric micelles are relatively small, spherical structure composed of 
amphiphilic polymers (Croy and Kwon 2006). The polymers used in the micelle helps to 
orient lipophilic hydrocarbon chain towards center leaving aqueous groups in contact to 
aqueous medium. The concentration of polymers at which micelles are formed is known 
as critical micelle concentration (CMC).  Polymeric micelles have been investigated for 
improving oral bioavailability of hydrophobic drugs molecules (Francis, Piredda, and 
Winnik 2003; Dabholkar et al. 2006; Pierri and Avgoustakis 2005). Polymeric micelles 
have been tested to increase aqueous solubility of cyclosporin A (Francis, Cristea, and 
Winnik 2005; Francis et al. 2005; Francis et al. 2003). Further, pH-sensitive polymeric 
micelles have also been tested to enhance intestinal absorption of hydrophobic compounds 
(Pierri and Avgoustakis 2005; Ould-Ouali et al. 2005). Polyethylene glycol (PEG)-b-
P(alkyl(meth)acrylate-co-methacrylic acid)s (PEG-b-P(Al(M)Aco-MAA)s) is a diblock 
copolymer and shows pH-dependent micellization in aqueous media. Polymeric micelles 
formed from this diblock copolymers have been studied for the delivery of several 
hydrophobic drugs. Several studies shown that fluid phase endocytosis pathway is the 
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major cell uptake mechanism for polymeric micelles (Allen et al. 1999; Luo et al. 2002). 
Table 5 lists some representative examples polymeric micelles used for oral drug delivery. 
 
Table 4: Representative synthetic and natural polymers for oral drug delivery. 
Class of polymers Examples 
Polyesters Poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), 
polyglycolic acid (PGA), and poly(ɛ-caprolactone). 
Polyanhydrides Poly(sebacic acid), poly(adipic acid), poly(terephthalic acid), and 
their copolymers) 
Polyamides Poly(imino carbonates) and polyamino acids) 
Polyethers Polyethylene glycol (PEG) and polypropylene glycol 
Cellulose 
derivatives 
Carboxymethyl cellulose, hydroxypropyl methyl cellulose 
(HPMC), ethyl cellulose, hydroxypropyl methyl cellulose acetate 
succinate (HPMC-AS), and cellulose acetate succinate (CAS) 
Protein Collagen, gelatin, and albumin 
Polysaccharides Chitosan, alginate, carrageenan, cyclodextrin, and hyaluronic acid 
Reproduced from Kapoor et al. (2015) and De Jong and Borm (2008). 
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Figure 12: Different techniques used for the preparation of polymeric nanocarriers. Adapted from Bennet and Kim (2014). 
43 
 
Table 5: Representative list of polymeric nanocarriers used for oral drug delivery.  
Polymers Drug Key findings Reference 
PEG-b-PCL NHS-PEGb- PCL solution of 
7pep (Transferrin receptor (TfR) specific 
7peptide nanocarrier)  
Coumarin 6 The functional nanocarriers specifically interact 
with gastrointestinal epithelial cells and increased 
drug transport. 
Du et al. (2013) 
Tocopherol succinate glycol chitosan (GC-
TOS) conjugates (Micelles)  
Ketoconazole GC-TOS increased the solubility of ketoconazole 
(BCS class II drug) and enhanced the intestinal 
permeation. 
Duhem et al. 
(2012) 
Pluronic copolymers and LHR conjugate 
(Mixed polymeric micelles)  
Paclitaxel Pluronic/ LHR micelles enhanced the oral 
bioavailability of paclitaxel. 
Dahmani et al. 
(2012) 
Alginate-oligochitosan-Eudragit(®) L100-
55 (ALG-OCH-EL) (Microparticles) 
NSAIDs Improved the stability and reduced drug release in 
acidic pH (stomach). 
Calija et al. 
(2013) 
Alginate coated chitosan core-shell 
(Nanoparticles) 
Naringenin Effective in the treatment of dyslipidemia, 
hyperglycemia compared to free Naringenin  
Maity et al. 
(2017) 
Vitamin B12-Chitosan (Nanoparticles) Scutellarin 2-3 fold greater oral bioavailability than free 
scutellarin 
Wang et al. 
(2017) 
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N-trimethyl chitosan-palmitic acid 
(Micelles) 
Resveratrol 3.8-fold increase in oral bioavailability Ramalingam 
and Ko (2016) 
PLGA (Nanoparticles) Lopinavir 13.9-fold increase in oral bioavailability Joshi, Kumar, 
and Sawant 
(2016) 
PEG-PLGA (Nanoparticles) Ginsenoside 3 to 9-fold increase in oral bioavailability Voruganti et al. 
(2015) 
Methacrylate copolymer (Eudragit 100) 
(Nanoparticles) 
Efavirenz Higher serum drug concentration than free drug Hari et al. 
(2016) 
sericin/poly(ethylcyanoacrylate) 
(Nanospheres) 
Fenofibrate 70% increase in oral absorption Parisi et al. 
(2015) 
Gelatin-pluronic F68 (Nanoparticles) Acyclovir 2-fold increase in drug exposure Kharia and 
Singhai (2015) 
PEG-PAMAM dendrimer (Nanoparticles) Probucol Increased plasma concentration and lipid-
lowering effect when delivered using 
nanoparticles 
Qi et al. (2015) 
Basic methacrylate copolymer 
RL100 (Nanoparticles) 
Atazanavir 2.91-fold increase in drug exposure Singh and Pai 
(2016) 
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Poly(butyl cyanoacrylate) and Poly(ε-
Caprolactone) (Nanoparticles) 
5-Fluorouracil 
Increased the mice survival rate against advanced 
or recurrent colon cancer compared to free 5-
Fluorouracil. 
Ortiz et al. 
(2015) 
Mucoadhesive dendrimer (Nanoparticles) Albendazole 2.4-fold increase in Cmax. Mansuri et al. 
(2016) 
Poly(amido amine) dendrimers 
(Nanoparticles) 
Camptothecin Cationic and anionic PAMAM dendrimers were 
effective in enhancing the oral absorption of 
camptothecin. 
Sadekar et al. 
(2013) 
Poly(ethylene glycol)-b-
poly(alkyl(meth)acrylate-co-
methacrylic acid) micelles 
Candesartan 
cilexetil 
 
pH-dependent micellization and high drug 
loading. 
Satturwar et al. 
(2007) 
Poly(lactide)-poly(ethylene glycol) micelles Griseofulvin High drug loading, stable micelle in simulated 
gastrointestinal fluid. 
Pierri and 
Avgoustakis 
(2005) 
PMMMA-PLGA:poly[(methyl methacrylate)-co-(methyl acrylate)-co-(methacrylic acid)]-poly(D,L-lactide-co-glycolide), PAMAM: 
Poly(amidoamine), PCL: Poly(caprolactone).
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1.5. Natural polymers  
Natural polymers are attractive materials for developing nanoparticulate based oral 
drug delivery systems due to their biocompatibility. Natural polymers are derived from 
plant sources like corn, cellulose, potato, soybean, or animal sources or synthesized by 
bacteria (Nair and Laurencin 2007). The characteristics of natural polymers can be 
improved by changing the surface chemistry such as dextran, cyclodextrins, and derivatives 
of starch, cellulose, chitosan (Cumpstey 2013). These polymers have been widely 
investigated for their application in drug delivery (Mogosanu and Grumezescu 2014). For 
example, characteristics of cyclodextrins have been further improved by the substitution of 
some of the hydrogen bonds with methyl groups result in increased solubility, stability, and 
bioavailability, while decreasing the toxicity of polymer or drug (Figueiras et al. 2007). 
Several research groups have studied natural polymers to develop nanocarriers for 
oral delivery of drugs (Alqahtani et al. 2017; Hu et al. 2015; Bagre, Jain, and Jain 2013; 
Huang et al. 2015; Santipanichwong et al. 2008). 
Both polysaccharide and protein-based natural polymers have been investigated for 
oral drug delivery applications.  
 
1.5.1. Polysaccharide-based polymers 
Polysaccharide-based polymers are ubiquitous and mainly obtained from algae, 
plants, microbes, and animals. These polymers have been studied for drug delivery 
applications (Cumpstey 2013). The diversity of structure and availability of derivable 
functional groups provide enormous potential for the development of non-toxic, safe, and 
cost-effective nanocarriers (Zhang, 2013). Polysaccharides are mainly divided into 
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polyelectrolyte and non-polyelectrolyte polymers (dextran, dextrin, pullulan, etc.). 
Polyelectrolyte polysaccharides can also be divided into positively charged (chitosan) and 
negatively charged (heparin, hyaluronic acid) polymers (Sinha and Kumria 2001). 
Electrostatic interaction of oppositely charged polymers have been used for the formation 
of polysaccharide-based nanocarriers (Boddohi et al. 2009; Boddohi et al. 2010). Some 
polysaccharide polymers such as chitosan exhibit efficient mucoadhesion due to the 
formation of non-covalent bonds with intestinal mucosa and modifies the GI transit time 
(Guggi, Krauland, and Bernkop-Schnurch 2003). Alginate, chitosan, guar gum, pectin, 
xanthan gum, gellan gum and carrageenan based nanocarriers have been investigated for 
oral drug delivery applications (Bhatia 2016; Jana 2011). Alginate has been used in 
combination with other synthetic or natural polymer to modulate the functional 
performance (Bacon 2002). Chitosan is a cationic, biodegradable, and non-toxic polymer 
and has been extensively investigated alone or in combination with other polymers for oral 
drug delivery applications (George and Abraham 2006). Alginate can be modified by cross-
linking to control the release of encapsulated drugs (Pillay et al. 1998). Alginate has also 
been grafted with albumin, PLGA, PEG, heparin, and guar gum to control the drug release 
from polymer matrix (Hauptstein et al. 2015; Moebus, Siepmann, and Bodmeier 2009; 
Davidovich-Pinhas, Harari, and Bianco-Peled 2009; El-Sherbiny et al. 2011; Mennini et 
al. 2012; Pongjanyakul and Puttipipatkhachorn 2007; Wells and Sheardown 2011). For 
example, rifampicin loaded PLGA-alginate core-sehll microsphere was shown to modify 
drug release kinetics and achieved near zero-order release pattern (Wu et al. 2013).  
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1.5.2. Protein polymers  
Protein polymers are versatile class of biopolymers with a wide-range of amino 
acid composition and varying physicochemical properties, which in-turn can  influence its 
functional performance (Podaralla 2009). The protein polymers have gained increased 
attention due to the following advantages such as i) availability of various modifiable 
functional groups (-NH2, -COOH and -SH), ii) renewable source and low cost, iii) protein 
polymers are obtained from natural source and do not require initiators for synthesis, and 
iv) proven biocompatibility compared to some of the synthetic polymers (Mukherjee et al. 
2014). The formation of nanocarriers using protein polymers is mainly dictated by the 
protein structure and subsequent intra- or inter-molecular interaction. (Ko and 
Gunasekaran 2006). 
However, the purity of protein polymers is difficult to control compared to synthetic 
polymers. In addition, immunogenicity is one of the major concerns with protein polymers 
(Podaralla 2009). The major limitation of natural protein polymers is batch-to-batch 
variation (Podaralla 2009). Table 6 lists the physicochemical properties of some of the 
protein polymers used for drug delivery.  
 
 
 
 
 
 
 
49 
 
Table 6: Physicochemical properties of protein polymers. 
Protein Source Composition Molecular 
weight 
Isoelectric 
point 
Gelatin Collagen 4-hydroxylysine, 
hydroxyproline, glycine, 
alanine, and proline 
15-250 KDa 7-9 (Type 
A), 4-5 
(Type B) 
Albumin Plasma 
protein 
Single polypeptide with 585 
amino acids 
66 KDa 4.7 
Whey 
protein 
Milk protein α-lactoglobulin (LG), β-LG, 
lactalbumin, 
immunoglobulin, lactoferrin. 
β-LG-18 KDa 
α-LG-14 KDa 
3.5-5.2 
Casein Milk protein Proline- α s1, α s2, β and k 
subunits 
α s1-23 KDa 
α s2- 25 KDa 
β – 24 KDa 
k – 19 KDa 
4.6 
Zein Zea mays L. High proportion of glutamine 
and proline 
α-zein-22-24 
KDa, β-zein-
44 KDa, γ-
zein-14 KDa 
5.0-9.0 
Gliadin Wheat flour Glutamine, Proline 28-55 KDa 6.8 
Reproduced from Podaralla (2009). 
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1.5.2.1. Animal proteins 
1.5.2.1.1. Gelatin 
Gelatin is the hydrolytic product of collagen and has a long history of use in 
pharmaceutical industry as gelatin capsules (Marty, Oppenheim, and Speiser 1978; Ziv, 
Avtalion, and Margel 2008). Gelatin is non-toxic, non-immunogenic, cost-effective and 
can be easily modified to develop nanocarriers (Jahanshahi, Sanati, and Babaei 2008; 
Boulle et al. 2008). The presence of multiple ionizable functional groups in gelatin (-
COOH, -NH2, phenol, guanidine, imidazole) favors conjugation of a variety of molecules 
(Saxena et al. 2005; Shutava et al. 2009). However, unmodified gelatin is less stable and is 
water insoluble (Lohcharoenkal et al. 2014). Addition of cross-linking agent such as 
glutaraldehyde can overcome the limitations associated with gelatin’s stability and can be 
used to control the release of encapsulated drugs (Jameela and Jayakrishnan 1995). For 
example, glutaraldehyde cross-linked gelatin microsphere coated with alginate or chitosan 
improved the stability of gelatin microsphere and controlled the release of methotrexate 
after oral administration in rats (Narayani 1995). 
 
1.5.2.1.2. Albumin 
Albumin (66 kDa) can be obtained from different sources such as egg white, bovine 
serum albumin (BSA), and human serum albumin (HSA). Albumin maintains the osmotic 
pressure in human blood and is responsible for binding of nutrients. Albumin is highly 
soluble at physiological pH and is an attractive carrier due to its ability to bind to various 
molecules (Peters 1985). The reactive functional groups in albumin can be manipulated to 
conjugate drug molecules depending on the application (Casi and Neri 2012). For example, 
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emulsion solidification method has been used to prepare fluorouracil loaded BSA-alginate. 
The nanoparticles were found to be distributed in liver, kidneys, lungs and brain after oral 
delivery in rat (Yi, Yang, and Pan 1999).  The major limitation of natural protein polymers 
is batch-to-batch variation and may hinder the scaling-up for industrial application 
(Elzoghby, Samy, and Elgindy 2012). HSA is obtained by fractionation of human plasma 
and can carry bloodborne pathogens. However, recombinant HSA can overcome these 
limitations (Chuang, Kragh-Hansen, and Otagiri 2002). It is important to note that human 
serum albumin-bound paclitaxel (Abraxane®) is currently in clinical use for the treatment 
of breast cancer, lung cancer and pancreatic cancer.  
 
1.5.2.1.3. Milk proteins 
Milk proteins include casein (80%) and whey proteins (20%). (Livney 2010) Casein 
is a mixture of α-, β-, γ-, and κ-casein. Sodium caseinate is widely used as a stabilizer and 
emulsifier in dairy and food products (Kimpel and Schmitt 2015). Beta-casein is a globular 
protein and has been explored for oral delivery of hydrophobic molecules (Kytariolos et 
al. 2013; Bachar et al. 2012; Shapira et al. 2010). 
Whey protein is isolated from bovine milk has several proteins including β-
lactoglobulin, α-lactalbumin, lactoferrin, bovine serum albumin, immunoglobulins, 
glycomacropeptide, and enzymes. It is widely used for its nutritional value in infants and 
children due to the presence of essential amino acids (Baer et al. 2011; Coker et al. 2012; 
Miller, Alexander, and Perez 2014). β-lactoglobulin (LG) is a major protein in the whey 
protein and has been investigated as a carrier for drug and nutraceuticals, because of its  
ability to bind with lipophilic molecules (Dufour, Genot, and Haertle 1994) such as 
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retinoids (Collini, D'Alfonso, and Baldini 2000), hemin (Frapin, Dufour, and Haertle 
1993), aromatic and carcinogenic hydrocarbons (Farrell, Behe, and Enyeart 1987; Tavel et 
al. 2010), palmitic acids (Ragona et al. 2000; Wu et al. 1999), cholesterol and tocopherol 
(Wang, Allen, and Swaisgood 1997), omega-3-fatty acids (Zimet and Livney 2009), and 
anti-neoplastic agents (Eberini et al. 2008). β-lactoglobulin is relatively less affected by 
peptic enzymes and is a promising vehicle for oral delivery of therapeutics (Miranda and 
Pelissier 1983; Yvon et al. 1985). 
Lactoferrin is an iron-binding glycoprotein which possesses multiple biological 
activities including antibacterial, antiviral, antioxidant and anticancer activity (Baker and 
Baker 2009). Lactoferrin acts as a natural iron transporter and has been investigated as a 
ligand for targeting blood-brain barrier and intestinal epithelium through the transferrin 
receptors (Zhang, Wang, Ayman, et al. 2013; Singh et al. 2016). 
 
1.5.2.2. Plant proteins 
1.5.2.2.1. Gliadin  
Gliadin is a gluten protein found in wheat and is water-insoluble due to the presence 
of high proportions of glutamine and proline residues (Thewissen et al. 2011; Delcour et 
al. 2012). Gliadin proteins are divided into two groups based on solubility. These includes 
monomeric gliadin (soluble in 70% alcohol) and polymeric glutenin (insoluble precipitate). 
The presence of neutral and hydrophobic amino acids in gliadin favors interaction with the 
epithelium by forming hydrogen and hydrophobic bonds (Ramteke and Jain 2008). Gliadin 
can also interact with mucin due to the presence of disulfide groups (Arangoa et al. 2001; 
Gulfam et al. 2012). Gliadin based nanoparticles have been tested for oral delivery of 
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retinoic acid and vitamin E (Duclairoir et al. 2003). However, some individuals with gluten 
intolerance can be sensitive to gliadin, thus limiting its application as a drug carrier 
(Ciclitira et al. 2005; Dewar, Pereira, and Ciclitira 2004; Friis 1996; Joye, Nelis, and 
McClements 2015).  
 
1.5.2.2.2. Zein 
 Zein is one of the few water-insoluble natural proteins with a high proportion 
(>50%) of hydrophobic amino acids (proline, alanine, and leucine). It is the major storage 
protein in corn and is composed of α, β, γ, and δ zein, classified based on the solubility in 
hydroalcoholic solvents (Joshi et al. 2015). Commercial zein is mainly composed of α-zein 
(22−27 kDa). Zein is a US-FDA approved Generally recognized as safe (GRAS) material 
and is widely used in the food and packaging industries to provide an impervious moisture 
barrier (Corradini et al. 2014). Zein has also been used to encapsulate hydrophobic 
compounds and sustain the release from microspheres, nanoparticles, and nanofibers 
(Table 7) (Zhang, Cui, Che, et al. 2015; Gong et al. 2011; Hashem et al. 2015; Zhang, Cui, 
Chen, et al. 2015; Zhang et al. 2016). However, Zein nanoparticles exhibit poor colloidal 
stability leading to particle aggregation and thus require additional polymer or other 
materials to form stable nanoparticles (Joye, Davidov-Pardo, and McClements 2015; Chen 
and Zhong 2014).  
 
1.5.2.2.3. Soy proteins 
Soy protein isolate (SPI) contains a high concentration of protein rich in essential 
amino acids. Glycinin and β-conglycinin constitutes the major portion of SPI (Yaklich 
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2001). The presence of polar, non-polar and charged amino groups facilitates the 
incorporation of a variety of drug molecules (Teng, Luo, and Wang 2012).  The globular 
protein forms a hydrophobic core in the presence of water and the addition of crosslinking 
agent leads to aggregation and formation of microspheres (Lazko, Popineau, and Legrand 
2004). Curcumin nanocomplexation with SPI significantly enhanced the solubility of 
curcumin and stability in GI tract (Table 7) (Chen, Li, and Tang 2015). The 
physicochemical properties of SPI are variable and dependent on nature and composition 
of starting materials (defatted soy flour or flakes), processing and preparation procedure 
used, and environmental conditions (Liu and Tang 2013; Keerati and Corredig 2009). In 
addition, some portion of SPI remains as aggregated particles during the process of 
isolation of SPI from its starting materials, and the surface hydrophobicity significantly 
increases with heat treatment (Keerati and Corredig 2009; Liu and Tang 2013).  
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Table 7: Natural protein polymers for oral drug delivery applications. 
Protein polymers Drugs Findings Reference 
Zein nanoparticles  Folic acid Two-times higher oral 
bioavailability of folic acid 
compared to free folic acid. 
Peñalva (2015) 
Zein-alginate nanoparticles Superoxide 
Dismutase 
Reduced intracellular reactive 
oxygen species. 
Lee, Kim, and Park (2016) 
Zein nanoparticles Quercetin Sustained plasma level of 
quercetin and anti-inflammatory 
activity. 
Penalva et al. (2017) 
Compressed zein microsphere Ivermectin Increased oral bioavailability of 
ivermectin in dogs. 
Gong et al. (2011) 
Zein microsphere Aceclofenac 
sodium 
Sustained release oral drug 
delivery system. 
Karthikeyan et al. (2012) 
Casein nanoparticles Cisplatin Increased oral absorption of 
cisplatin.  
Zhen et al. (2013) 
Casein nanoparticles Flutamide Enhanced oral bioavailability of 
flutamide for the treatment of 
prostate cancer. 
(Elzoghby, Helmy, et al. 2013b, 
2013a; Elzoghby, Saad, et al. 
2013) 
Bovine Lactoferrin Doxorubicin Increased doxorubicin 
bioavailability in hepatic tumor 
model. 
Golla et al. (2012) 
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β-Casein Nanomicelles 
 
Paclitaxel Increased stability and availability 
of paclitaxel in gastric carcinoma 
animal model. 
 
Bar-Zeev, Assaraf, and Livney 
(2016) 
β-Casein micelle Curcumin Increased solubility and cell 
uptake of curcumin in human 
leukemia cells. 
Esmaili et al. (2011) 
β-Lactoglobulin nanoparticles Epigallocatechin 
gallate (EGCG)  
Prevent oxidation and degradation 
of EGCG 
(Li et al. 2012; Shpigelman, 
Cohen, and Livney 2012) 
β-Lactoglobulin nanoparticles Curcumin Enhanced Solubility of curcumin  Teng, Li, and Wang (2014) 
Nanocomplexation of curcumin with 
soy protein isolate nanoparticles 
Curcumin Enhanced antioxidant properties of 
curcumin 
Tapal (2012) 
Nanocomplexation of curcumin with 
Soy Protein Isolate nanoparticles 
Curcumin Significantly enhanced solubility 
and permeability of of curcumin 
Chen, Li, and Tang (2015) 
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1.6. Scope and objectives  
Food-grade polymers are promising materials for developing oral drug delivery 
systems due to their biocompatibility and proven safety. This study focuses on the use of 
food protein-based nanoparticles/micelles for oral drug delivery applications. 
Zein has been used to form nanoparticles for various drug delivery applications 
(Penalva et al. 2017; Irache and Gonzalez-Navarro 2017; Penalva et al. 2015; Luo et al. 
2013; Podaralla and Perumal 2012). However, in the absence of a stabilizer, zein 
nanoparticles tend to aggregate (Davidov-Pardo et al. 2015; Chen and Zhong 2014). To 
this end, the goal of this study is to develop stable core-shell nanocarriers using other 
proteins or polymers as shell. The overall goal of this study was to systematically study the 
influence of shell composition on the physicochemical and functional performances of zein 
nanocarriers for oral drug delivery applications. The study was based on the hypothesis 
that the hydrophobic core can be used to encapsulate water-insoluble compounds and 
achieve sustained release, while the shell biopolymer can be used to provide unique 
functional characteristics and good sensory properties for oral drug delivery applications.  
Six different core−shell nanocarriers were prepared including zein-β-casein (ZC) 
nanoparticles, zein-lactoferrin (ZLF) nanoparticles, zein-polyethylene glycol (ZPEG) 
micelles, zein-β-lactoglobulin (ZLG) nanoparticles, zein-whey protein isolate (ZWP) 
nanoparticles and zein-pluronic-lecithin (ZPL) nanoparticles. The core-shell nanocarriers 
in addition to stabilizing the zein core, offers the following advantages i) enhanced 
dispersibility and enzymatic stability, ii) sustained drug release, and iii) enhanced 
permeability and bioavailability of encapsulated drugs.  
58 
 
The overall goal is to demonstrate the feasibility and application of core-shell 
nanocarriers for oral drug delivery. 
 
To achieve this goal, following were the specific aims of this study:  
Objective 1: Preparation and study of the structure-function relationship of core-shell zein 
nanocarriers for oral drug delivery applications. 
 
Objective 2: Use of core-shell nanocarriers for oral delivery of a model antiretroviral 
drug. 
 
Objective 3: Use of core-shell nanocarriers for oral delivery of an investigational anti-
cancer drug molecule. 
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CHAPTER TWO 
PREPARATION AND STUDY OF THE STRUCTURE-FUNCTION 
RELATIONSHIP OF CORE-SHELL NANOCARRIERS 
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2.1. Introduction 
 
Given that oral delivery is the most common and convenient route of drug 
administration with high patient compliance, several strategies (nanoparticles, micelles, 
emulsions, and lipid-based carriers) have been explored to address the oral delivery 
challenges (Agrawal et al. 2014; Zhang, Wang, Zhang, et al. 2013; Kohli et al. 2010; 
Simoes et al. 2015). Considering the versatility of nanocarriers for oral drug delivery 
applications, a wide range of materials (natural and synthetic polymers) have been tested 
for developing nanoformulations (Agrawal et al. 2014; Zhang, Wang, Zhang, et al. 2013). 
However, very limited studies have focused on the development of nanocarriers for 
pediatric oral drug delivery. The major concern in developing nanocarriers in general and 
pediatric in particular to ensure that excipients are safe.  
Given the dynamic change in physiology from birth through adolescence, 
development of medicines for pediatrics remains a challenge in formulation development 
(Ivanovska et al. 2014; Nahata 1999). The Pediatric Research Equity Act (PREA) was 
introduced in 2012 (Christensen 2012; Ren and Zajicek 2015). The Best Pharmaceuticals 
for Children Act (BPCA) and Pediatric Research Equity Act (PREA) together was 
introduced to develop safe and effective medicines for pediatric patients (Ren and Zajicek 
2015; Christensen 2012). Formulations developed for adult per say may not suitable for 
pediatric patients. The excipients that are suitable for adults may not necessarily be safe 
for pediatrics. Therefore, a comprehensive assessment of the excipients is essential before 
in pediatric drug formulations (Schmitt 2015; Salunke et al. 2013; Salunke, Giacoia, and 
Tuleu 2012). There have been some efforts to develop easy, reliable, and flexible pediatric 
formulations such as minitablets, pellets, orally dispersible tablets, chewable tablets, 
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powders for reconstitutions, liquid syrup, and suspension (Ivanovska et al. 2014). 
However, there is an unmet need especially to improve the oral bioavailability of drugs 
with poor physicochemical properties.   
In this regard, food-grade biopolymers especially protein polymers are promising 
for developing oral drug delivery vehicles since they are edible, safe and biocompatible. 
Protein polymers that have been explored for oral drug delivery applications include 
gelatin, casein, whey proteins, soy proteins, zein, and wheat proteins (Arangoa et al. 2001; 
Liu et al. 2005). Zein is a water-insoluble protein GRAS protein polymer that is widely 
used in food and packaging industry (Corradini et al. 2014). Zein has been used to 
encapsulate hydrophobic compounds and sustain the release from microspheres, 
nanoparticles, and nanofibers (Zhang, Cui, Che, et al. 2015; Gong et al. 2011; Hashem et 
al. 2015; Zhang, Cui, Chen, et al. 2015; Zhang et al. 2016). However, zein nanoparticles 
exhibit poor colloidal stability leading to particle aggregation (Joye, Davidov-Pardo, and 
McClements 2015; Chen and Zhong 2014). To this end, the main goal of this study is to 
develop zein-based nanocarriers using different food-grade biocompatible polymers as 
stabilizers on the outer shell of the nanocarrier. The focus of this study is to systematically 
investigate the influence of shell composition on the physicochemical and functional 
performance of core-shell zein nanocarriers for oral delivery applications. 
In this study, milk proteins including casein whey protein as a whole or individual 
proteins ( (lactoglobulin and lactoferrin which differ in their physicochemical properties 
were used (Livney 2010). Beta-casein can form microsphere and micelles, and it has been 
explored as an oral drug delivery vehicle for hydrophobic compounds (Willmott et al. 
1992). Beta-casein is comparatively more hydrophobic among the milk proteins and 
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therefore can stabilize zein nanoparticles by utilizing hydrophobic interaction between zein 
and casein. Whey protein which is isolated from bovine milk has several proteins (β-
lactoglobulin, α-lactalbumin, lactoferrin, bovine serum albumin, immunoglobulins, 
glycomacropeptide, and enzymes) and is widely used for its nutritional value in infants and 
children due to the presence of essential amino acids (Coker et al. 2012; Miller, Alexander, 
and Perez 2014). β-lactoglobulin (LG) is the major portion of Whey protein and has been 
investigated as drug or nutraceutical carrier for its binding capacity with lipophilic 
molecules (Dufour, Genot, and Haertle 1994; Collini, D'Alfonso, and Baldini 2000; Frapin, 
Dufour, and Haertle 1993; Farrell, Behe, and Enyeart 1987; Tavel et al. 2010; Ragona et 
al. 2000; Wu et al. 1999; Wang, Allen, and Swaisgood 1997; Zimet and Livney 2009; 
Eberini et al. 2008). β-lactoglobulin was less affected by peptic enzymes and is a promising 
vehicle for oral delivery of therapeutics. (Miranda and Pelissier 1983; Yvon et al. 1985). 
Lactoferrin (LF) is an iron-binding glycoprotein that belongs to the transferrin family 
(Baker and Baker 2009). Lactoferrin has a high nutritional value for infants and children 
as an iron transporter. (Manzoni 2016). It also has been used as targeting ligand for 
improving the delivery across the blood−brain barrier and intestinal epithelial barrier 
through lactoferrin receptors. (Singh et al. 2016; Zhang, Wang, Ayman, et al. 2013). 
 Nanoparticles prepared using zein per se results in larger particles with wide size 
distribution, particle aggregation, and low drug encapsulation. Our lab previously has 
reported the use of pluronic F68 and lecithin to stabilize zein nanoparticles and achieve 
higher drug encapsulation (Podaralla and Perumal 2010). A combination of pluronic F68 
and lecithin in 2:1 ratio stabilized the zein nanoparticles (Podaralla and Perumal 2010, 
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2012). In this study, we will explore the use of zein-pluronic-lecithin (ZPL) nanoparticles 
for oral drug delivery.    
Polyethylene glycol (PEG) is an FDA approved biocompatible polymer that has 
been used to modify the surface of nanoparticles and proteins (D'Souza A and Shegokar 
2016). Further, PEG is a widely used water-soluble excipient in oral and other formulations 
(D'Souza A and Shegokar 2016). Earlier research from our group has demonstrated the 
ability of PEGylated zein to form self-assembled micelles with hydrophobic zein as the 
core and hydrophilic PEG chain as the shell (Podaralla et al. 2012). The PEG-zein (ZPEG) 
micelles enhanced the aqueous solubility and chemical stability of curcumin, a water-
insoluble anticancer agent. Further, the curcumin-loaded PEG-zein micelles showed higher 
cell uptake than free curcumin in drug-resistant cancer cells and reduced the IC50 value of 
curcumin by 3-fold (Podaralla et al. 2012). However, the ZPEG micelles is yet to be 
investigated for oral drug delivery. 
In this study, six different core−shell nanocarriers were prepared including zein-β-
casein (ZC) nanoparticles, zein-lactoferrin (ZLF) nanoparticles, zein-polyethylene glycol 
(ZPEG) micelles, zein-β-lactoglobulin (ZLG) nanoparticles, zein-whey protein isolate 
(ZWP) nanoparticles and zein-pluronic-lecithin (ZPL) nanoparticles. The six nanocarriers 
differ in their surface charge and hydrophilicity. The influence of shell composition on the 
physical stability, enzymatic stability, release kinetics, cell/tissue uptake, intestinal 
permeability, and in vivo biodistribution of zein nanocarriers was evaluated. Nile red (NR) 
was used as a model hydrophobic compound for in vitro studies, while Cy 5.5, a near-
infrared dye, was used for the in vivo imaging studies. 
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Specific aims of this study were: 
i) To develop and characterize zein-based core-shell nanocarriers. 
ii) To test the release of encapsulated Nile Red (NR) from the nanocarriers in 
simulated gastrointestinal fluids. 
iii) In vitro cell uptake studies in Caco-2 cells to determine the kinetics and the 
mechanism of cell uptake of the nanocarriers. 
iv) Test the bioadhesive properties of the core-shell nanocarriers. 
v) Oral immunogenic studies of core-shell nanocarriers in mice. 
vi) Oral biodistribution of core-shell nanocarriers in rats.  
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2.2. MATERIALS AND METHODS 
2.2.1. Materials 
White zein (Zein F-4000) was purchased from Freeman Industries Inc, (Tuckahole, 
NY, USA). Nile red, β-casein, β-lactoglobulin, and D-α-Tocopherol polyethylene glycol 
1000 succinate (TPGS 1000) were purchased from Sigma-Aldrich Company (St. Louis, 
MO, USA). Bovine lactoferrin and whey protein isolate were provided by Dr. Hasmukh 
Patel from the Department of Dairy Science, South Dakota State University. Trehalose was 
obtained from Acros Organics (Bridgewater, NJ, USA). Precast-Gels and reagents for 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were purchased 
from Bio-Rad (Hercules, CA). Pepsin, trypsin, sodium azide and Dulbecco’s Modified 
Eagle Medium were purchased from Fisher Scientific (Bridgewater, NJ, USA). Dialysis 
membrane (MWCO 10 kDa) was purchased from Spectrapor (Houston, TX, USA). 
ProLong Gold Antifade mounting medium with DAPI was purchased from Invitrogen-
Molecular Probes (Eugene, OR, USA). Polyethylene glycol (PEG, 5kDa) was purchased 
from Jenkem Technology (Plano, TX, USA). Cyanine 5.5 NHS ester dye was purchased 
from Lumiprobe (Hallandale Beach, FL, USA).  
 
2.2.2. Preparation of zein-based core-shell nanocarriers 
The core-shell nanoparticles were prepared using the phase separation method 
based on differential solubility of zein and milk proteins (Alqahtani et al. 2017; Podaralla 
et al. 2012). Briefly, 15 mg of zein was dissolved in 2 mL of 90% ethanol containing 1 mg 
of Nile red (NR) or Cy5.5 dye. The alcoholic phase was added dropwise under probe 
sonication (Sonics & Materials, Inc., Danbury, CT, USA) to the aqueous phase consisting 
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of 15 mL 0.1 M citrate buffer (pH 7.4) and 0.2% w/v of milk protein (β-casein or 
lactoferrin) or pluronic (0.9%, w/v)-lecithin (0.45%, w/v) (PL).  
Zein-β-lactoglobulin (ZLG) and zein-whey protein isolate (ZWP) nanoparticles 
were prepared by preheating 15 mg of β-lactoglobulin (LG) or whey protein isolate (WP) 
in 15 mL of 0.1 M citrate buffer (pH 6.8) for 30 minutes at 60°C before adding in zein 
hydroalcoholic solution. The resulting colloidal dispersion was placed on a magnetic stirrer 
(200 rpm) for 3 hours to evaporate the ethanol. The nanoparticles were separated using 
centrifugal filter (10 kDa MWCO) (EMD Millipore, Billerica, MA, USA) at 4000 rpm and 
washed with deionized water to remove the free NR or Cy 5.5. Trehalose (30 mg) was 
added as a cryoprotectant before lyophilization. The lyophilized formulations were stored 
in a desiccator at 4°C until further use. 
 
Polyethylene glycol (PEG5000) was conjugated to zein to prepare PEGylated zein 
micelles as reported earlier (Podaralla et al. 2012). Briefly, zein and methoxy PEG-
succinimidyl succinate (5KDa) in the weight ratio of 1:2 (zein: mPEG ester) were dissolved 
in 90% ethanol and incubated overnight. The reaction was stopped by adding 1 M of 
glycine followed by dialysis (10 kDa MWCO) for 24 h against water to remove the free 
PEG. To prepare the micelles, NR or Cy 5.5 was dissolved in 20 mL of 90% alcohol along 
with zein-PEG (5.5 × 10−2 g/L), and the mixture was stirred overnight in a magnetic stirrer 
to allow for partitioning of the dye into the hydrophobic zein core. Ethanol was removed 
using a rotary evaporator, and the resultant film was hydrated with citrate buffer (pH 7.4) 
to form ZPEG micelles. The mixture was dialyzed (10 kDa MWCO) against deionized 
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water (100 mL) to remove the free dye. The dye-loaded ZPEG micelles was lyophilized 
and stored in a desiccator at 4°C until further use.  
 
2.2.3. In vitro characterization and optimization 
The particle size, size distribution, and zeta potential were determined using the 
Malvern Zetasizer Nano-ZS (Malvern Instruments Inc., Southborough, MA) by dispersing 
lyophilized nanoparticles in deionized water (0.1 mg/mL). For morphological analysis, the 
nanocarriers were visualized by transmission electron microscopy (TEM). The specimen 
was prepared by placing a dilute dispersion of the nanoparticles on carbon-coated 200 mesh 
copper grid and the sample was evaporated overnight. TEM images were acquired using a 
Tecnai Spirit G2 TEM (FEI, Hillsboro, OR, USA), operated at an accelerating voltage of 
120 kV.  The electron micrographs were recorded using Orius SC200 CCD camera coupled 
to TEM. Image analysis was performed using Digital Micrograph software.  
 
2.2.4. Determination of Nile Red (NR) encapsulation efficiency 
Briefly, 5 mg of NR loaded lyophilized particles was dispersed in deionized water 
and centrifuged at 14000 rpm for 10 minutes. After decanting the supernatant, the 
nanoparticles were digested in 90% alcohol to extract the encapsulated NR. The 
concentration of NR was determined using a calibration curve (0.2 to 5µg/ml) of NR in 
90% alcohol. The samples were analyzed by spectrofluorimetry (SpectromaxM2, 
Molecular Devices, Sunnyvale, CA) using the excitation and emission wavelength of 559 
and 629 nm respectively. The encapsulation efficiency (EE%) was calculated using the 
following equation 
NR Encapsulation Efficiency (%) = 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑁𝑅 𝑖𝑛 𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓  𝑎𝑑𝑑𝑒𝑑 𝑁𝑅
 x 100 
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2.2.5. In vitro Release of NR 
The in vitro release of NR from the nanocarriers was determined in simulated 
gastric (SGF) and intestinal fluid (SIF). SGF was prepared using 0.1 M HCl and 0.32% 
w/v pepsin (pH 1.2), while SIF was prepared using 0.05M KH2PO4 with 0.1 M NaOH (pH 
7.5) and 1% w/v pancreatin. For release studies, 20 mg of NR loaded nanocarriers (ZC, 
ZLF, ZLG, ZWP, ZPL, and ZPEG) was suspended in 5 ml release medium and placed in 
a dialysis cassette (EMD Millipore, 10KDa MWCO). The cassette was placed in 200 ml 
release medium containing Tween 80 (0.1% v/v) to maintain sink conditions. At pre-
determined intervals, 1 ml of the release medium was removed and replaced with an equal 
volume of release medium. The sample was mixed with 1ml of ethanol, and the 
concentration of NR was determined by spectrofluorimetry as described earlier. 
 
2.2.6. Enzymatic degradation of core-shell nanocarriers 
The degradation profile of nanoparticles was determined by incubating the 
nanoparticles in simulated gastric fluid (SGF) and intestinal fluid (SIF) for up to 4 hours. 
The samples were analyzed by SDS-PAGE gel electrophoresis (12%). ZC and ZLF was 
stained with Coomassie blue, while for ZPEG, ZLG, and ZWP the gels were stained with 
Gel Code Blue Staining Reagent (Life Technologies).  
 
 
2.2.7. Influence of pH and ionic strength on nanoparticle stability 
To determine the effect of pH on particle size and zeta potential, lyophilized blank 
nanocarriers were dispersed in solution varying in pH from 2 to 10. The pH was adjusted 
using 0.1 M HCl or 0.1 M NaOH. Similarly, the effect of salt concentrations (0-200 mM 
of NaCl) on particle size and zeta potential of the nanocarriers were also determined. 
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2.2.8. Cell culture 
Caco-2 cells (ATCC, Rockville, MD, USA) cells were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) (4.5 g/L glucose) supplemented with 20% FBS 
(HyClone; Thermo Scientiﬁc, Waltham, MA, USA), 1% non-essential amino acids, 1% L-
glutamine, 1% streptomycin (100 μg/ml) and penicillin (100 IU/ml). The growth medium 
was changed every day in the first two weeks followed by replacement of the medium three 
times a week.  
 
2.2.9. Mechanism of cellular uptake of NR loaded nanocarriers 
Caco-2 cells were seeded in a 12-well plate at a concentration of 1 x 105 cells/well 
(passage number 10-15). Next day, the culture medium was removed, and the cells were 
treated with one µg of NR loaded different nanocarriers in Hank’s Balanced Salt Solution 
(HBSS) for 30 minutes to 2 hours at 37°C. At the end of the treatment period, the cells 
were washed with HBSS three times followed by trypsinization. The cells were washed 
with ice-cold HBSS and fixed using 2% paraformaldehyde. The mean fluorescence 
intensity was analyzed by flow cytometry (FACS, BD Biosciences, San Jose, CA). To 
understand the mechanism of cell uptake of the nanoparticles, the experiments were 
performed at 4°C and compared with the cell uptake at 37°C.  
In a separate set of experiments, Caco-2 cells were pre-incubated with endocytosis 
inhibitors including 1µM phenyl arsine oxide (PAO), 4µM Filipin and 10 µM Cytochalasin 
D for 30 minutes, followed by cell uptake experiment using 1 µg NR loaded nanocarriers 
for 2 hours.  
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2.2.10. Calcein uptake assay 
  For P-gp- inihibition assay, Caco-2 cells were seeded in a 96-well plate (1x104 
cells/mL) 24 hours before treatment with nanocarriers. Blank nanocarriers were dispersed 
in HBSS buffer (1 mg/mL) and cells were incubated with 50 μL of blank nanocarriers for 
30 minutes. Cells were washed three times with HBSS buffer followed by addition of 200 
μL of 0.5 μM calcein AM, a P-gp substrate (Molecular Probes, Eugene, OR, USA) and 
incubated for 2 hours. Cells were washed three times with ice-cold HBSS and lysed using 
0.5% Triton X-100. A control experiment was performed following the same procedure, 
but without the addition of nanocarriers. Calcein uptake was measured by 
spectrofluorimetric analysis using 485 and 530 nm as excitation and emission wavelengths 
respectively. To determine P-gp inhibition, the relative calcein fluorescence (FL) was 
calculated for the nanocarrier treated and non-treated groups using the following equation, 
% 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 = [
𝐹𝐿 (𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) − 𝐹𝐿(𝑛𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑒𝑑)
𝐹𝐿 (𝑛𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑒𝑑)
]𝑥100 
 
 
2.2.11. In vitro transepithelial transport of core-shell nanocarriers 
Caco-2 cells (1×105 cells/well) were seeded onto Transwell polyester insert (pore 
size 3.0 µm, surface area 1.12 cm2) in a 12-well plate (Transwell®, Corning Costar Corp., 
Cambridge, MA, USA). The cells were grown in an atmosphere of 5% CO2 and 95% air 
with 95% relative humidity at 37°C. The cells were allowed to grow for three weeks, and 
the formation of a monolayer was confirmed by measuring the transepithelial electrical 
resistance (TEER) using EVOM meter (Sarasota, FL). Before starting the experiment, the 
medium in the apical side was replaced with 2mg/ml of nanoparticle dispersion in Hank’s 
balanced salt solution (HBSS), and the permeability of NR loaded nanoparticles was 
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determined for 4 hours. Samples (200µl) were withdrawn from the basolateral 
compartment at pre-determined time points and replaced with an equal volume of fresh and 
pre-warmed HBSS buffer solution. The apparent permeability coefficient (Papp) was 
calculated using the following equation  
Papp (cm/s) = [
(dQ/dt)
𝐴𝐶𝑜
 ] x 100 
Where dQ/dt is the flux of NR across Caco-2 monolayer, C0 is the initial concentration of 
NR in the apical chamber, and A is the surface area of the 12-well plate Transwell insert 
(1.12 cm2).  
 
2.2.12. Cell uptake studies using confocal laser scanning microscopy 
To visualize the cell uptake of core-shell nanocarriers, Caco-2 cells (5x104 
cells/well) were seeded in a chamber slide (Nunc Lab-TEK®II Chamber SlideTM system, 
Thermo Scientific, Waltham, MA) and was incubated overnight. Next day, the growth 
medium was replaced with HBSS buffer (pH 7.4) and equilibrated for 30 min at 37°C. 
Then, the nanoparticle dispersion (500µg/mL) was added to the wells and incubated for 
30-60 min. At the end of treatment period, cells were washed three times with cold HBSS 
to remove the surface adsorbed nanoparticles. Cells were then fixed using 4% 
paraformaldehyde for 20 min at room temperature followed by staining F-actin with Alexa 
Fluor 488-Phalloidin (Life Technologies, Carlsbad, CA).  DAPI containing mounting 
medium (Vector Labs) was used to stain the nucleus. Images were taken using Olympus 
FluoView 1200 (FV 1200) confocal laser scanning microscope (CLSM) at a 60x 
magnification.  
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2.2.13. Ex vivo adhesion assay 
2.2.13.1. Everted sac method 
To determine the mucoadhesive properties of core-shell nanoparticles, everted sac 
method was used (Reineke, Cho, Dingle, Cheifetz, et al. 2013). Pig jejunum was procured 
from the Department of Animal Science at South Dakota State University. Briefly, a 
section of freshly collected pig jejunum (6 cm length) was everted using a glass rod to 
expose the mucosal side, and the open ends were tied to form a sac (Fig. 11). The loose 
mucus was removed from the intestine. The sac was filled with phosphate buffered saline 
glucose (PBSG). The everted sac was placed in NR loaded nanoparticle suspension (100 
mg/ml) in PBSG and incubated at 37˚C in a shaker water bath for 1 hour to allow time for 
the nanoparticles to adhere to the tissue. Fluorescent-labeled polystyrene nanoparticles 
(200nm, Phosphorex, Hopkinton, MA, USA) were used as a positive control. Following 
incubation, the everted sac was removed and processed (adherent mucus and remaining 
suspension collected as bound and unbound fractions, respectively) for determining the NR 
concentration by spectrofluorimetry. The ratio of NR concentration in the bound and 
unbound nanoparticles was used to calculate the percent adhesion. 
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Figure 13: Schematic presentation of everted sac method to test the bioadhesion of 
nanocarriers on the mucosal surface. Reproduced from Alam, Al-Jenoobi, and Al-Mohizea 
(2012). 
 
 
2.2.13.2. Determination of bioadhesive property of nanocarriers using Texture 
Analyzer 
The bioadhesive property of the nanocarriers was further determined using a texture 
(Reineke, Cho, Dingle, Cheifetz, et al. 2013). Bioadhesive property of the nanocarriers was 
determined by measuring the maximum force required to separate the nanocarriers from 
mucosal surface of the intestinal tissue (Thirawong et al. 2007).  Polystyrene nanoparticles 
(PS) (Phosphorex Inc., Hopkinton, MA, USA) of 200 nm size was used as a positive 
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control. Briefly, ‘T’ shapped metal-head probe was coated by dip and dry method using 
5% (w/v) aqueous nanoparticle dispersion. A thin uniform layer of the coat was obtained 
by repeated cycles of dipping and drying the metal head for eight times. The coated probe 
was then fitted in the loading arm of the texture analyzer. Freshly collected piglet jejunum 
was washed with pre-warmed oxygenated PBS (pH 7.4) and placed below the probe. The 
coated metal probe was programmed to descend at 0.5 mm/s until a final force of 5 g was 
achieved between the coated probe and the intestinal tissue. The probe was incubated for 
7 minutes to allow for interaction (Mathiowitz et al. 1997; Santos et al. 1999; Reineke, 
Cho, Dingle, Cheifetz, et al. 2013; Thanos et al. 2003) between the coated probe and 
intestinal tissue. Then the probe was ascended with the same speed, and the peak loads 
were recorded during start of the fracture between tissue and probe. The fracture strength 
was calculated and normalized using projected surface area (PSA). The following equation 
was used for calculation of PSA (Reineke, Cho, Dingle, Cheifetz, et al. 2013): 
PSA = 
1
2
× 6 × 𝑎 × ℎ 
Where, a is the length of each side of the hexagon and h is the radius of the probe surface.  
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Figure 14: Texture analyzer set up to determine the force required to remove nanoparticle 
coated probe from the excised intestinal tissue. Modified from Shaikh et al. (2011). 
 
 
 
 
2.2.14. Ex vivo tissue uptake studies in pig jejunum 
To determine the tissue uptake of NR loaded nanocarriers, pig jejunum was used.  
The jejunum was collected from 11-day old pig and maintained in Krebs buffer at 37°C. A 
6 cm jejunum was flushed with buffer, tied open ends, and filled with NR loaded 
nanocarriers (10µg/ml) followed by incubation in HBSS (pH 7.4) for 2 hours at 100rpm 
(37°C). At the end of the treatment, the jejunum was washed and fixed with 4% 
paraformaldehyde overnight at 4°C. The fixed tissue was embedded using optimal cutting 
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temperature medium (OCT), and 10µm sections were prepared using a cryo microtome 
(Leica, Buffalo Grove, IL). F-actin was stained with Alexa Fluor 488-Phalloidin and the 
nucleus was stained with DAPI. The images were taken at 20x magnification. 
 
2.2.15. Animal studies 
2.2.15.1. Immunogenicity studies 
Female Balb/c mice (4 weeks old) were used for the immunogenicity study. The 
experiments were conducted according to the approved protocol by the Institutional 
Animal Care and Use Committee (IACUC) at SDSU. Mice were randomly divided into 
five groups with four animals in each group. Nanocarriers (100µg of total protein) was 
administered by oral gavage at 0 and 3rd week (booster dose). Blood samples were collected 
from the retro-orbital plexus at 0, 3rd and 5th week. The samples were then processed to 
separate the serum and analyzed for IgG antibody titers. Intestinal contents were also 
collected and processed (Kim et al. 2002; Pecquet et al. 2000). to determine the mucosal 
IgA levels. Briefly, freshly collected intestinal contents were diluted in 1:32 (w/v) ratio of 
intestinal content and chilled PBS containing 50mM EDTA and 0.1mg/mL trypsin 
inhibitor. The samples vortex vigorously to disperse the tissue contents. Then the sample 
was centrifuged at 650g for 10 minutes. The supernatant was separated and mixed with 
0.03 mL of 100 mM phenyl methyl sulfonyl fluoride (PMSF). Then the sample was 
centrifuged at 27000xg for 20 minutes at 4°C to further clarify the secretions. Another 0.02 
mL of PMSF and 0.02 mL of sodium azide was added to each of the 2 mL clarified 
solutions. The solution was incubated for 15 minutes and 0.2 mL of fetal bovine serum 
(FBS) as added as substrate. The final samples were stored in -80°C until further analysis. 
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All the samples were analyzed for anti-zein, anti-ZC, anti-ZLF, anti-ZLG, anti-
ZWP and anti-ZPEG IgG and IgA antibodies by Enzyme-linked Immunosorbent Assay 
(ELISA). Briefly, 96-well plates were coated with 200ul of 0.1% (w/v) total protein 
(nanocarriers). After overnight incubation at 4°C, the plates were washed with buffer (PBS 
in 1% Tween 20) and blocked with 3% normal goat serum for 1 hour at 37°C. A second 
washing step was done with PBS buffer (pH 7.4), followed by incubation with 1/16 diluted 
mouse serum for 2 hours at room temperature. The intestinal samples were also analyzed 
to determine the level of IgA antibody. The plate was washed with PBS buffer (4 times) 
and incubated with Horse Reddish Peroxidase (HRP) conjugated goat anti-mouse IgG or 
anti-mouse IgA for 1 hour. Then the plate was washed for four times using PBS buffer and 
incubated with 100µL TMB (3, 3’, 5, 5’-tetramethylbenzidine) substrate. The reaction was 
stopped after 10 minutes using 50µL 1M H2SO4. The optical density was recorded at 450 
nm in a plate reader (SpectraMax2, microplate reader, Molecular Devices, Sunnyvale, CA). 
 
2.2.15.2. In vivo biodistribution 
To determine the in vivo oral biodistribution of core-shell nanocarriers, Cy 5.5, a 
near infra-red dye was used. Male Sprague-Dawley rats (6–8 weeks of age, 200-250 g) 
were used for the study. The animal studies were conducted after approval from IACUC at 
SDSU. The animals were acclimatized one week before the start of the study and had free 
access to water and food. Cy 5.5 loaded nanoparticles (50µg) were dispersed in water (2ml) 
and administered using a flexible oral gavage tube under mild isoflurane anesthesia. The 
time-dependent biodistribution (2, 6, 12, and 24 hrs) of nanocarriers was determined using 
the in-vivo imaging system (Xtreme, Bruker, Billerica, MA, USA). The free dye was used 
as a control. The animal was placed in the imaging chamber, and a short exposure of x-ray 
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was used to record the anatomy followed by determination of fluorescence. After 6 and 24 
hours, the animals were sacrificed, and the gastrointestinal tract (GIT) was separated, and 
the fluorescence was recorded using the in-vivo imaging system. All images were captured 
at 0.1-second exposure using the excitation and emission wavelengths as 690 and 750 nm 
respectively. Bruker MI software was used to process the images. 
 
2.2.15.3. In vivo tissue uptake studies through rat jejunum 
To determine the tissue uptake of Cy 5.5 loaded nanocarriers, the jejunum was 
collected at 6 hours after oral administration of nanocarriers and the tissue was fixed with 
4% paraformaldehyde overnight at 4°C. The fixed tissue was embedded using optimal 
cutting temperature medium (OCT), and 10µm sections were prepared using a cryo-
microtome (Leica, Buffalo Grove, IL). F-actin was stained with Alexa Fluor 488-
Phalloidin and the nucleus was stained with DAPI. The images were taken at 20x 
magnification. 
 
2.3. Statistical analysis 
All the experiments were conducted in triplicate. Data is represented as the mean ± 
standard deviation. Statistical evaluation was performed by one-way analysis of variance 
(ANOVA) followed by Tukey’s post-hoc test using Minitab® statistical software (Minitab 
Inc., State College, PA) at a significance level of p < 0.05. 
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2.4. RESULTS AND DISCUSSION 
 
Core-shell nanocarriers were developed using zein, a hydrophobic plant protein as 
the core and milk proteins (β-casein or lactoferrin or β-lactoglobulin or whey protein 
isolate), polyethylene glycol or pluronic-lecithin as the shell. The physicochemical 
characteristics of the six nanocarrier formulations is shown in Table 8. Part of the work 
related to zein-β-casein (ZC) nanoparticles, zein-lactoferrin (ZLF) nanoparticles and 
PEGylated zein (ZPEG) micelles was previously reported by us and reproduced here for 
comparison. 
 
2.4.1. Characteristics and Stability of core-shell nanocarriers 
All the three nanocarriers had a particle size in the range of 100-200 nm with a 
uniform size distribution, as seen from the low polydispersity index (Table 8). The 
nanoparticles in this size range have been reported to increase drug solubility and 
permeability through the membrane (Desai et al. 1996; Win and Feng 2005). 
The shell composition influenced the NR encapsulation efficiency in the 
nanocarriers (Table 8). Encapsulation efficiency was relatively high with ZLF followed by 
ZLG, ZPL, ZWP, ZC nanoparticles and ZPEG micelles (Table 8). The properties of the 
shell polymer and the kinetics of nanoparticle formation can influence the encapsulation 
efficiency of nanoparticles (Joye, Davidov-Pardo, and McClements 2015). On the other 
hand, similar loading efficiency with all the six formulations indicate that the loading 
efficiency is mainly influenced by the affinity of NR with hydrophobic zein core.  
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Table 8: Characteristics of NR loaded nanocarriers. 
Formulation Size (d.nm) PDI 
Zeta 
potential (mV) 
NR Encapsulation 
Efficiency (%) 
ZC nanoparticles 118.6 ±6.3 0.180 ±0.05 -36.3 ±4.5 71.6 ±9 
ZLF nanoparticles 175.2 ±6.8 0.251 ±0.02 28.6 ± 3.12 82.5 ±7 
ZPEG micelle 102.3 ±8.2 0.233 ±0.014 -1.63 ±4.3 56.1 ±4 
ZLG nanoparticles 222.7±14.0 0.09±0.019 -35.5±1.83 78.51±3.68 
ZWP nanoparticles 248.9±0.14 0.29±0.01 -29.7±1.55 74.68±1.04 
ZPL nanoparticles 291.86±2.89 0.34±0.065 -49.68±3.13 76.3±3.4 
PDI: Polydispersity Index; NR: Nile Red; ZC: Zein-β-casein nanoparticles; ZLF: Zein-
Lactoferrin nanoparticles; ZPEG: PEGylated zein micelles; ZLG: Zein-β-Lactoglobulin 
nanoparticles; ZWP: Zein-whey protein isolate nanoparticles; ZPL: Zein-Pluronic-Lecithin 
nanoparticles; Each value represents mean±SD (n= three different batches). Data for ZC, 
ZLF, and ZPEG is reproduced from our earlier study (Alqahtani et al. 2017) and included 
here for comparison. 
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The spherical morphology and the core-shell structure of the nanocarriers was 
confirmed from the TEM images (Fig. 15). The formation of core-shell architecture was 
further confirmed by the zeta potential values (Table 8). The negative zeta potential of ZC, 
ZLG, ZWP, and ZPL nanoparticles is attributed to β-casein, β-lactoglobulin, whey protein 
isolate, and lecithin respectively, while lactoferrin imparted a positive charge to the ZLF 
nanoparticles. The ZPEG micelles had a very weak negative charge and was close to zero.  
ZPEG micelles was characterized by MALDI-TOF analysis to determine the degree of 
PEGylation. The PEG is covalently conjugated to zein. MALDI-TOF analysis (Fig. 16) 
indicated that one PEG molecule covalently conjugated with zein where PEG provides a 
steric barrier against particle aggregation.  
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As can be seen from the TEM images, the nanocarriers were spherical with a  
 
 
 
 
 
Figure 15: TEM images of blank nanocarriers. ZC: Zein-β-casein nanoparticles; ZLF: 
Zein-Lactoferrin nanoparticles; ZPEG: PEGylated zein micelles; ZLG: Zein-β-
Lactoglobulin nanoparticles; ZWP: Zein-whey protein isolate nanoparticles; ZPL: Zein-
Pluronic-Lecithin nanoparticles; Representative images are presented here. TEM images 
for ZC and ZLF nanoparticles are reproduced from our earlier study (Alqahtani et al. 
2017) and is included here for comparison. Scale bar for ZC, ZLF is 100 nm, for ZPEG, 
ZLG, ZWP scale bar is 200 nm and for ZPL scale bar showing 500 nm. 
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Figure 16: MALDI-TOF analysis of free zein and ZPEG. 
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The nanocarriers were found to be stable at different pH encountered in the 
gastrointestinal tract and there was no significant particle aggregation (Table 9, 10 11, 12, 
13, and 14). Casein (pI= 4.6) is positively charged at acidic pH in the stomach and is 
negatively charged in the alkaline pH of the intestine (Tavares et al. 2014). Earlier studies 
have used sodium casein to stabilize zein nanoparticles, but significant aggregation was 
observed at pH close to the isoelectric point of casein (pH 3-5) (Joye, Davidov-Pardo, and 
McClements 2015; Patel, Bouwens, and Velikov 2010). Sodium casein contains a mixture 
of caseins (α, β and κ caseins) with different physicochemical characteristics (Cross et al. 
2005). The caseins differ in the number of hydrophilic and hydrophobic domains which in 
turn influences the interaction with zein (Cross et al. 2005). Patel et al. formed zein-sodium 
casein nanoparticles through electrostatic interaction between the zein and sodium casein 
by controlling the pH of the solution (Patel, Bouwens, and Velikov 2010). Unlike sodium 
casein, β-casein used in the present study stabilized the zein nanoparticles mainly through 
hydrophobic interactions.  
Lactoferrin (pI=8.7) is positively charged throughout the entire pH range of the 
gastrointestinal tract (Tavares et al. 2014). Zein, which is negatively charged at pH 7.4 
(pI=6.8), is stabilized through electrostatic interaction with the positively charged 
lactoferrin (Podaralla and Perumal 2012). However, there was a slight increase in the 
particle size of ZC and ZLF nanoparticles closer to the isoelectric pH of casein and 
lactoferrin respectively, as a result of a reduction in the electrostatic charge on the 
nanocarriers (Table 9 and 10).  
ZLG and ZWP nanoparticles has negative surface charge and the electrostatic 
repulsive force can prevent particle aggregation (Xiong 1992; Zhang and Zhong 2009). 
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ZLG and ZWP nanoparticles nanoparticles were found to be stable with respect to size, 
PDI and zeta potential when exposed to a wide range of pH (2-9) (Table 11 and Table 
12). β-Lactoglobulin is the major protein in whey protein isolate, and its isoelectric point 
is 5.3. (Aich, Batabyal, and Joardar 2015) Below the isoelectric point (pH 2.0) the surface 
zeta potential of both of ZLG and ZWP nanoparticles shifted towards positive zeta potential 
with less impact on particle size (Table 11 and Table 12). At lower pH (pH <4), the 
proteins used in our study are expected to be positively charged. This can lead to 
electrostatic repulsion resulting in desorption of the shell protein and particle aggregation. 
The fact that the nanocarriers did not aggregate signify that hydrophobic interactions and 
steric repulsion play a major role in preventing particle aggregation (Tokle, Mao, and 
McClements 2013). 
In case of ZPL nanoparticles, the particle size, PDI and zeta potential did not change 
at different pH (Table 13). The isoelectric point of lecithin is 4 and the presence of pluronic 
may reduce the influence of pH on size and surface charge of nanoparticles by providing a 
steric barrier (Chain and Kemp 1934). 
In case of ZPEG micelles, the particle size remains unchanged, except at pH 2, 
where the particle size increased (Table 14). Zein is known to undergo structural changes 
in acidic pH to form aggregates (Cabra et al. 2006). However, the zeta potential of ZPEG 
micelles did not change much with an increase in pH and stayed close to zero (Table 14). 
 
 
 
 
86 
 
Table 9. Influence of pH on particle size and PDI of zein-casein (ZC) nanoparticles.  
pH Particle size (nm) PDI 
2 146.7 ±12.27 0.110 ±0.008  
3 156.1 ±18.32 0.184 ±0.125 
4 179.9 ±11.23 0.128 ±0.058 
5 138.6 ±9.23 0.113 ±0.014 
6 135.8 ±8.91 0.095 ±0.014 
7 130.6 ±11.10 0.097 ±0.009 
8 132.7 ±11.31 0.093 ±0.011 
9 130.4 ±13.82 0.103 ±0.016 
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). This data is reproduced 
from our earlier study (Alqahtani et al. 2017) and is included here for comparison. 
 
 
Table 10. Influence of pH on particle size and PDI of zein-lactoferrin (ZLF) 
nanoparticles.  
PDI: Polydispersity Index Each value represents mean±SD (n= 3). This data is reproduced 
from our earlier study (Alqahtani et al. 2017) and is included here for comparison. 
 
 
pH Particle size (nm) PDI 
2 157.21 ±12.24 0.194 ±0.012 
3 179.55 ±7.93 0.189 ±0.035 
4 165.32 ±9.43 0.188 ±0.018 
5 181.63 ±8.71 0.167 ±0.018 
6 165.91 ±5.65 0.188 ±0.005 
7 175.21 ±6.8 0.251 ±0.02 
8 201.35 ±19.11 0.247 ±0.021 
9 202.15 ±17.29 0.289 ±0.013 
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Table 11. Influence of pH on particle size and PDI of zein-β-lactoglobulin (ZLG) 
nanoparticles. 
pH Particle Size 
(d.nm) 
PDI Zeta Potential (mV) 
2 248.43±3.36 0.18±0.01 -25.7±1.47 
3 248.66±2.80 0.12±0.03 -38.1±1.91 
4 263.42±3.94 0.189±0.02 -40.7±1.25 
5 268.17±8.78 0.20±0.025 -40.13±1.06 
6 251.7±9.79 0.13±0.05 -40.73±1.45 
7 242.5±5.28 0.064±0.04 -36.9±1.65 
8 251.63±6.08 0.12±0.02 -37.4±0.95 
9 270.1±17.74 0.26±0.02 -34.93±2.03 
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). 
 
 
Table 12. Influence of pH on the mean particle size and PDI of zein-whey protein isolate 
(ZWP) nanoparticles. 
pH Particle Size 
(d.nm) 
PDI Zeta Potential (mV) 
2 219.33±2.11 0.10±0.05 -27.43±1.79 
3 234.9±4.51 0.19±0.02 -36.53±1.95 
4 239.63±4.95 0.19±0.05 -35.5±1.56 
5 236.93±4.13 0.16±0.02 -36.9±1.44 
6 235.03±4.38 0.17±0.01 -36.16±1.66 
7 235.2±3.56 0.10±0.03 -33.8±3.17 
8 244.01±4.16 0.20±0.01 -34.7±1.3 
9 271.76±27.73 0.27±0.08 -32.43±2.87 
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). 
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Table 13. Influence of pH on mean particle size and PDI of zein-pluronic-lecithin (ZPL) 
nanoparticles. 
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). 
 
 
 
Table 14. Influence of pH on the mean particle size and PDI of PEGylated zein (ZPEG) 
micelles. 
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). 
 
 
 
 
pH Particle size (nm) PDI Zeta potential (mV) 
2 291.86±2.89 0.34±0.06 -49.68±3.13 
3 286.12±3.43 0.20±0.07 -45.05±1.25 
4 292.12±5.15 0.3±0.026 -50.58±3.24 
5 299.05±9.07 0.2±0.01 -52.34±1.26 
6 291.71±5.04 0.20±0.04 -42.89±5.32 
7 296.61±10.23 0.25±0.02 -48.87±3.56 
8 299.66±3.87 0.26±0.03 -46.57±6.89 
9 287.75±3.90 0.25±0.01 -53.66±4.98 
pH Particle size (nm) PDI 
2 161.76±6.98 0.25±0.012 
3 86.12±3.43 0.23±0.073 
4 92.12±9.15 0.25±0.026 
5 99.05±7.87 0.23±0.015 
6 91.71±8.14 0.23±0.043 
7 96.61±13.23 0.23±0.024 
8 99.66±3.87 0.21±0.031 
9 87.75±5.76 0.24±0.011 
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Nanocarriers were also stable at different ionic strength (Table 15, 16, 17, 18, 19, 
and 20). There was no significant change in the particle size of ZC and ZLF nanoparticles 
when exposed to ionic strength (10-200 mM), typically encountered in the gastrointestinal 
tract. However, the magnitude of the zeta potential decreased with increase in ionic strength 
for ZC and ZLF nanoparticles can be attributed to the electrostatic screening effect from 
the adsorption of counterions (sodium or chloride ions) around the charged nanoparticles 
(Table 15 and 16) (Tokle, Mao, and McClements 2013). 
ZLG and ZWP nanoparticles have negative surface charge and which prevented 
aggregation by electro repulsion. ZLG and ZWP nanoparticles were found to be stable at 
different ionic strength (10-500 mM). There was a change in surface charge with the 
increase in ionic strength (Table 17 and 18). The magnitude of change of zeta potential 
was higher for ZLG nanoparticles (-32.06 mV to -5.8 mV) compared to ZWP nanoparticles 
(-30.55 mV to -15.2 mV). This variation may arise from the presence of other proteins in 
whey protein isolate. A higher change in surface charge with higher ionic strength may be 
attributed to the adsorption of counterions on the nanoparticles (Tokle, Mao, and 
McClements 2013). Similar to the impact of pH, particle size and surface charge of ZPL 
nanoparticles remained unchanged at different ionic strength of the dispersing medium 
(Table 19). 
For ZPEG micelles, the particle size was relatively small at higher ionic strength 
(≥100 mM) (Table 20). Given that PEG-zein micelles has a weak charge, the adsorption 
of ions at higher ionic strength provided a charge barrier to prevent aggregation. However, 
no specific trend was observed in the zeta potential of ZPEG micelles with change in the 
ionic strength. 
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Table 15. Influence of ionic strength on particle characteristics of zein-casein (ZC) 
nanoparticles.  
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). This data is reproduced 
from our earlier study (Alqahtani et al. 2017) and is included here for comparison. 
Table 16. Influence of ionic strength on particle characteristics of zein-lactoferrin (ZLF) 
nanoparticles.  
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). This data is reproduced 
from our earlier study (Alqahtani et al. 2017) and is included here for comparison. 
 
 
 
Ionic strength 
(mM) 
Particle size (nm) PDI Zeta potential (mV) 
0 118.6 ± 6.3 0.18 ± 0.05 -36.3 ± 4.5 
10 131.7 ±13.29 0.085 ±0.025 -35.25 ±2.495 
20 134.2 ±12.02 0.115 ±0.015 -30.8 ±3.414 
50 128.9 ±13.15 0.105 ±0.016 -22.15 ±3.909 
100 130.7 ±14.35 0.106 ±0.018 -20.05 ±2.281 
150 128.8 ±12.73 0.108 ±0.021 -17.6 ±1.849 
200 133.4 ±12.15 0.092 ±0.018 -14.15 ±2.201 
Ionic strength (mM) Particle size 
(nm) 
PDI Zeta potential (mV) 
0 175.2 ±6.8 0.251 ±0.02 28.6 ± 3.12 
10 187.95 ±24.4 0.188 ±0.018 32.21 ±2.838 
20 174.35 ±27.08 0.197 ±016 26.85 ±4.849 
50 183.9 ±29.6 0.184 ±045 20.32 ±3.788 
100 175.35 ±24.11 0.187 ±0.021 14.85 ±2.758 
150 169.25 ±14.21 0.183 ±0.017 9.55 ±3.869 
200 175.1 ±32.9 0.191 ±0.030 6.19 ±2.687 
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Table 17. Influence of ionic strength on particle characteristics of zein-β-lactoglobulin 
(ZLG) nanoparticles. 
Ionic Strength (mM) Particle Size 
(d.nm) 
PDI Zeta Potential 
(mV) 10 256.7±7.85 0.07±0.03 -32.06±4.81 
20 260.26±7.23 0.14±0.005 -19.9±0.65 
50 257.66±3.84 0.12±0.02 -17.06±0.37 
100 270.56±2.11 0.15±0.02 -14.8±0.85 
250 249.43±2.65 0.09±0.07 -11.93±1.30 
500 258.43±2.63 0.16±0.04 -5.8±2.98 
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). 
 
 
Table 18. Influence of ionic strength on particle characteristics of zein-whey protein isolate 
(ZWP) nanoparticles. 
Ionic Strength (mM) Particle Size 
(d.nm) 
PDI Zeta Potential 
(mV) 10 280.9±3.93 0.23±0.047 -30.55±3.04 
20 264.63±2.3 0.15±0.057 -28.2±1.55 
50 260.1±6.18 0.19±0.078 -18.45±1.76 
100 253.66±6.68 0.08±0.039 -17.35±0.91 
250 257.1±3.11 0.17±0.036 -12.15±0.77 
500 267.7±4.10 0.11±0.066 -15.2±2.82 
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). 
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Table 19. Influence of ionic strength on mean particle size and PDI of zein-pluronic-
lecithin (ZPL) nanoparticles. 
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). 
 
Table 20. Influence of ionic strength on particle characteristics of PEGylated zein (ZPEG) 
micelles. 
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). 
 
The enzymatic stability of the core-shell nanocarriers was tested in SGF and SIF in 
presence of pepsin and pancreatin respectively. In general, all the six formulations were 
enzymatically more stable in SGF compared to SIF (Fig. 17 and 18). SDS-PAGE analysis 
indicating that nanocarriers are relatively stable in SGF in presence of pepsin (Fig. 17) 
while slow degradation was observed in SIF in presence of pancreatin (except ZPEG) (Fig. 
18).  
Ionic strength (mM) Particle size 
(nm) 
PDI Zeta potential 
(mV) 
0 289.81±2.12 0.31±0.06 -58.60±3.02 
10 280.02±5.65 0.25±0.17 -55.01±3.65 
20 288.12±6.54 0.3±0.06 -55.12±2.35 
50 290.5±8.70 0.3±0.01 -50.02±5.45 
100 292.70±6.14 0.30±0.05 -45.09±1.32 
150 300.61±8.93 0.26±0.01 -45.80±2.50 
200 296.06±5.80 0.27±0.02 -56.51±6.50 
Ionic strength (mM) Particle size 
(nm) 
PDI Zeta potential 
(mV) 
0 102.3 ±8.2 0.233 ±0.014 -1.63 ±4.3 
10 125.16±29.17 0.26±0.053 -4.21±1.67 
20 130.34±30.55 0.29±0.050 -0.85±0.37 
50 131.33±24.30 0.25±0.024 -2.30±2.33 
100 91.30±2.54 0.26±0.012 -1.26±0.233 
150 92.86±9.56 0.25±0.042 -1.07±1.43 
200 91.10±6.36 0.25±0.039 -0.96±0.83 
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This is in agreement with the reported enzymatic stability of the proteins used in 
our study (Hurtado-Lopez and Murdan 2006; Luo, Pan, and Zhong 2015; Lonnerdal, Jiang, 
and Du 2011). SDS-PAGE analysis indicating that nanocarriers are relatively stable in SGF 
in presence of pepsin (Fig. 17) while slow degradation observed in SIF in presence of 
pancreatin (Fig. 18).  
 
 
 
 
Figure 17: Enzymatic Stability of nanocarriers in Simulated Gastric Fluid (SGF) with 
pepsin after incubation for different time points and analyzed by SDS-PAGE. ZC and 
ZLF data is reproduced from our earlier study (Alqahtani et al. 2017) and included for 
comparison. 
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Figure 18: Enzymatic Stability of nanocarriers in Simulated Intestinal Fluid (SIF) with 
pancreatin after incubation for different time points and analyzed by SDS-PAGE. ZC and 
ZLF data is reproduced from our earlier study (Alqahtani et al. 2017) and included here for 
comparison. 
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2.4.2. In vitro release of NR from core-shell nanocarriers  
The in-vitro release of NR from the nanocarriers was tested in simulated gastric 
fluid (SGF) and simulated intestinal fluid (SIF). As can be seen from Fig. 19, the NR 
release was sustained from all the six nanocarriers, but the release kinetics was strongly 
influenced by the shell composition. PEG, which is the most hydrophilic polymer among 
the six formulations showed faster release (Fig. 19) and significantly higher burst release 
(20% within the first few hours). ZPL nanoparticles showed the slowest release of NR in 
both SGF and SIF. The release was relatively high in SIF compared to SGF for ZC 
nanoparticles, while the release was high in SGF for ZLF, ZPEG and ZLG formulations 
(Fig. 19). The low solubility of casein in acidic pH resulted in slow release in SGF 
compared to the release in SIF. Unlike ZLG, ZWP nanoparticles released less NR in SGF 
than in SIF.  
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Figure 19: Cumulative percent of NR release from different nanocarriers in presence of 
Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). ZC: Zein-β-casein, ZLF: 
Zein-lactoferrin, ZPEG: PEGylated zein, ZLG: Zein-β-lactoglobulin, ZWP: Zein-whey 
protein isolate. Each value represents mean±SD (n=3). Data for ZC, ZLF and ZPEG is 
reproduced from our earlier study (Alqahtani et al. 2017) and included for comparison. 
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To understand the release kinetics and to guide future formulation optimization, the 
data was fitted to different release kinetic models. The release of NR from the nanocarriers 
followed mixed order kinetics that was a combination of diffusion and erosion (Table 21). 
The release of the entrapped hydrophobic compounds from the zein matrix has been 
reported to occur through the diffusion-degradation mediated process (Liu et al. 2010; 
Parris, Cooke, and Hicks 2005). During the early phases, the drug release occurs mainly 
by diffusion through the protein matrix, while in the later phases; release is mediated by 
both diffusions of the entrapped molecule and enzymatic degradation of the protein itself 
(Parris, Cooke, and Hicks 2005). The release kinetics was influenced by the shell 
composition including the molecular weight, enzymatic stability, and hydrophobicity of 
the polymer. The initial release is controlled by the polymer swelling and diffusion through 
the swollen matrix, while erosion of the polymer controls the release at later time points 
(Hu et al. 2012). The release of NR from ZC nanoparticles showed a good fit to the Peppas 
model, indicating initial zero-order kinetics (by diffusion) followed by first-order kinetics 
(polymer erosion by hydrolytic and enzymatic degradation) in both SGF and SIF (Table 
21). ZLF nanoparticles showed a biphasic release with an initial burst release (~10%) from 
the NR trapped in the shell, followed by sustained drug release at later time points (Table 
21). In case of ZPEG micelles, the release followed first-order kinetics (Table 21) by 
hydrolytic and enzymatic degradation of zein. The release of NR from ZLG, ZWP and ZPL 
nanoparticles showed mixed order kinetics. However, ZLG, ZWP and ZPL nanoparticles 
showed a better fit to Peppas model indicating that NR release was diffusion controlled at 
the early phases followed by polymer erosion at later time points. The mixed order kinetics 
observed in this study agrees with reported studies for zein particulate systems in the 
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literature (Hu et al. 2012; Mehta, Kaur, and Verma 2011). The release did not directly 
correlate with the enzymatic stability of the core-shell matrix in SGF and SIF (Fig. 17 and 
18) This is because other factors (pH, ionic strength, etc.) may influence the release of NR 
from nanoparticles.  
The chemical properties of both the core and the shell dictate the extent of water 
diffusion and polymer erosion. For casein, which is relatively more hydrophobic of the 
among the milk protein-based shell composition, in the early stage of drug release the 
diffusion of water through the nanoparticle matrix appears to be the rate-limiting step, 
while for PEG-zein micelles, the polymer erosion appears to influence the release. On the 
other hand, ZLF nanoparticles appeared to show varying extent of diffusion-erosion to 
sustain the release of NR. For ZLG and ZWP nanocarriers, the relatively higher enzymatic 
stability causes slower surface erosion and controlled the release of encapsulated NR. In 
ZPL nanocarriers, the hydrophobic lecithin has a role in controlling the release of NR in 
SGF and SIF. In addition to polymer characteristics, the relative binding affinity of the 
encapsulant and the encapsulation/loading efficiency also can influence the release. 
Overall, results from this study demonstrate that the shell matrix has a strong influence on 
the drug release kinetics from the core-shell zein nanocarriers.  
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Table 21: Summary of nonlinear fit of NR release kinetics using different models. 
Formulation 
(Medium) 
R2 
 Peppas 
𝐹 = 𝐾 ∗ 𝑡𝑛 
Hixson-Crowell 
𝐹 = 100 ∗ (1 − (1 − 𝑘 ∗ 𝑡)^3) 
Zero Order 
C=C0-K0t 
First Order 
F=100*(1-exp(-k*t)) 
Higuchi 
F = k ∗ sqrt(t) 
ZC (SGF) 0.9758 0.8992 0.9233 0.8780 0.7007 
ZC (SIF) 0.9903 0.9902 0.9884 0.9903 0.8929 
ZLF (SGF) 0.9573 0.5202 0.7661 0.5976 0.9114 
ZLF (SIF) 0.9682 -0.4053 0.6926 -0.3524 0.6320 
ZPEG (SGF) 0.8146 0.4173 0.4368 0.9718 0.4450 
ZPEG (SIF) 0.8940 0.7376 0.6169 0.9501 0.7049 
ZLG (SGF) 0.9906 0.9838 0.9923 0.9771 0.8252 
ZLG (SIF) 0.9986 0.9238 0.9604 0.9212 0.6669 
ZWP (SGF) 0.9845 0.7870 0.9095 0.8157 0.9845 
ZWP (SIF) 0.9728 0.9729 0.9717 0.9655 0.8435 
ZPL (SGF) 0.976 0.972 0.970 0.974 0.852 
ZPL (SIF) 0.980 0.980 0.984 0.980 0.800 
SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R2 calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles, ZLF: 
Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein 
isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Highlighted values indicate the best fit model. 
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2.4.3. In vitro transepithelial transport and cell uptake of nanocarriers  
Caco-2 cells, a well-established model for oral drug transport was used to study the 
influence of shell composition on the in-vitro transepithelial transport and cell uptake of 
nanocarriers. The permeability of NR loaded nanoparticles was determined using polarized 
Caco-2 monolayers, and the formation of a polarized monolayer was confirmed from 
TEER measurements (>400 ohms/cm2). There was a time-dependent increase in the apical 
to basolateral transport of NR loaded nanoparticles (Fig. 20). ZPL nanoparticles showed 
the highest permeability, while ZC nanoparticles showed the lowest permeability among 
the six formulations. ZWP showed faster cell uptake than other nanocarriers. (Fig. 20) In 
general, the apparent permeability (Papp) increased over time for all the six nanocarriers. 
All the six nanocarriers increased the permeability of NR, and there was no detectable 
permeation of free NR under the experimental conditions. Apparent permeability of 
nanocarriers was in the following decreasing ranks order: 
ZPL>ZLG>ZPEG>ZWP≥ZLF>ZC (Fig 20). The nanocarriers did not affect the cell 
viability of Caco-2 cells (data not shown).  
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Figure 20: Transepithelial permeability of NR loaded nanocarriers across Caco-2 cell 
monolayers. Apparent Permeability coefficient (Papp) from apical to basolateral chamber 
(A→B) was determined at different time points. Each value represents mean±SD (n=4), 
*P<0.05 compared to free NR permeability. ZC, ZLF and ZPEG data is reproduced 
from our earlier study (Alqahtani et al. 2017) and included for comparison. 
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To confirm the transcellular uptake of the nanoparticles, the cell uptake studies 
were conducted using sub-confluent culture of Caco-2 cells. As shown in Figure 21, there 
was a time-dependent increase in the uptake of NR loaded nanoparticles. Unlike the 
transepithelial transport studies shown in Figure 21, ZWP nanoparticles showed the 
highest cell uptake, while ZC nanoparticles showed the lowest cell uptake among the six 
formulations (Fig. 21). This is contrary to the Papp values which may be attributed by the 
presence of minor proteins in whey protein isolate. For example, the presence of positively 
charged lactoferrin in whey protein isolate may favor the interaction with negatively charge 
cell membrane. In addition, lactoferrin receptor may also be involved in higher cell uptake. 
minor proteins in whey protein isolate may synergistically work with lactoglobulin for 
enhancing cell uptake, while delayed exocytosis due to minor proteins may explain the 
lower permeability in first two hours (Fig. 25). Further studies are required to understand 
the differences in cell uptake between the nanocarriers. 
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Figure 21. Flow cytometry analysis of time dependent cell uptake of free NR or NR 
loaded nanocarriers in Caco-2 cells. Each value represents mean±SD (n=3), *P<0.05. 
ZC, zein-casein nanoparticles; ZLF, zein-lactoferrin nanoparticles; ZPEG, zein-PEG 
micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP, zein-whey protein nanoparticles; 
ZPL, Zein-pluronic-lecithin nanoparticles. NR, ZC, ZLF and ZPEG data is from our 
earlier study (Alqahtani et al. 2017) and included for comparison. 
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There was less than 10% release of NR from the nanocarriers under the 
experimental conditions (data not shown here), signifying that most of the cell uptake is 
attributed to the encapsulated NR. The cell uptake decreased by 50% when the temperature 
was reduced to 4oC indicating that nanocarriers were taken up by energy-dependent process 
(Fig. 22).  
 
 
 
 
 
Figure 22: Cell uptake of NR loaded nanocarriers at 4°C and 37°C after incubation for 
2 hours. Each value represents mean±SD (n=4).  ZC and ZLF data is reproduced from 
our earlier study (Alqahtani et al. 2017) and included for comparison. 
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To determine the mechanism of cell uptake, different endocytosis inhibitors were 
used. When phenyl arsine oxide (PAO) was used as an inhibitor for clathrin-dependent 
endocytosis, the cell uptake of ZLF, ZPEG, ZLG, ZWP, and ZPL nanocarriers decreased 
by 50%, 36%, 39%, 52% and 65% respectively (Fig 23). On the other hand, there was only 
a slight decrease in the uptake of ZC nanoparticles. In presence of filipin, an inhibitor for 
lipid raft-mediated endocytosis, there was minimal decrease in the cell uptake of ZC, ZLF 
and ZPEG nanocarriers (12-25%), while cell uptake of ZLG, ZWP and ZPL nanocarriers 
significantly decreased (45-55%). Cytochalasin-D, an inhibitor for macropinocytosis, 
reduced the uptake of ZPEG, ZC, ZLG, ZWP and ZPL nanocarriers by 64%, 42%, 43%, 
32% and 31% respectively, while the uptake of ZLF nanoparticles was reduced by 20% 
(Fig 23).  
 
 
 
 
 
 
 
 
  
 
 
 
106 
 
 
 
The fluorescence microscopy studies showed that the nanoparticles were taken up 
by endocytosis, as evidenced from the punctuated fluorescence of NR loaded nanoparticles 
(Fig. 24). Images from confocal microscopy showed that all nanocarriers enhanced cell 
uptake compared to free NR control. The images are consistent with flow cytometry data 
indicating that ZWP and ZLG nanocarriers showed higher cell uptake among the six 
nanocarriers. ZC, ZLF, ZPEG and ZPL nanocarriers showed comparable cell uptake after 
incubation for 30 minutes (Fig. 24). 
 
Figure 23: Mechanism of in vitro cell uptake of NR loaded nanocarriers by Caco-2 
cells. Cells were treated with different endocytosis inhibitors for 30 minutes followed 
by cell uptake studies using different NR loaded nanocarriers. Each value represents 
mean ± SD (n=4).  ZC, ZLF and ZPEG data is reproduced from our earlier study 
(Alqahtani et al. 2017) and included for comparison. 
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Figure 24. Confocal microscopy images of polarized Caco-2 cells showing the 
internalization of Nile red (NR) loaded nanocarriers after 30 min incubation. Blue is 
nucleus stained with DAPI, green is Alexa Fluor 488 labeled with Phalloidin for F-actin, 
and red is NR loaded nanoparticles (magnification 60x). ZC, zein-casein nanoparticles; 
ZLF, zein-lactoferrin nanoparticles; ZPEG, zein-PEG micelles; ZLG, zein-lactoglobulin 
nanoparticles; ZWP, zein-whey protein nanoparticles; ZPL, Zein-pluronic-lecithin 
nanoparticles. Free NR, ZC, ZLF and ZPEG images are reproduced from our earlier 
study (Alqahtani et al. 2017) and included for comparison.  
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The cell uptake is strongly influenced by the particle size, surface charge and 
surface hydrophobicity of the nanoparticles (Bannunah et al. 2014). Nanoparticles can be 
taken up by non-specific and specific endocytosis pathways (Bannunah et al. 2014; He et 
al. 2013). Lactoferrin receptor is expressed in the intestinal epithelial cells, and they are 
mainly found in the clathrin vesicles (Jiang et al. 2011). The results from the competitive 
uptake studies and endocytosis inhibitor studies suggest that ZLF nanoparticles are taken 
up predominantly through lactoferrin receptor (Alqahtani et al. 2017). Nevertheless, the 
ZLF nanoparticles can also be taken up by non-specific endocytosis pathways. The 
positively charged ZLF nanoparticles can be taken up through adsorptive endocytosis by 
binding to the negative charge glycocalyx in the cell membrane (Bannunah et al. 2014). In 
contrast, the cell uptake of negatively charged ZC nanoparticles can be limited by the 
charge repulsion from the cell membrane. Macropinocytosis is a nonspecific process for 
the uptake of fluid and particles into the cells (He et al. 2013). The results from the 
endocytosis inhibitor studies suggest that both ZC nanoparticles and ZPEG micelles are 
predominantly taken up by macropinocytosis. Similarly, ZLG and ZWP nanoparticles are 
also predominantly taken up by macropinocytosis pathway. Our results are in agreement 
with the non-specific uptake of nanoparticles reported in the literature (Luo et al. 2013; 
Song et al. 2013). The formulations used in the present study showed 3 to 8-fold higher 
permeability compared to the permeability reported for zein-sodium casein nanoparticles 
(Luo et al. 2013). The β-casein unlike the sodium casein does not cause charge-induced the 
aggregation of zein particles, which may be attributed to the enhanced cell uptake of ZC 
nanoparticles (Alqahtani et al. 2017).  
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In case of beta-lactoglobulin, the amino acid sequence has similarity with lipocalin-
1 (Lcn-1), a ligand of lipocalin-interacting membrane receptor (LIMR) which is highly 
expressed in intestine (Fluckinger et al. 2008; Sawyer and Kontopidis 2000; Kontopidis, 
Holt, and Sawyer 2002). The presence of only beta-lactoglobulin on the surface of ZLG 
nanoparticles may favor the uptake by its receptor, although this was not investigated in 
this study. Unlike, ZLG, ZWP nanoparticles may be taken taken up by additional non-
specific endocytosis pathway, thus contributing to the higher uptake of ZWP nanoparticles 
(Fig 22 and Fig.23). ZPL nanoparticles was found to be taken up by both clathrin and 
caveolae-mediated endocytosis indicating that the shell components (pluronic and lecithin) 
in ZPL favored the interaction with clathrin-coated pit as well as lipid-rafts (Gu et al. 2016; 
Batzri and Korn 1975; Pagano, Huang, and Wey 1974). The difference in the transepithelial 
transport of the nanoparticles is influenced by the kinetics of the different endocytosis 
processes and the intracellular release of cargo from the nanocarriers.  
The efflux proteins expressed in the intestinal epithelial cells can prevent uptake of 
drug or nanocarriers. Previous results support our findings that PEG can inhibit P-gp 
activity although the mechanism remains to be elucidated (Shen et al. 2008). Pluronic F127 
was reported to inhibit P-gp (Wei et al. 2013) and used as positive control (Fig. 25). 
However, in spite of having pluronic F127 in ZPL nanoparticles, the presence of lecithin 
might be a contributing factor in the lower P-gp inhibitory activity of ZPL nanoparticles.   
(Fig. 25). Further studies are required to clarify the mechanism. ZLG and ZWP 
nanoparticles did not show P-gp inhibitory activity (Fig. 25).  ZC and ZLF nanoparticles 
showed small increase in calcein uptake with the increase in concentration of nanoparticles 
used for the treatment of cells.  
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Overall, the difference in the transepithelial transport of the nanoparticles is 
influenced by the kinetics of the different endocytosis processes and the intracellular 
release of cargo from the nanocarriers.  
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Figure 25. P-gp inhibition activity of nanocarriers by calcein AM uptake assay. Each 
value represents mean±SD (n=3). ZC, zein-casein nanoparticles; ZLF, zein-lactoferrin 
nanoparticles; ZPEG, zein-PEG micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP, 
zein-whey protein nanoparticles; ZPL, Zein-pluronic-lecithin nanoparticles. Pluronic 
F127 used as positive control. Data for ZC, ZLF and ZPEG P-gp iniibition assay is 
reproduced from our earlier study (Alqahtani et al. 2017) and included for comparison. 
X-axis represents nanocarrier concentration, Y-axis represents fluorescence intensity 
from calcein. 
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2.4.4. Oral biodistribution of nanocarriers  
 The in-vivo oral biodistribution of core-shell nanoparticles was studied in rats using 
Cy 5.5, a near-IR dye. The nanocarriers prolonged the retention of the Cy 5.5 dye up to 12-
24 hrs, while the free dye was cleared within 6 hrs. ZC, ZLG, ZWP and ZPL nanoparticles 
were found to be retained in the gastrointestinal tract for 24 hours, while the other two 
formulations (ZPEG and ZLF) were retained only up to 12 hours (Fig. 26 and 27). To 
confirm these results, the animals were sacrificed at 6 and 24 hours after oral administration 
to image the gastrointestinal tract. At 6 hours, all the six formulations were retained in the 
small intestine, with ZC, ZLG and ZWP nanoparticles compared to the other three 
formulations (Fig. 28). At 24 hours, there was still a strong signal from ZC, ZLG, ZWP 
and ZPL nanoparticles in the caecum and colon, while there was only a faint signal from 
the other two formulations (Fig 26). The tissue sections taken from the rat jejunum at 6 
hours showed that the nanocarriers were taken up by the epithelial cells in the villi through 
endocytosis, as evidenced from the punctuated fluorescence (Fig. 29). These results were 
consistent with ex-vivo tissue uptake studies in pig jejunum (Fig. 30). Among the six 
nanocarriers, ZPL and ZPEG nanocarriers showed higher uptake in intestinal epithelial 
tissue (Fig. 30). 
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Figure 26. Biodistribution of Cy 5.5 loaded nanocarriers after oral administration. 
Whole body image of rats at different time points and rat gastrointestinal tract 24 h after 
oral administration of nanocarriers. This is a representative image of four animals in 
each treatment group. ZC, zein-casein nanoparticles; ZLF, zein-lactoferrin 
nanoparticles; ZPEG, zein-PEG micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP, 
zein-whey protein nanoparticles.  
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Figure 27. Biodistribution of Cy 5.5 loaded nanoparticles after oral administration in rats. 
Images shows the fluorescence in rat gastro-intestinal tract 24 hrs after oral administration 
of nanoparticles. This is a representative image of four animals in each treatment group. 
ZC, zein-casein nanoparticles; ZLF, zein-lactoferrin nanoparticles; ZPEG, zein-PEG 
micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP, zein-whey protein nanoparticles; 
ZPL, Zein-pluronic-lecithin nanoparticles.  
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Figure 28. Biodistribution of Cy 5.5 loaded nanoparticles after oral administration in 
rats. Images shows the fluorescence in rat gastro-intestinal tract 6 hrs after oral 
administration of nanoparticles. This is a representative image of four animals in each 
treatment group. ZC, zein-casein nanoparticles; ZLF, zein-lactoferrin nanoparticles; 
ZPEG, zein-PEG micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP, zein-whey 
protein nanoparticles.  
 
ZC ZLF ZPEG 
ZPL 
ZLG ZWP 
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Figure 29: In vivo distribution of Cy 5.5 loaded nanocarriers in rat jejunum. Rats were 
sacrificed at 6 hours after oral delivery of nanocarriers.  The jejunum was separated, 
washed, fixed with 4% paraformaldehyde and sectioned for imaging by confocal 
microscopy. Magnification is 20X. 
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Figure 30: Ex vivo uptake of NR loaded nanocarriers in pig jejunum. Magnification is 
20X.  
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2.4.5. Ex vivo bioadhesion assay 
Since the nanocarriers were retained for a prolonged period in the gastrointestinal 
tract, the mucoadhesive properties were evaluated using everted pig jejunum and texture 
analyzer. All the six formulations were found to be mucoadhesive (Fig. 31 and 32) and 
were comparable to polystyrene nanoparticles, a known mucoadhesive polymer (Reineke, 
Cho, Dingle, Cheifetz, et al. 2013). ZLG and ZWP nanoparticles showed significant 
bioadhesive/mucoadhesive property among the six formulations (Fig. 31 and 32). 
Bioadhesion can occur through intermolecular interaction such as electrostatic attraction, 
hydrophobic interactions, hydrogen or disulfide bonding (Andrews, Laverty, and Jones 
2009; Sosnik A. 2014). Increased interaction of cationic polymers such as chitosan, 
lactoferrin and polylysine with anionic glycoproteins or glycolipids (abundant in small 
intestinal membrane) resulted in enhanced mucoadhesion and cell uptake (Liu 2012; 
Thongborisute and Takeuchi 2008; Bengoechea 2011; Tang et al. 2012). Cationization of 
beta-lactoglobulin was also reported to enhance interaction with negatively charged mucus 
(Teng et al. 2016; Teng et al. 2014; Teng et al. 2013). In addition, thermal denaturation of 
whey protein has previously been reported to show increased interaction with mucin by 
hydrogen and disulfide bonding (Hsein et al. 2015). ZLG and ZWP nanocarriers were 
prepared by pre-heating β-LG and WP which results in unfolding the protein and exposure 
of hydrophobic regions or thiol groups resulting in hydrophobic interaction with mucus 
layer.  Further, zein nanoparticles have been reported to show increased interaction with 
mucus layer by hydrophobic interaction (González-Navarro 2017; Penalva et al. 2015). 
Taken together, enhanced bioadhesive/mucoadhesive of ZLG and ZWP nanocarriers may 
be attributed to prolonged in vivo retention after oral delivery in rats.  
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Figure 31. Ex vivo mucoadhesion of Nile red (NR) loaded nanocarriers to pig jejunum 
after 1 h treatment. Y-axis represents the percentage of nanocarriers bound to the 
tissue. Each value represents mean ± SD of four independent experiments, *P<0.05 
compared to PS nanoparticles. PS, polystyrene nanoparticles used as positive control; 
ZC. zein-β-casein nanoparticles; ZLF, zein-lactoferrin nanoparticles; ZPEG, zein-
PEG micelles; ZLG. Zein-β-lactoglobulin nanoparticles; ZWP. Zein-whey protein 
nanoparticles; ZPL, Zein-pluronic-lecithin nanoparticles.  
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Figure 32. Ex vivo mucoadhesion of Nile red (NR) loaded nanocarriers using Texture 
Analyzer to determine fracture strength (mN) between Piglet jejunum and nanoparticle 
coated probes. Each value represents mean ± SD of four independent experiments, 
*P<0.05 compared to PS nanoparticles.  PS, polystyrene nanoparticles used as positive 
control; ZC. zein-β-casein nanoparticles; ZLF. zein-lactoferrin nanoparticles; ZPEG, 
zein-PEG micelles; ZLG. Zein-β-lactoglobulin nanoparticles; ZWP. Zein-whey 
protein nanoparticles; ZPL. Zein-pluronic-lecithin nanoparticles. 
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2.4.6. Immunogenicity of core-shell nanocarriers 
The nanocarriers were found to be non-immunogenic when orally administered to 
mice. The nanoparticles were administered during the first week followed by a second dose 
on the third week. There was no significant change in the serum IgG levels compared to 
the saline-treated group (Fig. 33).  
 
 
 
 
 
 
 
Figure 33: Oral immunogenicity of nanoparticles in mice. Serum IgG level determined 
after oral delivery of blank nanoparticles to Balb/c mice at 0 and 3rd week. Serum IgG 
was measured at 0, 3rd and 5 weeks. Each value represents mean±SD (n=4), *P<0.05. 
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The nanoparticles can be taken up by multiple pathways from the GIT. The 
intestinal epithelium consists of different cell types including enterocytes, mucin-secreting 
goblet cells, and M-cells. (Pridgen, Alexis, and Farokhzad 2015) The M-cells are 
associated with Peyer’s patches, which is part of the gut-associated lymphoid tissue 
(GALT). The M-cells in the intestine can take up the nanoparticles based on their charge, 
surface hydrophobicity and the presence of specific ligands (Beloqui, des Rieux, and Preat 
2016). The protein biopolymers used in this study are GRAS food proteins that are used 
for daily consumption.  In general, there is oral immune tolerance to commonly used food 
proteins (Pabst and Mowat 2012; Paula-Silva et al. 2015). Furthermore, the denaturation 
of the protein during the preparation of the nanoparticles can also reduce the 
allergenicity/immunogenicity of protein biopolymers (Livney 2010). Given that the M-
cells make up only 5-10% of the epithelium, the enterocytes serve as the major absorptive 
cell population in the intestine for endocytosis of nanoparticles (Pridgen, Alexis, and 
Farokhzad 2015; Beloqui, des Rieux, and Preat 2016; Sass, Dreyer, and Seifert 1990). 
However, the mucus covering the surface of the nanoparticles can limit drug absorption 
through the enterocytes (Lai, Wang, and Hanes 2009; Ensign, Cone, and Hanes 2012). To 
this end, the mucoadhesive polymers can interact with the intestinal mucus layer to increase 
the retention and absorption of encapsulated drug at the site of absorption (Smart 2005). 
As discussed in section 2.4.5., different shell structure can interact differently with the 
mucus in GI tract. Although, zein protein has mucoadhesive property (Irache and 
Gonzalez-Navarro 2017), the presence of LG and WP in the shell enhanced the 
mucoadhesiveness. The differences in the mechanism of mucoadhesion of the core-shell 
nanoparticles can be attributed to the observed differences in the in-vivo retention of 
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nanoparticles. Further studies are required to understand the mechanism of mucoadhesion 
of the core-shell nanoparticles in different regions of the GIT. 
The shell composition can be varied to develop nanocarriers with specific 
functional attributes. ZC nanoparticles in addition to provid a sustained drug release for 
systemic drug absorption. The ZPEG micelles can be especially useful for improving the 
oral bioavailability of drugs that are susceptible to P-gp efflux (Alqahtani et al. 2017). ZLF 
nanoparticles can be used to increase the drug absorption through receptor-mediated 
endocytosis. The ZLG and ZWPO nanocarriers can be a potential delivery vehicle for colon 
diseases. Taken together, the findings from this study demonstrate that the functional 
properties of the protein biopolymers can be used for rational development of core-shell 
nanocarriers for various oral drug delivery applications.  
 
2.5. Conclusions 
The findings from this study demonstrate the influence of shell composition on the 
physicochemical, biological, and functional characteristics of zein nanocarriers for oral 
drug delivery applications. The shell composition influenced the drug release kinetics, cell 
uptake, permeability, retention, and absorption through the oral route. ZC nanoparticles 
showed the slowest release of NR, while ZWP nanoparticles showed the highest cell 
uptake. Among six nanocarriers, ZPL nanoparticles showed the highest apparent 
permeability across Caco-2 cell monolayer. ZPEG micelles inhibited P-gp efflux. ZLF 
nanoparticles were taken up by lactoferrin receptors in the intestinal cells. All the six 
formulations were mucoadhesive and increased the retention of the dye in the 
gastrointestinal tract of rats. ZWP and ZPL nanocarriers showed the longest retention (>24 
hours) in GI tract. Although, all six nanocarriers have higher bioadhesive/mucoadhesive 
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property compared to polystyrene nanoparticles, ZLG and ZWP nanocarriers showed the 
highest bioadhesive property. Overall, the results demonstrate the potential of using food 
protein based core-shell nanocarriers to develop a safe and effective oral drug delivery 
vehicle in general and pediatric formulations in particular. 
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CHAPTER THREE 
USE OF CORE-SHELL NANOCARRIERS FOR ORAL DELIVERY OF A 
MODEL ANTIRETROVIRAL DRUG 
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3.1. Introduction 
Acquired immune deficiency syndrome (AIDS) is a disease of human immune 
system caused by human immunodeficiency virus (HIV) (Tuset 1935). HIV infection 
gradually reduce the effectiveness of human immune system leading the individuals 
susceptible to opportunistic infections (Freed 2001). As per the latest estimates, about 36.7 
million people are living with HIV infection including 1.8 million children (WHO 2016). 
Despite significant progress in the diagnosis and treatment, the number of newly infected 
people (especially children) remains unacceptably high. The rate of progression of the 
disease is higher in infants than adults at the developmental stages of the immune system. 
(Newell et al. 2004). Further, treatment of HIV infection in young patients hindered by the 
delayed diagnosis, lack of a reliable marker to predict rapid disease progression, lack of 
evidence-based treatment guidance, and more importantly lack of child friendly drug 
formulations (Coovadia et al. 2010; Kuhn et al. 2012; Palumbo et al. 2010; Violari et al. 
2008; Prendergast et al. 2012). The standard treatment for HIV infection consists of a 
combination of at least three different class of anti-retroviral drugs known as highly active 
anti-retroviral therapy (HART) (Althoff et al. 2012). These anti-retroviral drug classes 
include protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase 
inhibitors (NTRTIs), and integrase strand transfer inhibitors (INSTIs) (Viswanathan et al. 
2015). A typical HAART combination includes two NRTIs and one PI, NNRTI, INSTI, or 
NNRTI. HAART combination is effective in lowering viral load by interfering at the 
different stages of viral life-cycle, and significantly improves patients’ quality of life 
(Thompson et al. 2012; Gunthard et al. 2014; Piacenti 2006; Vadlapatla et al. 2014). 
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Among the anti-retroviral drugs, majority of the regimen include PI as one of the main 
class of drugs. 
PIs suppress HIV protease enzymes, responsible for the progression and maturation 
of viral gag and gag-pol polyproteins. (Vadlapatla et al. 2014) Inhibition of these protein 
results in immature and non-infectious viral particles. First generation PIs include 
saquinavir, ritonavir, nelfinavir, indinavir, and fosamprenavir, while the second-generation 
PIs are lopinavir, darunavir, atazanavir, and tipranavir. All PIs administered suffer from 
porr oral bioavailability with values ranging from 4% (saquinavir) to 70% (nelfinavir) 
(Vadlapatla et al. 2014). The poor oral bioavailability of PIs attributed to the poor water 
solubility, poor membrane permeability and first-pass metabolism in the intestine 
(Williams and Sinko 1999). Ritonavir is a potent inhibitor for CYP3A4 and serve as 
pharmacokinetic enhancer for other PIs. As a result, all PIs (except nelfinavir), is used in 
combination with low dose ritonavir to improve the oral bioavailability of PIs. (Vadlapatla 
et al. 2014) 
Lopinavir (LPV) is a first-line PI used for the treatment of HIV infections, 
especially in children. LPV is coformulated withritonavir (LPV/r). The current pediatric 
oral liquid formulation contains LPV and ritonavir in a mixture of propylene glycol and 
alcohol (42.4%, v/v).  Both lopinavir and ritonavir are very bitter, which results in poor 
patient compliance of this formulation (Pham et al. 2016). Further, high alcohol 
concentration has the potential for toxicity in younger children (Marek and Kraft 2014). 
Addition of ritonavir in the formulation causes the multiple drug interactions leading to 
adverse effects (Pandie et al. 2016).   
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Figure 34: Chemical structure of lopinavir Stoll et al. (2002). 
 
To this end, the goal of this chapter is to use zein based nanocarriers for improving 
the oral bioavailability of LPV and test the feasibility of developing a ritonavoir free LPV 
pediatric formulation. The impact of shell composition on the functional properties of LPV 
loaded nanocarriers was evaluated in vitro and in vivo.  
 
The specific aims of the study are as follows: 
i) Preparation and characterization of LPV loaded nanocarriers. 
ii) Determination of in vitro release of LPV from the nanocarriers in simulated GI 
fluids and food matrices (milk and applesauce). 
iii) Determination of in vitro enzymatic stability of LPV loaded nanoparticles. 
iv) Determination of apparent permeability (Papp) of LPV loaded nanocarriers in 
Caco-2 cell monolayers. 
v) Determine the pharmacokinetics LPV loaded nanocarriers in rats. 
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3.2. MATERIALS AND METHODS 
3.2.1. MATERIALS 
Lopinavir was purchased from AvaChem Scientific (San Antonio, TX, USA). 
Ritonavir was obtained from Selleckchem (Houston, TX, USA). 2% milk and applesauce 
were purchased from Hyvee Supermarket (Brookings, South Dakota, USA). Sterile saline 
and heparin lock flush syringes, and 23G syringe with blunt needles were purchased from 
SAI Technologies (Lake Villa, Illinois, USA). Acetonitrile and glacial acetic acid were 
obtained from Fisher Scientific (Hampton, NH, USA). All other chemicals and reagents 
were similar to the ones used in chapter two.  
 
3.2.2. METHODS 
3.2.2.1. Preparation of nanocarriers 
Nanocarriers were prepared by phase separation method as described in the earlier 
chapter (Section 2.2.2.). Briefly, 1 mg of LPV was dissolved in 1 mL of 90% ethanol and 
mixed with 15 mL hydroalcoholic solution of zein. LPV containing zein solution was 
added dropwise to the aqueous phase to form core-shell nanocarriers. LPV (1mg) loaded 
ZPEG micelles was prepared using the method reported in the earlier chapter (section 
2.2.2) All the other steps were similar to the ones mentioned in chapter two. Loading 
efficiency of LPV further optimized based the ratio of drug to polymer, ratio of core to 
shell and alcohol concentration. Drug to core polymer (zein) ratio was found to be an 
important parameter for drug loading and therefore different drug/polymer ratio was varied 
from 1 mg to 5 mg to achieve higher LPV loading.  
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3.2.2.2. Characterization of LPV loaded nanocarriers 
 LPV loaded nanocarriers were characterized for particle size and zeta potential 
using Malvern Zeta Sizer Nano ZS (Malvern Instrument Inc., Southborough, MA). The 
morphology of LPV loaded nanocarriers was visualized by TEM as described in chapter 
two (Section 2.2.3.).  
 
3.2.2.3. Differential Scanning Calorimetry (DSC) 
Thermal analysis of free LPV and LPV loaded nanocarriers was performed by 
Differential Scanning Calorimetry (DSC Q200, TA Instruments Inc., USA). Three to five 
mg of LPV loaded nanocarriers was placed in an aluminum pan in DSC (T zero Lid # 
T100819), and the heat flow was maintained at 10°C/minutes from 25 to 300°C under 
nitrogen gas ( 20 mL/minute). The Thermograms were processed using TA Universal 
software (TA Instruments Inc., USA).  
 
3.2.2.4. HPLC analysis of LPV 
  HPLC analysis of LPV was performed on a Waters system (Milford, MA) 
equipped with an isocratic pump, a degasser, an autosampler and data processing software 
(Breeze version 3.30 SPA). LPV was separated on a symmetry® C18 Column (Waters 
Corporation, Milford, USA) (5 µm, 4.6 mm X 150 mm). The mobile phase was a mixture 
of 10 mM ammonium acetate (pH 6.5) and acetonitrile (35:65 v/v).(Vats, Murthy, and Ravi 
2011) The mobile phase was pumped at a flow-rate of 1.0 mL/min. LPV was monitored at 
a wavelength of 210 nm. The calibration curve (peak area versus drug concentration) was 
linear (R2=0.999) in the LPV concentration range of 0.39–2.5 μg/mL. 
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3.2.2.5. Determination of encapsulation and loading efficiency of LPV 
 To determine the encapsulation/loading efficiency, around 2 mg LPV loaded 
lyophilized nanocarriers was dispersed in 1 mL of water and centrifuged at 1000 rpm for 
10 minutes. The supernatant was discarded, and the nanocarriers was dispersed in 1 mL of 
90% ethanol to digest the nanocarrier. The LPV extracted from the nanocarrier was filtered 
through 0.2 µm syringe filter, and 50 µL was injected into HPLC column. Encapsulation 
efficiency (EE%) and loading efficiency (LE%) was calculated using the following 
equations: 
EE% = 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐿𝑃𝑉 𝑖𝑛 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐿𝑃𝑉 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦 𝑎𝑑𝑑𝑒𝑑
  x 100 
LE% = 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐿𝑃𝑉 𝑖𝑛 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
 x 100 
 
3.2.2.6. In vitro release of LPV from nanocarriers 
 The release of LPV from nanocarriers was performed using dialysis method in 
simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) in the presence of pepsin 
and pancreatin enzymes respectively (as described in section 2.2.5.). Briefly, 50 mg of LPV 
loaded nanocarrier was dispersed in 5mL of SGF or SIF and placed inside the dialysis tube 
(Snakeskin dialysis membrane, 10 kDa molecular weight cutoff). The dialysis sac was 
placed in a beaker containing 25 mL SGF or SIF. 0.1% (w/v) Tween 80 mixed with release 
medium to maintain sink condition. The beaker was placed in a temperature controlled 
shaker at 37°C and agitated at 100 rpm. Around 400 µL of sample was withdrawn at 
predetermined time points up to 24 hours, and an equal volume of pre-warmed SGF or SIF 
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was replaced in the beaker. The sample was diluted with equal volume of ethanol and 
analyzed by HPLC. 
 Sequential release of LPV was determined by incubating LPV loaded nanocarriers 
in food matrices (2% milk or applesauce) and transferred to SGF followed by SIF. Briefly, 
50 mg LPV nanocarriers was dispersed in 5 mL of 2% milk or 5 mL apple sauce (diluted 
2 times using water) and transferred into a dialysis sac (10 kDa molecular weight cutoff). 
Nanocarrier containing dialysis sac placed in a beaker containing 25 mL of 2% milk or 
apple sauce and was incubated for 1 hour. After 1 hour, the dialysis sac was placed in equal 
volume of SGF containing 0.32% pepsin and in a separate beaker containing 25 mL SGF 
with 0.1% Tween 80 and 0.32% pepsin. At the end of 2 hours, in the dialysis sac was placed 
in 10 mL SIF containing 1% pancreatin in a separate beaker containing 30 mL SIF with 
0.1% Tween 80 and 1% pancreatin. About 400 µL of the sample was withdrawn at pre-
determined time points (1, 2, 4, 8, 12, and 24 h) and was mixed with equal volume of 
ethanol followed by analysis in HPLC. 
 
3.2.2.7. Solid state stability of free LPV and LPV in nanocarriers 
The solid-state stability of free and encapsulated LPV in nanocarriers was evaluated 
for three months according to the ICH guidelines. Briefly, 5 mg of LPV loaded nanocarriers 
was placed in a constant climate chamber (Binder, Tuttlingen, Germany) at 
30°C±2°C/65% RH±5% RH for three months. At predetermined time points, particle size, 
PDI and zeta potential of LPV nanocarriers were measured and the LPV content in the 
nanocarriers was determined using HPLC.  
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3.2.2.8. Transepithelial permeability of LPV nanocarriers 
The transepithelial permeability of 10 µg/mL free LPV, 10 µg/mL LPV with low 
dose of ritonavir (2.5 mg/mL) and 10 µg/ml of LPV loaded nanocarriers was studied using 
Caco-2 cell monolayer. Caco-2 cells (Passage number # 20-25) was maintained in Eagle’s 
Minimum Essential Medium (EMEM from ATCC: American Type Cell Culture 
Collection, Manassas, VA, USA) with 10% FBS, 1% streptomycin/penicillin antibiotic and 
placed in incubator with 5% CO2. Briefly, 5x10
4 cells were seeded in collagen-coated 12-
well plate transwell inserts (3 µm pore size) with an area of 1.12 cm2 (Transwell®, Corning 
Costar Corp. Cambridge, MA, USA). The growth medium was changed every two days 
for 15 days. The integrity of the Caco-2 cell monolayers was determined by measuring the 
transepithelial electrical resistance (TEER) using EVOM instrument (World Precision 
Instrument, Sarasota, FL, USA). Cell monolayers with TEER value >400 Ω.cm2 was used 
for the permeability study. Cell monolayers were incubated with 0.5 mL of Hank’s 
Balanced Salt Solution (HBSS) in the apical chamber and 1 mL of HBSS in the basolateral 
compartment for 30 minutes at 37°C. For permeability studies, the donor solution was 
replaced with 500 μL of free LPV suspension (10 μg/mL) or equivalent LPV in LPV/r 
combination (2.5 μg/mL ritonavir) or equivalent LPV loaded nanocarriers dispersed in 
HBSS buffer. Around 100 μL of the sample was collected at each time point (0h, 1h, 2h 
and four h) from the basolateral chamber. An equal volume of pre-warmed HBSS buffer 
was added to the basolateral chamber to maintain the volume. The samples were mixed 
with equal volume of ethanol for analysis by HPLC. The apparent permeability coefficient 
(Papp) of free LPV, LPV/r, and LPV loaded nanocarriers across Caco-2 cell monolayers 
was calculated using the following equation  
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Papp (cm/s) = [
(dQ/dt)
𝐴𝐶𝑜
 ] x 100 
Where dQ/dt is the flux of LPV across Caco-2 monolayer, C0 is the initial concentration of 
LPV in the apical chamber, and A is the surface area of the 12-well plate Transwell insert 
(1.12 cm2).  
 
3.2.2.9. Enzymatic metabolism studies 
To determine the metabolic stability of LPV, human intestinal microsomes was 
purchased from Sekisui Xenotech, LLC (Kansas City, KS, USA) and incubated with LPV 
nanoformulations. The microsomal protein was diluted with rapid start solution (5mM 
magnesium chloride, 5mM glucose-6-phosphate, 1mM b-NADPI, and 1U/mL glucose-6-
phosphate dehydrogenase) supplied by Sekisui Xenotech, LLC (Kansas City, KS, USA). 
Briefly, 0.3 mg/mL of microsomal protein was incubated with 10 μg/mL of LPV, LPV/r, 
and LPV loaded nanocarriers. The study was performed for 30 minutes at 37°C under 100 
rpm. Around 50 μL of the reaction mixture was collected at 15 and 30 minutes followed 
by mixing with equal volume of cold acetonitrile to stop the reaction. The LPV content 
was determined by HPLC. 
 
3.2.2.10. Pharmacokinetic studies in Rats 
Based on the results from in vitro permeability study, LPV loaded ZPEG, ZLG and 
ZWP nanocarriers were selected for pharmacokinetic studies in the rat. Free LPV and 
marketed liquid LPV formulation (Kaletra®) were used as controls. All animal 
experiments were carried out after approval from the IACUC at SDSU. Male Sprague 
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Dawley rats (3–4 weeks of age) weighing 115-150g were used for the study. Rats with 
surgically placed jugular vein catheter were purchased from Charles River (Wilmington, 
MA) and acclimatized for one week. After fasting for 12 hours, free LPV or LPV/r in water 
with 2% Tween 20, LPV loaded ZPEG and ZPL nanoparticles in water (LPV: 52 mg/kg 
body weight) were administered by oral gavage to rats. Blood samples (200 µL) were 
collected at 0, 15 min, 30 min, 1 h, 3 h, 6 h, 12 h, 15 h, 18 h and 24 h in heparinized tubes. 
After centrifugation (15 minutes, 4000 rpm), the plasma was collected and stored at -80 °C 
until further analysis by HPLC. LPV concentration in the plasma samples was determined 
by HPLC using a calibration plot prepared by spiking known amount of LPV in rat plasma. 
The LPV was extracted from the plasma by liquid-liquid extraction method using a mixture 
of ethyl acetate and n-hexane (50:50, v/v). An equal volume of the organic solvent mixture 
was added to plasma and centrifuged to separate the organic LPV layer. The extraction was 
repeated for three times to ensure complete LPV extraction from the plasma. The organic 
solvent was evaporated under dry nitrogen atmosphere. The residue was reconstituted in 
90% ethanol and used for HPLC analysis. The lower limit for the detection of LPV was 
found to be 50 ng/mL, and the extraction efficiency was 90.96±4.36%. The 
pharmacokinetic parameters such as peak concentration (Cmax), time to reach peak 
concentration (Tmax), area under the plasma concentration-time (AUC), and half-life (t1/2) 
were calculated by non-compartmental analysis using PK-solution software. Percent 
relative bioavailability (Frel%) of LPV was calculated using the following formula, 
Frel (%) = 
𝐴𝑈𝐶 (𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠)
𝐴𝑈𝐶 (𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛)
𝑋100 
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Based on the AUC values obtained after single dose PK study, the multiple dose 
pharmacokinetics of ZPEG micelle was studied. In the multiple dose study, 52 mg/kg 
(similar to the single dose study) LPV containing Kaletra® liquid formulation and ZPEG 
micelle were orally administered twice a day for 2 days. Blood samples were collected 
from the jugular vein catheter at 0, 0.5, 1, 3, and every 3 hours up to 48 hours. All the blood 
samples were processed as described above and the plasma concentration of LPV was 
determined by HPLC. Steady state PK parameters such as Css max, Css min, AUCss 0-t were 
calculated using PK-solution software. Average steady state plasma concentration (Cavg ss) 
was calculated using the following equation, 
Cavg ss = 
𝐴𝑈𝐶0−𝜏
𝜏
 
Where, τ is the dose interval (12 hours). 
 
3.3. Statistical analysis 
All the experiments were conducted in triplicate using three independent batches 
of nanoparticles. The data is represented as a mean ± standard deviation. Student t-test and 
analysis of variance (ANOVA) was performed to determine statistical significance at p < 
0.05. 
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3.4. Results  
3.4.1. Development and characterization of LPV loaded nanocarriers 
 The particle size of the nanocarriers was in the range of 100 to 250 nm with a 
uniform size distribution (PDI 0.1 to 0.36) (Table 22). ZPEG micelles showed the smallest 
in size (97 nm), while ZLG nanoparticles was was relatively the largest nanoparticles (251 
nm) among the six formulations. The zeta potential of the nanocarriers varied from 30 to -
58 mV based on the shell composition. The LPV loaded nanocarriers had a spherical 
morphology as was visualized by TEM (Fig. 35). The encapsulation efficiency of LPV was 
above 65% for all nanocarriers and zein-pluronic-lecithin (ZPL) nanoparticles showed the 
highest encapsulation efficiency (Table 22). The loading efficiency was optimized and 
increasing drug to core polymer (zein) ratio was found to increase the loading efficiency. 
The loading efficiency of LPV varied from 2.14% to 5.3% depending on the shell 
composition (Table 22). ZPL and ZC nanocarriers showed the highest loading efficiency, 
while ZLF nanoparticles showed the lowest loading efficiency. LPV was entrapped in the 
nanocarriers and was confirmed by thermal analysis (DSC) (Fig. 36). DSC thermogram 
showed the presence of melting peak for free LPV at around 100°C and absence of LPV 
peak in LPV loaded nanocarriers confirmed the encapsulation of LPV in the nanocarriers 
(Fig. 36).  
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Table 22: Characteristics of LPV loaded nanocarriers. 
Nanoparticle Particle size 
(d.nm) 
PDI Zeta 
Potential 
(mV) 
EE (%) LE (%) 
ZC 130.25±0.070 0.18±0.06 -29.3±1.93 70.47±2.15 5.12±0.20 
ZLF 185.12±4.32 0.27±0.25 30.24±4.58 64.86±1.84 2.14±0.19 
ZPEG 97.56±7.26 0.15±0.012 -3.12±2.23 71.56±4.21 4.58±0.15 
ZLG 251.36±3.52 0.093±0.07 -29.6±3.34 84.46±1.62 3.08±0.25 
ZWP 215.03±10.94 0.24±0.06 -21.3±1.28 81.36±0.57 3.32±0.22 
ZPL 247.5±1.13 0.36±0.02 -58.45±0.49 87.92±7.19 5.31±0.38 
EE%: Encapsulation efficiency in percent; LE%: Loading efficiency in percent; ZC: Zein-
β-casein nanoparticles; ZLF: Zein-lactoferrin nanoparticles; ZPEG: PEGylated zein 
micelles; ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein 
nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Each value represents mean±SD 
(n=3). 
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Figure 35: TEM images of lopinavir loaded nanocarriers. ZC: Zein-β-casein 
nanoparticles; ZLF: Zein-lactoferrin nanoparticles; ZPEG: PEGylated zein micelles; 
ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein nanoparticles; ZPL: 
Zein-pluronic-lecithin nanoparticles. 
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Figure 36: DSC thermograms of free lopinavir and lopinavir loaded nanocarriers. ZC. 
Zein-β-casein nanoparticles, ZLF. Zein-lactoferrin nanoparticles, ZPEG. PEGylated zein 
micelles, ZLG. Zein-β-lactoglobulin nanoparticles, ZWP. Zein-whey protein 
nanoparticles, ZPL. Zein-pluronic-lecithin nanoparticles. X-axis shows the Temperature 
(°C) and Y-axis shows the Heat Flow (W/g). Red line: Free LPV; blue line: LPV loaded 
nanocarriers; black line: blank nanocarriers.  
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3.4.2. In vitro release of LPV from nanocarriers 
 All six nanocarriers showed sustained release of LPV in simulated gastric fluid 
(SGF) and simulated intestinal fluid (SIF) for 24 hours. ZPEG micelles showed the slowest 
release (<30%), while relatively faster (~80%) release was seen with ZPL nanoparticles 
(Fig. 37). ZC, ZLF, ZLG and ZWP nanocarriers released 40% to 65% of LPV in both SGF 
and SIF within 24 hours. ZLG nanocarriers showed relatively faster release of LPV in SGF 
than SIF, due to the higher solubility of β-lactoglobulin in acidic pH (Taulier and Chalikian 
2001). There was no significant difference in LPV release between SGF and SIF for other 
nanocarriers (Fig. 37).  
To understand the mechanism of LPV release, the data was fitted to different 
empirical release kinetic models (Table 23). The release of LPV from the nanocarriers 
followed Peppas model in both SGF and SIF, except for ZLG nanocarriers. This is 
indicative of polymer swelling and diffusion from polymer matrix followed by surface 
erosion of polymer due to hydrolytic cleavage (Sivakumar and Rao 2003). In case of ZLG 
nanocarriers, the release of LPV in SGF followed first-order kinetics which was consistent 
with NR release shown in second chapter (Section 2.4.2.). LPV release from ZLG 
nanocarriers in SIF followed Hixon-Crowell model indicating that the release is dissolution 
limited. In case of ZWP and ZPL nanocarriers, LPV release in SGF followed Peppas 
model, while in the presence of SIF followed mixed order kinetics (Table 24). 
The nanocarriers was stable when incubated with food matrices (milk and 
applesauce). In general, less than 40% of LPV was released within two hours when 
incubated with food matrices and less than 80% of LPV was released from the nanocarriers 
in 24 hours after transferring to SGF followed by SIF (Fig. 38). ZPEG micelles showed 
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slowest release of LPV in both milk and applesauce, while ZLG and ZWP nanocarriers 
released LPV faster in milk and applesauce. However, the release of LPV in SGF and SIF 
(Fig. 37) did not change much after treating the nanoparticles with milk or applesauce, 
which indicates that there was no influence of the presence of food matrices on the release 
of LPV from the nanocarriers. This property concludes that nanocarriers have the potential 
to use as food sprinkle.  
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Figure 37: Cumulative percent of lopinavir released from different zein-based 
nanocarriers in Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF). 
ZC: Zein-β-casein nanoparticles, ZLF: Zein-lactoferrin nanoparticles, ZPEG: 
PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey 
protein isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Each value 
represents mean±SD (n=3). 
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Table 23: Summary of nonlinear fit of LPV release kinetics using different models. 
Formulation 
(Medium) 
R2 
 Peppas 
𝐹 = 𝐾 ∗ 𝑡𝑛 
Hixson-Crowell 
𝐹 = 100 ∗ (1 − (1 − 𝑘 ∗ 𝑡)^3) 
Zero Order 
C=C0-K0t 
First Order 
F=100*(1-exp(-k*t)) 
Higuchi 
F = k ∗ sqrt(t) 
ZC (SGF) 0.909 0.853 0.820 0.890 0.900 
ZC (SIF) 0.957 0.907 0.904 0.932 0.939 
ZLF (SGF) 0.983 0.790 0.859 0.839 0.982 
ZLF (SIF) 0.994 0.920 0.945 0.941 0.976 
ZPEG (SGF) 0.924 0.307 0.665 0.354 0.862 
ZPEG (SIF) 0.994 0.896 0.946 0.910 0.975 
ZLG (SGF) 0.891 0.906 0.853 0.919 0.860 
ZLG (SIF) -0.717 0.843 0.890 0.822 0.629 
ZWP (SGF) 0.981 0.873 0.905 0.905 0.979 
ZWP (SIF) 0.970 0.969 0.972 0.966 0.820 
ZPL (SGF) 0.982 0.824 0.925 0.877 0.979 
ZPL (SIF) 0.981 0.951 0.984 0.957 0.960 
SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R2 calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles, 
ZLF: Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-
whey protein isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. The highlighted value indicates the best fit model. 
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Figure 38: Sequential release of LPV from different zein nanocarriers in food matrices 
(milk or apple sauce) for 1 h followed by 1 h in SGF and up to 24 h in SIF. Zein-β-casein 
nanoparticles, ZLF: Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, 
ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein isolate 
nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Each value represents 
mean±SD (n=3). 
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Table 24: Summary of non-linear fit of lopinavir sequential release kinetics using different models. 
Formulation (Medium) R2 
 Peppas 
𝐹 = 𝐾 ∗ 𝑡𝑛 
Hixson-Crowell 
𝐹 = 
100 ∗ (1 − (1 − 𝑘 ∗ 𝑡)^3) 
Zero 
Order 
C=C0-K0t 
First Order 
F= 
100*(1-exp(-k*t)) 
Higuchi 
F = k ∗ sqrt(t) 
ZC (milk to SGF to SIF) 0.969 0.910 0.888 0.942 0.969 
ZC (apple sauce to SGF to SIF) 0.981 0.915 0.933 0.943 0.980 
ZLF (milk to SGF to SIF) 0.987 0.961 0.962 0.977 0.964 
ZLF (applesauce to SGF to SIF) 0.977 0.931 0.937 0.949 0.975 
ZPEG (milk to SGF to SIF) 0.995 0.989 0.977 0.992 0.949 
ZPEG (applesauce to SGF to SIF) 0.989 0.826 0.913 0.856 0.989 
ZLG (milk to SGF to SIF) 0.942 -6.67 0.500 0.130 0.643 
ZLG (applesauce to SGF to SIF) 0.969 -0.230 0.571 -0.161 0.579 
ZWP (milk to SGF to SIF) 0.941 0.0065 0.490 0.157 0.636 
ZWP (applesauce to SGF to SIF) 0.973 -0.235 0.549 -0.136 0.547 
ZPL (milk to SGF to SIF) 0.975 0.464 0.671 0.591 0.842 
ZPL (applesauce to SGF to SIF) 0.958 0.138 0.688 0.201 0.746 
SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R2 calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles, ZLF: 
Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein 
isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Highlighted values indicate the best fit model. 
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3.4.3. Stability of LPV loaded nanocarriers 
Solid state stability of LPV in ZC and ZLG nanoformulations was determined by 
storing the formulation at 30°C±2°C/65% RH±5% RH for three months (according to ICH 
guidelines) (ICH 2013). More than 90% of LPV remained at the end of 3 months and there 
was no significant difference in the stability of free LPV and LPV loaded nanoformulations 
(Fig. 39a). However, the particle size of ZLG nanoparticles increased after two months 
indicating, aggregation of particles (Fig. 39b). On the other hand, the physicochemical 
characteristics of ZC nanocarriers did not change over time (Fig. 39c and Fig. 39d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Solid state stability of free LPV and LPV loaded ZC and ZLG nanoparticles. 
Nanoparticles were kept in constant climate chamber for 3 months at 30°±2°C and 
65±5% relative humidity. Each value represents mean±SD (n=3). 
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3.4.4. Transepithelial permeability of LPV loaded nanocarriers across Caco-2 cell 
monolayers  
 All the nanocarriers significantly enhanced apparent permeability (Papp) of 
LPV across the Caco-2 cell monolayers (Fig. 40a). LPV loaded ZPEG micelles showed 
the highest permeability of LPV (6-fold) compared to free LPV. The apparent permeability 
of LPV loaded nanocarriers was found to be in the following decreasing rank order 
ZPEG>ZC>ZLF>ZWP>ZLG>ZPL>LPV/r>LPV (Fig. 40a). Results from percent 
permeability indicates that percent of LPV permeated after 1 to 2 hours was comparable 
between free LPV and nanoformulations (Fig. 40b). However, after 4 hours the 
nanocarriers showed significantly higher permeability than the free LPV (Fig 40b) 
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3.4.5. Metabolic stability studies 
 
 
 
Figure 40: Apparent permeability coefficient (Papp) (a) and percent of dose of LPV 
permeated (b) across Caco-2 monolayer from LPV loaded nanocarriers. Each value 
represents mean±SD (n=3), *P<0.05. 
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3.4.5. Metabolic stability studies 
To understand the metabolic stability of LPV in vitro, human intestinal microsomes 
was used. Two different concentrations (10 and 20 μM) of free LPV, Kaletra®, and LPV 
loaded nanocarriers were incubated with human microsomal enzymes for 15 and 30 
minutes. After 15 minutes, 58% of LPV was metabolized when the initial LPV 
concentration was 10 μM, while only 20% metabolized when 20 μM LPV was used, 
indicating that higher concentration leads to saturation of CYP3A4 enzymes (Fig. 41a). 
However, there was no statistically significant effect of incubation time on the metabolic 
stability of LPV in the nanocarriers. More than 85% of LPV remained stable in nanocarriers 
after 15 minute incubation and was comparable to Kaletra®. After 30 minute incubation, 
around 30% LPV was metabolized in Kaletra® with 10 µM LPV, while there was no 
change in LPV concentration with 20 µM (Fig. 41b). 
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Figure 41: In vitro metabolic stability of LPV in presence of human intestinal 
microsomes. Free LPV, Kaletra®, and LPV loaded nanocarriers were incubated for 15 
minutes (a) and 30 minutes (b). Each value represents mean±SD (n=3), P<0.05. 
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3.4.6. In vivo pharmacokinetics in rats 
Based on the results from in vitro permeability study, ZLG, ZWP and ZPEG 
nanocarriers were selected for in vivo pharmacokinetic studies in rats. A dose of 52 mg/kg 
body weight of free LPV (1 mL water with 2% Tween 20), Kaletra®, ZLG, ZWP and 
ZPEG nanocarriers (dispersed in water) was administered by oral gavage to rats. Kaletra® 
increased the oral bioavailability of LPV by 3-fold compared to free LPV suspension. The 
nanocarriers increased the oral bioavailability of LPV by 5- to 6.5-fold compared to free 
LPV suspension. The highest oral bioavailability was obtained with LPV loaded ZPEG 
micelles followed by ZWP and ZLG nanocarriers (Fig. 42).  Further, the highest plasma 
concentration (Cmax) of LPV was achieved with ZPEG micelles, which was 4-fold higher 
compared to free LPV. Kaletra® liquid formulation enhanced the oral bioavailability by 3-
fold compared to free LPV. On the other hand, ZPEG micelles showed 2-fold higher oral 
bioavailability compared to Kaletra® liquid formulation (Table 25). The AUC of LPV was 
in the following decreasing rank order ZPEG>ZWP>ZLG>Kaletra®>free LPV.  
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Figure 42: Plasma concentration of free LPV suspension, Kaletra® and LPV loaded 
ZLG, ZWP and ZPEG nanocarriers delivered orally in rats. ZPEG: PEGylated zein 
micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein isolate 
nanoparticles. Each value represents mean±SD (n=3). 
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Table 25: PK parameters of free LPV, Kaletra®, and LPV loaded nanocarriers after oral 
delivery in rats.  
 LPV 
suspension 
Kaletra ® ZWP-LPV ZLG-LPV ZPEG-LPV 
C
max
 
(μg/mL) 
0.52±0.05 1.77±0.20 1.29±0.05 * 1.39±0.13 * 1.98±0.04* 
T
max
 (hr) 6.00±0.00 3.00±0.00 6.00±0.00 6.00±0.00 9.00±0.00 
t
1/2
 (hr) 5.81±1.28 6.53±1.45 11.72±3.30 11.81±2.07 8.63±3.60 
AUC
0-t 
(μg-hr/mL) 
5.04±0.18 15.86±0.68 18.12±0.28 16.99±0.59 28.11±0.30 
AUC
0-∞ 
(μg-hr/mL) 
5.04±0.18 15.86±0.68 23.63±2.21* 20.75±1.27 * 32.48±1.57 * 
MRT (hr) 6.30±0.10 6.70±0.31 16.97±3.51 15.04±1.20 14.26±1.96 
F (% rel) -- 323.71±14.06 149.00±13.95* 130.86±8.01* 204.81±9.91 * 
Each value represents mean±SD (n=3) *P<0.05. Cmax: Maximum plasma concentration; 
Tmax:- Time to reach maximum plasma concentration; AUC:- Area under plasma 
concentration-time curve; MRT:- Mean residence time; t1/2:- Elimination half-life; 
Kaletra®:-Lopinavir with a low dose of ritonavir; F (% rel):- Percent relative 
bioavailability. F(%rel) for Kaletra® is in comparison to LPV suspension, F(%rel) for 
nanocarriers is in comparison to Kaletra®. 
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Since ZPEG micelles showed the highest oral bioavailability, this formulation was 
used for steady-state pharmacokinetic studies by multiple dosing. The formulations were 
administered orally twice a day for two days. The LPV absorption increased after the 
second dose of Kaletra® and gradual accumulation of LPV was observed after subsequent 
doses of Kaletra® and ZPEG micelles (Fig. 43). Steady state plasma concentration of LPV 
was achieved after second dose (24-48 hours) and the PK parameters were comparable 
between Kaletra® and ZPEG micelles (Table 26). Steady state Cmax for both Kaletra® and 
ZPEG formulations was significantly increased (around 2.5-fold) compared to Cmax 
obtained with single dose (Table 25 and Table 26).  
156 
 
 
 
 
 
 
 
 
 
Figure 43: Plasma profile of LPV after multiple dose administration (52 mg/Kg twice 
a day for 2 days) of Kaletra® and LPV loaded ZPEG nanocarriers. Each value 
represents mean±SD. (n=3). 
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Table 26: Steady state PK parameters of Kaletra® and LPV loaded ZPEG micelles after 
oral delivery in rats.  
 Kaletra® ZPEG-LPV 
Css max (µg/mL) 5.50±0.65 4.24±0.49* 
Css avg (µg/mL) 4.43±0.73 4.0±0.27* 
Css min (µg/mL) 1.06±0.12 1.49±0.32* 
Tss max (hrs) 27.00±0.00 30.00±0.00* 
AUCo-12 ss (μg-hr/mL) 53.20±8.84 53.16±3.35* 
Css max. Maximum concentration during dosing interval at steady state; Css min. Minimum 
concentration during dosing interval at steady state; Css avg. Average plasma drug 
concentration at steady state; ZPEG: PEGylated zein micelles; Each value represents 
mean±SD (n=3); *P<0.05 compared to Kaletra®. 
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3.5. Discussion 
The main goal of this study was to test the feasibility of developing a water 
dispersible ritonavir free formulation of LPV using food-grade biopolymers. LPV was 
encapsulated in the hydrophobic zein core, while the external hydrophilic shell was used 
to increase the water solubility and permeability through the gastrointestinal membrane.  
The size and surface charge of LPV loaded nanocarriers were similar to NR loaded 
nanocarriers as described in chapter two (Section 2.4.1). The encapsulation and loading 
efficiency varied with different shell composition (Table 22). The highest encapsulation 
and loading efficiency of LPV obtained with ZPL nanocarriers can be attributed to the 
presence of both lecithin and pluronic in the shell. The lecithin in the shell favors the 
entrapment of LPV in the ZPL nanocarriers (Chen, Chen, Su, Hong, et al. 2016; Chen, 
Chen, Su, Wong, et al. 2016), while addition of pluronic F127 can sterically stabilize zein 
nanoparticles (Podaralla and Perumal 2012). Lecithin alone was not able to prevent 
aggregation of zein nanoparticles (Podaralla and Perumal 2012). Pluornic stabilizes the 
lecithin layer by hydrophobic interaction of polypropylene oxide unit of pluronic with 
hydrophobic tail of lecithin and hydrophilic interaction of polyethylene oxide chain of 
pluronic with polar head of lecithin (Schubert and Muller-Goymann 2005; Mosqueira et 
al. 2000; Zhang et al. 2008). The loading efficiency of LPV in ZC nanocarriers were 
comparable to ZPL due to the relatively higher hydrophobicity of β-casein among the milk 
proteins used in this study (Patel, Bouwens, and Velikov 2010). Lactoferrin has high 
aqueous solubility and thereby contributed to the lowest encapsulation and loading of LPV 
in ZLF nanocarrier (Table 22). In general, the results obtained with loading of NR (Section 
2.4.1) and LPV in nanocarriers suggest that the encapsulation and loading efficiency 
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dictated by both shell composition and the physicochemical properties of the encapsulated 
molecule. 
 The long-term stability study indicated that LPV remained stable both in free form 
and in nanocarriers with a gradual increase in ZLG particle size which may be attributed 
by the alteration in β-lactoglobulin (LG) conformation over time (Majhi et al. 2006).  
In vitro food compatibility study indicated that LPV loaded nanocarriers can be 
mixed with food matrices (milk and applesauce) and also suggest that the formulations 
have the potential to be used as food sprinkle. Water, milk and applesauce are commonly 
used vehicles to disperse drug formulations. (WHO 2010) Administration of multi-
particulate drug formulation by mixing with food or drinks (sprinkles) can improve 
organoleptic properties and thereby can increase the acceptability of the formulation 
especially for pediatric patients. However, compatibility of the formulation with food 
matrix, drug release in food matrix and bioavailability should be taken into account 
(MacDonald et al. 2006; den Uyl et al. 2010). Albertini et al. (2014) reported the 
compatibility of solid lipid microparticles with milk and yogurt and can be used as sprinkle 
for drug administration. The practice of crushing lopinavir/ritonavir (LPV/r) tablet and 
mixing with food leads to reduce the total lopinavir and ritonavir exposure by 45% and 
47% respectively (Best et al. 2011). In this regard, zein-based nanoformulations are 
advantageous to ensure flexibility in dosing. In addition, LPV loaded zein-based 
nanocarriers showed compatibility with food matrices due to less drug release and have 
potential to mask the bitter taste of drugs and can be used as food sprinkle.  However, 
further studies needed to confirm the palatability and taste masking using these core-shell 
nanoformulations. 
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In vitro metabolic stability study demonstrated the protection of lopinavir from 
CYP3A4 metabolic degradation. Apparent permeability (Papp) of LPV across Caco-2 cell 
monolayers was also significantly increased using nanocarriers compared to free LPV 
LPV/r combination. This result signifies that zein-based nanoformulations can be used to 
develop ritonavir free lopinavir formulation. The shell composition of nanocarriers play an 
important role in the interaction, uptake, and distribution of the nanoparticles. ZC and 
ZPEG nanocarriers are taken up by non-specific endocytosis in Caco-2 cells (Alqahtani et 
al. 2017). On the other hand, ZLF can be taken up through lactoferrin receptors in the 
intestinal epithelial cells by receptor mediated endocytosis (Alqahtani et al. 2017). The 
efflux pumps expressed in the intestinal cells limits the drug absorption.  The P-gp 
inhibitory activity of PEG in ZPEG micelles resulted in higher permeability  of LPV across 
Caco-2 monolayers (Alqahtani et al. 2017). ZLG and ZWP nanocarriers mainly taken up 
by non-specific endocytosis. Taken together, findings from the in vitro studies suggest that 
the shell composition influences the cell uptake kinetics and the mechanisms of 
transepithelial transport of zein based core-shell nanocarriers. 
Results from single-dose Pharmacokinetic study in rat demonstrated that the trough 
plasma concentration was 1 μg/mL, which is consistent with the concentration required to 
reduce the HIV viral load (Lopez-Cortes et al. 2013). Further, the half-life of LPV using 
nanocarriers significantly increased and was found to be useful to improve plasma level of 
LPV by gradual accumulation after administration of multiple dose (Fig. 43). The P-gp 
inhibitory activity of ZPEG contributed to suppress the interplay between CYP3A4 and P-
gp efflux pump to reduce the absorption of LPV. The steady-state plasma concentration of 
LPV using ZPEG micelle was obtained after administration of second dose and steady-
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state PK parameters were comparable to Kaletra® indicated the potential of developing 
ritonavir free LPV formulation using zein nanocarriers.  
The HIV treatment regimen includes 3 different groups of drugs and concomitant 
administration increases the chance of drug-drug interaction (Barry et al. 1999). For 
example, ritonavir in lopinavir/ritonavir combination can interact with non-nucleoside 
reverse transcriptase inhibitors by inducing drug metabolizing enzymes and thereby reduce 
the plasma concentration of protease inhibitors (Barry et al. 1999; Piscitelli and Allicano 
2001). The potential of developing ritonavir free lopinavir formulation can reduce the 
overall drug load and drug-drug interactions.  
Overall, the findings from this study demonstrated that food-grade biopolymers can 
be used to develop a safe and effective carrier for LPV. 
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3.6. Conclusions 
The present study demonstrates that zein based core-shell nanocarriers are 
promising for enhancing the oral bioavailability of LPV. In vitro studies showed that zein 
based core-shell nanocarriers significantly improved the water solubility of LPV, sustained 
the LPV release, and increased membrane permeability. Low LPV release in food matrices 
(milk and applesauce) indicated that LPV loaded nanocarriers are compatible with food 
matrices and have the potential to be used as a food sprinkle. In vitro metabolic stability 
study demonstrated that zein based core-shell nanocarriers protected LPV from CYP3A4-
mediated enzymatic degradation. Results from the pharmacokinetic study showed that the 
bioavailability obtained with ZPEG micelles was similar or higher compared to Kaletra® 
liquid formulation. Overall the results suggest the feasibility of developing a ritonavir 
pediatric formulation of LPV using zein based nanocarriers. 
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CHAPTER FOUR 
 
 
USE OF CORE-SHELL NANOCARRIERS FOR ORAL DELIVERY OF AN 
INVESTIGATIONAL ANTI-CANCER DRUG MOLECULE 
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4.1. Introduction 
Given the promising outcomes from chapter two and chapter three, the goal of this 
chapter is to use zein-based nanocarriers for encapsulation and oral delivery of fenretinide, 
an investigational anti-cancer compound. Fenretinide [N-(4-hydroxyphenyl) retinamide (4-
HPR)] is a poorly soluble and poorly permeable anti-cancer agent (Torrisi et al. 2001; 
Wischke et al. 2010; Orienti et al. 2007; Ledet et al. 2015). Further, the compound has poor 
chemical stability. Fenretinide has been investigated for its effectiveness against various 
cancers in clinical trials including breast (Kazmi et al. 1996), ovarian (Supino et al. 1996; 
Sabichi et al. 1998; Formelli and Cleris 1993), lung (Kalemkerian et al. 1995), pediatric 
neuroblastoma (Ponzoni et al. 1995; Di Vinci et al. 1994; Maurer et al. 2000), prostate 
(Hsieh, Ng, and Wu 1995; Igawa et al. 1994) and colorectal (Ziv et al. 1994) cancer. There 
are several mechanisms reported for fenretinide’s anticancer activity including i) formation 
of reactive oxygen species (ROS), ii) increasing the level of ceramides, iii) anti-angiogenic 
activity,  and iv) enhanced NK cell activity (O'Donnell et al. 2002; Maurer et al. 1999; 
Oridate et al. 1997; Delia et al. 1997; DiPietrantonio et al. 1998; Batra, Reynolds, and 
Maurer 2004; Rehman, Shanmugasundaram, and Schrey 2004; Ribatti et al. 2001; Zhao et 
al. 1994).  
However, a major challenge in realizing its therapeutic potential is the compound’s 
poor oral bioavailability. Fenretinide at a dose of 100 to 400 mg/day has been investigated 
as a chemoprevention agent in phase I, phase II and phase III trial using oral gelatin capsule 
(Villablanca et al. 2011). In the capsule formulation of fenretinide was dissolved in corn 
oil and a surfactant (polysorbate 80) and achieves very low blood concentration.  
Fenertinide has been observed to have dose-limited toxicity (Torrisi et al. 1994). A high-
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dose fenretinide (1800 mg/m2/day) when administered in pediatric patients with 
neuroblastoma was found to be associated withs hepatic toxicities and pseudotumor cerebri 
(Children's Oncology et al. 2006). Further, fenretinide using capsule formulation showed 
the high patient variability in plasma concentration (2-5 μg/mL) with rebound 
neuroblastoma (Garaventa et al. 2003; Villablanca et al. 2011; Children's Oncology et al. 
2006; Schneider et al. 2009). As a result of the  poor compliance with fenertinide capsule 
formulation, clinical trials have been discontinued (Caruso et al. 1998). 
 
An oral lipid formulation, Lym-X-Sorb® (LXS), has been investigated to enhance 
bioavailability of fenretinide with improved patient compliance (Kummar et al. 2011; 
Maurer et al. 2013). LXS® oral powder achieved 4-fold plasma and 7-fold tissue fenretinide 
concentration in mice compared to fenretinide capsule formulation (Maurer et al. 2007). 
LXS®-fenretinide powder formulation was successful in overcoming some of the 
difficulties with corn oil capsule (Kummar et al. 2011). However, there is a strong unmet 
need for an effective and safe oral formulation of fenertinide, especially for pediatric 
patients.      
 
 
 
 
 
Figure 44: Chemical structure of fenretinide. 
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To this end, the goal of this study is to develop and test the feasibility of using zein 
based core-shell nanocarriers for enhancing the oral bioavailability of fenretinide. Six 
different core-shell nanocarriers that were evaluated in previous two chapters, was used for 
this study with the goal of studying the influence of the shell composition on the in vitro 
and in vivo functional performance of fenretinide loaded nanocarriers and identifying a 
suitable formulation for further development 
The specific aims of this study are: 
i) To prepare and characterize fenretinide loaded core-shell nanocarriers. 
ii) Determine the in vitro release of fenretinide in simulated GI fluids and food 
matrices (milk and applesauce). 
iii) Determine the apparent permeability (Papp) of fenretinide and fenretinide loaded 
nanocarriers across Caco-2 cell monolayers. 
iv) Determine the oral Pharmacokinetics of fenretinide loaded nanocarriers in rats. 
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4.2. Materials and methods 
4.2.1. Materials  
Fenretinide was purchased from LC Laboratories (Woburn, MA, USA). All other 
materials and chemicals used in this study were similar to those mentioned in chapters two 
and three.   
 
4.2.2. Methods 
4.2.2.1. Preparation of fenretinide loaded nanocarriers 
Phase separation method used to prepare fenretinide loaded nanocarriers as 
described in the second chapter (section 2.2.2.). Briefly, 15 mg of zein was dissolved in 2 
mL of 90% ethanol and 1 mg of fenretinide was mixed with zein solution. The 
hydroalcoholic phase was added dropwise to aqueous phase containing milk protein (β-
casein-C or lactoferrin-LF or β-lactoglobulin-LG or whey protein isolate-WP) or pluronic-
lecithin under probe sonication.  Beta-lactoglobulin (LG) and whey protein isolate (WP) 
was preheated at 60°C for 30 minutes followed by slow addition of zein solution as 
described in the second chapter (section 2.2.2.). The dispersion was stirred for 3 to 4 hours 
at 100 rpm (room temperature) to evaporate the remaining ethanol. Free fenretinide was 
removed by centrifugation using centrifugal filters (EMD Millipore). The purification step 
was repeated for 3 to 5 times. The resultant formulation was lyophilized for 48 hours, and 
the dried powder was stored at 4°C in a desiccator until further analysis. 
Around 1 mg of fenretinide was loaded in ZPEG micelles using the same method 
as described in the second chapter (section 2.2.2.)  
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4.2.2.2. Characterization of fenretinide loaded nanocarriers 
Fenretinide loaded nanocarriers were characterized for particle size, PDI and zeta 
potential using Malvern Zeta Sizer Nano ZS (Malvern Instrument Inc., Southborough, 
MA). The morphology of fenretinide loaded nanocarriers was visualized using TEM using 
the procedure described in chapter two (section 2.2.3.). Differential Scanning Calorimetry 
(DSC) analysis was performed to determine the thermal properties of free fenretinide and 
fenretinide loaded nanocarriers using the same procedure as described in chapter 3 (section 
3.2.2.3.).  
 
4.2.2.3. HPLC analysis of fenretinide  
HPLC analysis of fenretinide was performed on a Waters system (Milford, MA) 
equipped with an isocratic pump, a degasser, an autosampler and data processing software 
(Breeze version 3.30 SPA). The separation of fenretinide was performed on a symmetry® 
C18 Column (Waters Corporation, Milford, USA) (5 µm, 4.6 mm X 150 mm). The mobile 
phase was a mixture of acetonitrile: water: glacial acetic acid (80:18:2, v/v). The mobile 
phase was pumped at a flow-rate of 0.8 mL/min. Fenretinide was monitored at a 
wavelength of 340 nm. The calibration curve (peak area versus drug concentration) was 
linear (R2=0.999) in the fenretinide concentration range of 0.39–2.5 μg/mL. 
 
4.2.2.4. Determination of encapsulation and loading efficiency of fenretinide 
Lyophilized fenretinide formulations were used to determine the encapsulation and 
loading efficiency. Briefly, 2 mg of fenretinide loaded nanocarriers was dispersed in 1 mL 
of water and centrifuged at 1000 rpm for 10 minutes, the supernatant was discarded, and 
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the nanoparticles was reconstituted in 1 mL 90% ethanol. The extracted fenretinide was 
filtered through 0.2 µm syringe filter, and 50 µL was injected into the HPLC column. The 
concentration of fenretinide in nanocarriers was calculated from the calibration curve of 
fenretinide in 90% ethanol. The encapsulation efficiency (EE%) and loading efficiency 
(LE%) were calculated using the following equations: 
EE% = 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑖𝑛 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦 𝑎𝑑𝑑𝑒𝑑
  x 100 
LE% = 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑖𝑛 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
 x 100 
 
4.2.2.5. In vitro release of fenretinide from nanocarriers 
The release of fenretinide from nanocarriers was performed by dialysis method in 
SGF and SIF using the proedure as described in chapter two (section 2.2.5.). Briefly, 50 
mg of fenretinide loaded nanocarriers was dispersed in 5mL of SGF or SIF and placed 
inside the dialysis tube (Snakeskin dialysis membrane, 10 kDa molecular weight cutoff). 
The dialysis sac was placed in a beaker and placed in a temperature controlled shaker at 
37°C and agitated at 100 rpm. Around 400 µL of the sample was withdrawn at 
predetermined time points, diluted with equal volume of ethanol and 50 µL of the sample 
was injected into the HPLC column.  
Sequential release of fenretinide was determined by incubating fenretinide loaded 
nanocarriers in 2% milk or applesauce and then transferred to SGF followed by SIF. 
Briefly, 50 mg fenretinide nanocarriers was dispersed in 5 mL 2% milk or 50% apple sauce 
and transferred into a dialysis sac (10 kDa molecular weight cutoff). All other procedure 
was similar to sequential release of LPV described in section 3.2.2.6.  
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4.2.2.6. Transepithelial permeability through Caco-2 cell monolayers 
The transepithelial permeability of free fenretinide and fenretinide loaded 
nanocarriers was studied using Caco-2 cell monolayers as described in the earlier chapter 
(section 3.2.2.8). Briefly, 5x104 cells were incubated in 12-well plate transwell inserts with 
an area of 1.12 cm2 (Transwell®, Corning Costar Corp. Cambridge, MA, USA). The 
growth medium was changed every two other days for 15 days. The tight junction integrity 
of the Caco-2 cell monolayers was determined using TEER measurements. Prior to 
applying the fenretinide formulations, caco-2 cell monolayers were incubated with Hank’s 
Balanced Salt Solution (HBSS) for 30 minutes at 37°C to polarize cell monolayers. About 
500 μL of free fenretinide suspension (10 μg/mL) or equivalent of fenretinide loaded 
nanocarriers dispersed in HBSS buffer was added to the apical chamber and 100 μL of the 
sample was collected at predetermined time points (0h, 1h, 2h and 4 h) from the basolateral 
chamber. An equal volume of HBSS buffer was added to maintain the volume in the 
basolateral compartment. The samples were mixed with an equal volume of ethanol and 50 
μL of the sample was injected into HPLC for determination of fenretinide concentration. 
The apparent permeability coefficient (Papp) of fenretinide loaded nanoparticle across 
Caco-2 cell monolayers was calculated using the equation described in second chapter 
(section 2.2.11.). 
 
4.2.2.7. Stability of fenretinide in nanocarriers 
The stability of fenretinide loaded ZC, ZLG and ZPL nanocarriers were evaluated. 
Briefly, 5 mg of fenretinide loaded nanocarriers was incubated in a constant climate 
chamber (Binder, Germany) at 30°C±2°C/65% RH±5% RH for three months (according 
171 
 
to ICH guidelines) (ICH 2013). Around 1 mg of free fenretinide was used as a control.  At 
predetermined time points, the particle size, PDI and zeta potential were measured using 
the particle sizer (Malvern instrument). Fenretinide content in the nanocarriers was 
determined using HPLC.  
 
4.2.2.8. Pharmacokinetic studies in Rats 
All the animal experiments were carried out after approval from the IACUC at 
SDSU. Male Sprague-Dawley rats (3–4 weeks of age) weighing 115-150g were used for 
the study. Rats with surgically implanted jugular vein catheter were purchased from 
Charles River (Wilmington, MA) and acclimatized for one week. After fasting for 
overnight, 20 mg/kg of free fenretinide (in water with 2% Tween 20) or fenretinide loaded 
ZC, ZLG, ZWP, and ZPL nanocarriers were administered by oral gavage. Blood samples 
(200 µL) were collected at 0, 15 min, 30 min, 1 h, 3 h, 6 h, 12 h, 15 h, 18 h and 24 h from 
the jugular vein. The plasma was separated by centrifuging at 4000 rpm for 10 minutes. 
Fenretinide was extracted from the plasma by adding an equal volume of ethyl acetate and 
n-hexane mixture (50:50, v/v) followed by centrifugation at 10000 rpm for 10 minutes. The 
supernatant was collected, and the extraction process was repeated three times to ensure 
complete extraction. The fenretinide concentration in the plasma was determined by HPLC 
method using a calibration plot prepared by spiking known amount of fenretinide (0.1-2.0 
µg/mL) in the plasma. The pharmacokinetic parameters including peak concentration 
(Cmax), time to reach peak concentration (Tmax), area under the plasma concentration-time 
(AUC), and half-life (t1/2) were calculated by non-compartmental analysis using PK-
solution software.  The percent relative bioavailability (Frel%) of fenretinide was calculated 
by using the following formula, 
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Frel (%) = 
𝐴𝑈𝐶 (𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠)
𝐴𝑈𝐶 (𝑓𝑟𝑒𝑒 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛)
𝑋100 
 
  
Based on the results from single dose PK study, fenrettinide loaded ZPL nanocarrier 
was further used for steady-state pharmacokinetic studies. Based on the half-life of 
fenretinide obtained after single dose PK study, the dose interval for multiple dose study 
was designed.  Fenretinide loaded ZPL nanocarrier (20 mg/kg fenretinide equivalent) was 
orally administered once a day for 4 days. Free fenretinde suspension (20 mg/kg) was 
administered orally twice a day. Blood samples were collected from the jugular vein at 0, 
0.5, 1, 3, and every 3 hours up to 96 hours. All the blood samples were processed as 
described above and the plasma concentration of fenretinide was determined by HPLC. 
Steady state PK parameters such as Css max, Css min, AUCss 0-t were calculated using PK-
solution software. Average steady state plasma concentration (Cavg ss) was calculated using 
the following equation, 
Cavg ss = 
𝐴𝑈𝐶0−𝜏
𝜏
 
Where, τ is the dose interval (12 hours for free fenretinide suspension and 24 hours for 
fenretinide loaded ZPL nanocarrier). 
 
4.3. Statistical analysis 
All the experiments were conducted in triplicate using three independent batches 
of nanocarriers unless noted otherwise. The data is represented as a mean ± standard 
deviation. Student t-test and One-way ANOVA was performed to determine statistical 
significance at p < 0.05. 
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4.4. Results 
4.4.1. Development and characterization of fenretinide loaded core-shell nanocarriers 
The particle size of the nanocarriers ranged from 100 to 250 nm diameter and had 
a uniform size distribution as evidenced from the low polydispersity index (0.08 to 0.3) 
(Table 27). The core-shell structure of nanocarriers was confirmed from TEM (Fig. 45) 
and the morphology of fenretinide loaded nanocarriers was similar to NR and LPV loaded 
nanocarriers (Fig. 15 and Fig. 35). The zeta potential varied from -45.75±0.91 to 
32.95±1.48 mV depending on the shell composition and the values are consistent with LPV 
and NR loaded nanocarriers (Table 8 and Table 22). The encapsulation efficiency (EE) 
for fenretinide was above 70% in all the nanocarriers with zein-β-casein (ZC) nanoparticles 
showing the highest encapsulation efficiency (89%) (Table 27). The EE of NR in ZPEG 
micelles was about 56%, while EE of fenretinide was 77% indicating that the interaction 
between fenretinide and zein core favors the higher entrapment of fenretinide in ZPEG 
micelles. The EE of LPV in ZPEG micelles was similar to EE of fenretinide. The EE of 
fenretinide in all other nanocarriers was similar to EE of NR and LPV (Table 8 and Table 
22). The loading efficiency was further optimized based on the ratio of drug to polymer, 
core to shell, and alcohol concentration. Drug to core polymer ratio was found to be 
important parameter and by increasing fenretinide from 1 mg to 5 mg resulted in increase 
in loading efficiency. The loading efficiency (LE) varied from 3 to 8% based on the shell 
composition (Table 27). The highest loading of fenretinide was obtained with ZPEG 
micelles, while ZPL nanocarriers showed the lowest loading efficiency. The LE for ZC 
nanocarriers (7.5%) was similar to ZPEG micelles. Further, LE of fenretinide was about 2-
fold higher than LE of LPV in ZPEG micelles (Table 22).  
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The encapsulation of fenretinide in the nanocarriers was confirmed by differential 
scanning calorimetry (DSC) (Fig. 46). DSC thermogram for free fenretinide showed two 
sharp endothermic peaks at around 175°C and 180°C, which indicates the presence of two 
polymorphic forms of fenretinide. (Walkling 1986) The absence of melting peak indicates 
loss of crystallinity due to entrapment in the nanocarriers.  
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Figure 45: Transmission electron microscopy images of fenretinide loaded 
nanocarriers. ZC: Zein-β-casein nanoparticles; ZLF: Zein-lactoferrin nanoparticles; 
ZPEG: PEGylated zein micelles; ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-
whey protein nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Scale bar is 200 
nm.  
 
176 
 
Table 27: Characteristics of fenretinide loaded nanocarriers. 
Characteristics 
Particle size 
(nm) 
PDI 
Zeta 
potential 
(mV) 
EE (%) LE (%) 
ZC 148.25±0.77 0.099±0.055 -40.95±1.06 89.32±0.091 7.5±0.09 
ZLF 240.1±3.53 0.15±0.02 32.95±1.48 70.11±0.49 3.75±0.035 
ZLG 272.2±7.63 0.30±0.01 
-23.25±1.0 78.51±3.68 3.5±0.037 
ZWP 
256.7±0.98 0.08±0.03 -36±3.25 74.68±1.04 3.09±0.012 
ZPL 
219.3±22.88 0.33±0.065 -45.75±0.91 76.05±0.918 3.01±0.23 
ZPEG 
114.43±2.90 0.34±0.018 -11.35±0.07 77.43±0.47 8.33±0.03 
Values represent mean±SD (n=3). EE (%): Encapsulation efficiency in percent; LE (%): 
Loading efficiency in percent; ZC: Zein-β-Casein nanoparticles; ZLF: Zein-Lactoferrin 
nanoparticles; ZPEG: Zein-Polyethylene Glycol micelles; ZPL: Zein-Pluronic-Lecithin 
nanoparticles; ZLG: Zein-β-Lactoglobulin nanoparticles; ZWP: Zein-Whey Protein isolate 
nanoparticles. 
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Figure 46: DSC analysis of free fenretinide and fenretinide loaded nanocarriers. ZC. Zein-
β-casein nanoparticle, ZLF. Zein-lactoferrin nanoparticle, ZPEG. PEGylated zein micelle, 
ZLG. Zein-β-lactoglobulin nanoparticle, ZWP. Zein-whey protein nanoparticle, ZPL. 
Zein-pluronic-lecithin nanoparticles. X-axis showing Temperature (°C) and Y-axis 
showing Heat Flow (W/g). Red line: Free fenretinide; Blue line: Fenretinide loaded 
nanocarriers; Black line: Blank nanocarriers. 
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4.4.2. In vitro release of fenretinide from nanocarriers 
The release of fenretinide was sustained both in SGF and SIF for 24 hours (Fig. 
47). The release of fenretinide was faster than the release of NR (Fig. 19), while it was 
similar to the release of LPV (Fig. 37) from ZC nanocarriers in both SGF and SIF. The 
ZLG and ZPEG nanocarriers showed the slowest release of fenretinide (<40% released) in 
both SGF and SIF over 24 hours, which was similar to NR and LPV release from these two 
nanocarriers. The release profile of fenretinide from ZWP nanocarriers (Fig. 47) was 
similar to the release of NR and LPV (Fig. 19 and Fig. 37) in both SGF and SIF. About 40 
to 50% burst release was observed with ZLF nanocarriers within first one hour in SGF and 
SIF (Fig. 47), while less than 10% burst release was observed in case of NR and LPV. The 
release profile of fenretinide from ZPL nanocarriers was similar NR, while the LPV release 
was slower both in both SGF and SIF (Fig. 47).  
The nanocarriers were stable when incubated with food matrices (milk or 
applesauce), and less than 30% of fenretinide was released within two hours when 
transferred to SGF. About 60% of fenretinide was released in 24 hours after transferring 
from SGF to SIF (Fig. 48). The compatibility with food matrices indicate that the 
fenretinide loaded nanocarriers can be used as a food sprinkle.  
The release kinetics was consistent with release of LPV from nanocarriers (Table 
23 and Table 24). The release of fenretinide from the nanocarriers predominantly followed 
Peppas model, except for ZLG nanoparticles (Table 28). This indicates that the release of 
fenretinide from nanocarriers depends on polymer swelling, diffusion of fenretinide and 
surface erosion of polymer (Sivakumar and Rao 2003). There was slow release of 
fenretinide in the presence of food matrices and release kinetics (R2-values) indicates that 
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food matrices have less impact on drug release from nanocarriers (Table 29). The release 
of fenretinide from all the six nanocarriers followed Peppas model indicating that the 
release is mediated by the diffusion due to surface erosion followed by hydrolytic cleavage 
or enzymatic degradation of the polymer (Table 28). In SIF, the release of fenretinide from 
ZLG nanocarriers was followed by Hixon-Crowell and first order model indicating that the 
release is dissolution limited. Similar release pattern (Fig. 48) and kinetics (Table 29) was 
obtained in the sequential release study in food matrices (milk and apple sauce) followed 
by SGF and SIF indicating that the food matrices had little influence on the release of 
fenretinide from the nanocarriers.  
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Figure 47: Cumulative percent of fenretinide released from different core-shell nanocarriers 
in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). ZC. Zein-β-casein 
nanoparticle, ZLF. Zein-lactoferrin nanoparticle, ZPEG. PEGylated zein micelle, ZLG. 
Zein-β-lactoglobulin nanoparticle, ZWP. Zein-whey protein nanoparticle, ZPL. Zein-
pluronic-lecithin nanoparticles. Each value represents mean±SD (n=3). 
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Table 28: Fenretinide release kinetics using different models. 
 
SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R2 calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles, ZLF: 
Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein 
isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Highlighted values indicate the best fit model. 
 
Formulation (Medium) R2 
 Peppas 
𝐹
= 𝐾 ∗ 𝑡𝑛 
Hixson-Crowell 
𝐹 = 100 ∗ (1 − (1 − 𝑘
∗ 𝑡)^3) 
Zero Order 
C=C0-K0t 
First Order 
F=100*(1-exp(-
k*t)) 
Higuchi 
F = k ∗ sqrt(t) 
ZC (SGF) 0.993 0.857 0.878 0.904 0.973 
ZC (SIF) 0.991 0.884 0.895 0.922 0.977 
ZLF (SGF) 0.993 -0.352 0.376 -0.239 0.313 
ZLF (SIF) 0.993 -0.417 0.312 -0.263 0.183 
ZPEG (SGF) 0.978 0.607 0.858 0.643 0.941 
ZPEG (SIF) 0.972 0.541 0.851 0.588 0.914 
ZLG (SGF) 0.987 0.844 0.944 0.856 0.982 
ZLG (SIF) 0.981 0.981 0.981 0.981 0.859 
ZWP (SGF) 0.981 0.875 0.932 0.883 0.969 
ZWP (SIF) 0.988 0.845 0.931 0.868 0.987 
ZPL (SGF) 0.986 0.684 0.869 0.741 0.940 
ZPL (SIF) 0.974 0.727 0.874 0.798 0.925 
182 
 
 
Figure 48: Cumulative percent of fenretinide released from different core-shell nanoparticles 
in milk (A), apple sauce (B) for 1 hour followed by release in simulated gastric fluid (SGF) for 
1 hour and followed by release in simulated intestinal fluid (SIF) up to 24 hours. Values 
represents mean±SD (n=3). 
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Table 29: Fenretinide sequential release kinetics using different models. 
Formulation (Medium) R2 
 Peppas 
𝐹
= 𝐾 ∗ 𝑡𝑛 
Hixson-Crowell 
𝐹 
= 100 ∗ (1 − (1 − 𝑘 ∗ 𝑡)^3) 
Zero 
Order 
C=C0-K0t 
First Order 
F 
=100*(1-exp(-k*t)) 
Higuchi 
F = k ∗ sqrt(t) 
ZC (milk to SGF to SIF) 0.947 0.745 0.656 0.850 0.790 
ZC (apple sauce to SGF to SIF) 0.912 0.707 0.750 0.789 0.897 
ZLF (milk to SGF to SIF) 0.793 0.567 0.583 0.665 0.773 
ZLF (apple sauce to SGF to SIF) 0.855 0.631 0.695 0.671 0.854 
ZPEG (milk to SGF to SIF) 0.998 0.928 0.957 0.946 0.974 
ZPEG (apple sauce to SGF to SIF) 0.994 0.995 0.993 0.995 0.850 
ZLG (milk to SGF to SIF) 0.976 0.421 0.791 0.465 0.924 
ZLG (apple sauce to SGF to SIF) 0.971 0.913 0.941 0.920 0.932 
ZWP (milk to SGF to SIF) 0.970 0.884 0.896 0.917 0.962 
ZWP (apple sauce to SGF to SIF) 0.954 0.934 0.915 0.948 0.906 
ZPL (milk to SGF to SIF) 0.952 0.906 0.851 0.948 0.946 
ZPL (apple sauce to SGF to SIF) 0.948 0.941 0.895 0.961 0.904 
 
SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R2 calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles, ZLF: 
Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein 
isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Highlighted values indicate the best fit model. 
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4.4.3. Transepithelial permeability of fenretinide loaded nanocarriers across Caco-2 
cell monolayers  
The nanocarriers enhanced the apparent permeability (Papp) of fenretinide across 
the Caco-2 cell monolayers (Fig. 49). The Papp was increased from 1 to 36-fold compared 
to free fenretinide. The Papp ranged from 2.09x10
-6 to 72.42x10-6 cm/s depending on the 
shell composition of the nanocarriers (Fig. 49). ZPL nanocarriers showed the highest 
permeability, while lowest permeability was observed with ZPEG micelles. The apparent 
permeability of fenretinide loaded nanocarriers was found to be in the following decreasing 
rank order ZPL>ZLG>ZC>ZWP>ZLF>ZPEG. The highest Papp values for NR was 
obtained with ZLG nanocarriers followed by ZPEG, while NR loaded ZC nanocarriers 
showed the lowest Papp value (section 2.2.2.). However, the rank order was different 
compared to LPV loaded nanocarriers (section 3.4.3). Unlike fenretinide formulations, 
LPV loaded ZPEG micelles showed the highest Papp, while the lowest value was obtained 
with ZPL nanocarrier (Fig. 49). Overall, from the results showed that the zein nanocarriers 
significantly enhanced the permeability of fenertinide.  
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Figure 49: Apparent permeability (Papp) of free fenretinide and fenretinide loaded 
nanocarriers across caco-2 cell monolayers. ZC: Zein-β-casein nanoparticles; ZLF: 
Zein-lactoferrin nanoparticles; ZPEG: PEGylated zein micelles; ZLG: Zein-β-
lactoglobulin nanoparticles; ZWP: Zein-whey protein nanoparticles; ZPL: Zein-
pluronic-lecithin nanoparticles. Each value represents mean±SD (n=3), *P<0.05. 
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4.4.4. Stability of fenretinide in nanocarriers 
Fenretinide in ZC and ZLG nanoformulations was chemically stable compared to 
free fenretinide in the solid state when tested for three months. Around 45% of fenretinide 
degraded in free-form, while more than 90% fenretinide remained stable after 
encapsulation in nanocarriers (Fig. 50a). The particle size of fenretinide loaded ZC 
nanocarriers increased slightly after two months, while the particle size of fenretinide 
loaded ZLG nanocarriers increased by 2-fold (Fig. 50b). The PDI for both ZC and ZLG 
nanocarriers increased after two months (Fig. 50c). The zeta potential for ZC nanocarrier 
changed gradually from -55 mV to -35 mV, while the charge of ZLG nanocarrier changed 
from -40 mV to slightly positive (+4.0 mV) (Fig. 50d). Particles with zeta potential values 
around ±30 mV is reported to be stable for overcoming particle aggregation (Bhattacharjee 
2016). The change of zeta potential is consistent with the aggregation of ZLG nanocarriers. 
Similar results were observed with LPV loaded ZLG nanocarrier (Fig. 39). Overall, the 
stability studied indicate that the zein based nanocarriers can enhance the chemical stability 
of fenertinide. 
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Figure 50: Solid state stability of free fenretinide, fenretinide loaded Zein-β-casein and zein-β-lactoglobulin nanocarriers. 
Nanocarriers and free drug were kept in constant climate chamber at 30°C and 65% RH for 3 months. Each value represents mean±SD 
(n=3).   
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4.4.5. In vivo pharmacokinetics 
Based on the results from in vitro permeability studies, ZC, ZLG, ZWP, and ZPL 
nanocarriers were selected for in vivo pharmacokinetic studies in rat. Free fenretinide 
suspension showed aCmax of 0.21 μg/mL at 3 hours (Tmax). ZPL nanocarrier showed the 
highest Cmax (0.61 μg/mL) of fenretinide at 6 hours (Tmax), while fenretinide loaded ZC 
nanocarrier showed the lowest Cmax (0.23 μg/mL) at the same Tmax (Fig. 51). ZLG and 
ZWP nanocarriers showed a Cmax of fenretinide of 0.49 and 0.58 μg/mL respectively. Free 
fenretinide showed a Cmax of 0.21 μg/mL at 3 hours (Tmax). The AUC of fenretinide was 
significantly increased with ZWP nanocarriers (~ 8-fold), whereas the AUC for ZLG, ZPL 
and ZC nanocarriers were about 6-, 5- and 3-fold higher compared to free fenretinide 
suspension (Table 30).  All the nanocarriers under investigation increased the elimination 
half-life (t1/2) of fenretinide. The t1/2 was increased by 8-, 6-, 5- and 4-fold with ZC, ZLG, 
ZWP and ZPL nanocarriers respectively (Table 30). Overall, the relative oral 
bioavailability (Frel%) of fenretinide in nanocarriers was increased significantly with all the 
nanocarriers. ZWP nanocarriers enhanced the oral bioavailability of fenretinide by 7-fold 
followed by ZLG (6-fold), ZPL (5-fold) and ZC (3-fold) nanocarriers. 
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Figure 51: Plasma concentration of free fenretinide and fenretinide loaded ZC, ZLG, 
ZWP, and ZPL nanocarriers after oral administration to rats. Each value represents 
mean±SD, (n=3). 
 
190 
 
Table 30: PK parameters of free fenretinide and fenretinide loaded nanocarriers after oral delivery in rats.  
  Fenretinide suspension ZC-Fenretinide ZLG-Fenretinide ZWP-Fenretinide ZPL-Fenretinide 
C
max 
(μg/mL) 
0.22±0.0087 0.23±0.005* 0.54±0.001* 0.58±0.01* 0.60±0.02* 
T
max 
(h) 3.00±0.00 6.00±0.00 6.00±0.00 6.00±0.00 6.0±0.00 
MRT (h) 4.37±0.08 16.61±7.09 11.28±0.53 9.07±0.04 8.49±0.21 
Ke (h-1) 0.71±0.60 0.08±0.04 0.09±0.04 0.09±0.02 0.12±0.04 
t
1/2 
(h) 1.50±0.06 12.90±6.49* 9.82±3.38* 7.84±2.11* 6.17±1.93* 
AUC
(0-inf)  
(μg-h/mL) 1.11±0.11 3.26±0.74* 7.03±0.47* 8.82±3.23* 5.57±0.07* 
F (% rel) -- 294.53±66.75* 633.51±42.68* 673.37±12.08* 502.19±6.58* 
Each value represents mean±SD (n=3), *P<0.05 compared to fenretinide suspension. Cmax: Maximum plasma concentration; Tmax: Time 
to reach maximum plasma concentration; AUC: Area under plasma concentration-time curve; MRT: Mean residence time; t1/2: 
Elimination half-life; F (% rel): Percent relative bioavailability.  
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Based on results from single dose PK study (Fig. 52), free fenretinide was 
administered twice a day, while fenretinide loaded ZPL nanocarriers was given once a day. 
Results from multiple-dose PK study show that ZPL nanocarriers increased the steady state 
plasma concentration of fenertinide by 5-fold (Fig. 52). It is important to note that the 
higher levels achieved with ZPL nanocarriers was achieved with a once-a-day dosing as 
opposed twice-a-day dosing with free fenertinide. Around 1.5-fold higher Cmax  of 
fenretinide was achieved at steady state with ZPL nanocarriers. However, there was no 
significant change in Cmax for free fenretinide suspension after multiple dose. (Table 31).  
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Figure 52: Plasma profile of free fenretinide and ZPL-fenretinide nanocarriers after oral 
administration of 20 mg/Kg fenretinide for 4 days. Free fenretinide administered twice 
a day, while fenretinide loaded ZPL nanoparticles administered once a day. Each value 
represents mean±SD. (n=3).  
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Table 31: Steady state PK parameters of free fenretinide and fenretinide loaded ZPL-
nanocarriers after oral delivery in rats.  
 Fenretinide suspension ZPL-fenretinide 
Cmax-ss (µg/mL) 0.33±0.01 0.95±0.13* 
Cavg-ss (µg/mL) 0.20±0.06 0.66±0.05* 
Cmin-ss (µg/mL) 0.11±0.04 0.13±0.03* 
Tmax-ss (hrs) 51.00±0.00 54.00±0.00* 
Each value represents mean±SD (n=3), *P<0.05 compared to fenretinide suspension. ZPL. 
Zein-pluronic-lecithin nanoparticles; Cmax-ss. Maximum concentration during dosing 
interval at steady state; Cmin-ss. Minimum concentration during dosing interval at steady 
state; Cavg-ss. Average plasma drug concentration at steady state t. Each value represents 
mean±SD (n=3). 
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At the end of multiple dose PK study, rats were sacrificed and different organs were 
collected to deterrmine the distribution of fenretinide in the body. Results show that 
significantly higher fenretinide was distributed in liver and kidney compared to other 
organs such as brain, lung and spleen (Fig. 53). In general, concentration of fenretinide in 
different organs were significantly higher than free fenretinide suspension which is 
consistent with plasma concentration of fenretinide.  
 
 
 
 
 
Figure 53: Organ distribution of free fenretinide and ZPL-fenretinide nanocarriers after 
oral administration of 20 mg/Kg fenretinide in rats for 4 days. Free fenretinide 
administered twice a day, while fenretinide loaded ZPL nanoparticles administered 
once a day. Each value represents mean±SD. (n=3), P<0.05.  
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4.5. Discussion 
The clinical investigation of fenretinide isfocused on its anticancer activity 
especially against pediatric neuroblastoma (Children's Oncology et al. 2006), oral 
leukoplakia (Lippman et al. 2006), and ovarian cancer (Garcia. A. A. 2004). However, 
fenretinide is reported to have low and variable bioavailability and dose escalation is 
required to achieve reasonable therapeutic concentration. One important impediment in the 
clinical application of fenretinide is the lack of a suitable delivery system to achieve high 
and sustained therapeutic concentration. A corn-oil capsule has been used and achieved 
around 5 µg/mL blood concentration of fenretinide with a daily dose of 4000 mg/m2 of 
fenretinide (Garaventa et al. 2003). Although a lipid formulation of fenretinide (LYM-X-
SORB) was reported to achieve 3- to 7-fold higher plasma level of fenretinide compared 
to corn-oil capsules, the safety of the lipid matrix in pediatrics especially infant patients is 
yet to be clarified  (Maurer et al. 2007).  
Fenretinide has poor oral bioavailability due to its poor water solubility and 
membrane permeability and poor chemical stability. The hydrophobic fenretinide was 
encapsulated in the zein core, while the external hydrophilic shell was used to increase the 
water solubility and permeability through the gastrointestinal membrane. In addition, the 
core-shell nanocarriers sustained the drug release, thus reducing the dose and dosing 
frequency in pediatric patients. The long-term stability study demonstrated the enhanced 
chemical stability of the zein nanoformulation. 
Apparent permeability coefficient (Papp) of fenretinide across Caco-2 cell 
monolayers was also significantly increased using nanocarriers compared with free 
fenretinide. The uptake of nanocarriers in Caco-2 cells was predominantly by non-specific 
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endocytosis. Lecithin favors the interaction with lipophilic cell membrane and results in 
higher cell uptake (Zhirnov et al. 2005). In addition, pluronic can inhibit P-gp and evade 
the P-gp mediated efflux (Wei et al. 2013). Both lecithin and pluronic in ZPL nanoparticles 
contributed to significantly higher permeability across cell monolayers. However, apparent 
permeability for all other nanocarriers (except ZPL) was comparable to free fenretinide in 
the first two hours, while a significant difference was observed at four hours indicating that 
of the cellular uptake and subsequent transport and release play an important role in the 
higher permeability observed with ZPL nanocarriers.  
Lower plasma concentration of fenretinide with ZC nanocarrier was obtained can 
be attributed to thefaster release of fenretinide in SGF and SIF. All other tested nanocarriers 
(ZLG, ZWP, and ZPL) significantly enhanced Cmax, AUC, t1/2 and oral bioavailability of 
fenretinide compared to fenretinide oral suspension. The enhanced membrane permeability 
and intestinal epithelial cell uptake contributed to the increased absorption and 
bioavailability of fenretinide using ZLG, ZWP, and ZPL nanocarriers. About 3-fold higher 
steady-state plasma concentration of fenreitnide was obtained using ZPL nanocarrier 
compared to free fenretinide suggests that lecithin composition in shell may favor the 
uptake by lymphatic systems in intestine (Randolph and Miller 2014). However, further 
studies are required to confirm the absorption mechanism of ZPL nanocarriers. We used 
fenretinide at a dose of 20 mg/kg body weight of rat, which is 18-times lower dose than 
reported for the lipid formulation of fenretinide (Maurer et al. 2007). Reported dose of 
fenretinide with lipid formulation used as divided dose (twice a day) and ZPL nanocarriers 
can be administered once day which is also advantageous in reducing dosing frequency 
(Maurer et al. 2007).. Our results demonstrated that fenretinide loaded nanocarriers can 
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achieve up to 0.6 μg/mL plasma concentration of fenretinide (Cmax), which is 13-fold less 
than maximum plasma concentration reported for the lipid formulation with same dosing 
frequency in mice (Maurer et al. 2007). Since the ZPL nanoformulation was able to 
significantly increase the fenretinide concentration in the various organs, this can be used 
for different types of cancers. A higher dose of ZPL nanoformulation is expected to achieve 
equivalent or higher plasma levels compared to the lipid formulation. In addition, the use 
of food-grade biopolymers offers significant advantages for developing a pediatric 
formulation as a food-sprinkle.  Further, the sustained release of fenertinide from ZPL 
nanocarriers can reduce the dose and dosing frequency, thus improving the safety and 
compliance in pediatric patients.   
 
4.6. Conclusion 
The present study demonstrated that zein based core-shell nanocarriers can be used 
to enhance the oral bioavailability of fenretinide. In vitro studies showed that core-shell 
nanocarriers significantly improved the stability and aqueous solubility/dispersibility of 
fenretinide, sustained the release of fenretinide, and increased membrane permeability. The 
compatibility with food matrices (milk and applesauce) indicate that fenretinide loaded 
nanocarriers can be used as a food sprinkle, especially for pediatric patients. In vivo 
pharmacokinetic study demonstrated that the oral bioavailability of fenretinide increased 
from 3- to 7-fold using zein nanocarriers. Results from this multiple dose pharmacokinetic 
study demonstrated that ZPL nanocarrier can be used to develop a once-a day orally 
bioavailable formulation of fenretinide. Overall, the findings from this study can be used 
to develop a safe, effective, and food compatible oral pediatric formulaton of fenretinide. 
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5. Summary 
 Six different core-shell nanocarriers were developed using zein (corn protein) as 
the core and milk protein (casein, lactoferrin, lactoglobulin, whey protein isolate) or PEG 
or pluronic-lecithin as the shell. The shell structure-function relationship of zein-based 
nanocarriers were evaluated in-vitro and in-vivo. The results were used to develop orally 
bioavailable formulation for two challenging drug molecules.  Zein nanocarriers were used 
to encapsulate lopinavir, an antiretroviral drug, and fenretinide, an investigational new 
chemical entity. Table 32 is a summary of the results from this dissertation and compares 
the functional performance of the different zein-based nanocarriers. The particle size of 
drug-loaded nanocarriers was 100 to 250 nm diameter with uniform size distribution. The 
zeta potential varied based on shell composition. All the carriers were non-immunogenic 
and safe for oral administration. Nanocarriers showed above 70% encapsulation efficiency 
with 3 to 8% drug loading efficiency. Nanocarriers sustained the release of drug in 
simulated gastric fluid, simulated intestinal fluid and in food matrices signifies the potential 
of using as food sprinkle and mask the taste of bitter drugs. The release was mainly 
dependent on shell the composition, physicochemical properties of encapsulated molecule, 
and nature of the release of the medium. As shown in Table 32, ZC and ZPL ranked high 
in terms of sustaining drug release. However, in presence of food matrices, these two 
systems ranked lower than the other nanoformulations. Among the six formulations, 
ZPEG, ZPL and ZLG showed relatively higher permeability than the other three 
formulations. Further, the ZPEG also has P-gp inhibitory activity, suggesting the potential 
use of this nanocarriers for enhancing the oral bioavailability of drugs that are substrates 
for P-gp efflux pump. This was evident from the enhanced oral bioavailability of LPV, 
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which was comparable to the oral bioavailability commercial LPV/r liquid formulation. On 
the other hand, ZLG and ZWP have high bioadhesive property and may be suitable to 
enhance the oral absorption of drugs by increasing the drug retention in the GI tract. These 
carriers may also be used for developing colon targeted delivery systems. Although the 
dissertation provides a general structure-function relationship for developing zein based 
nanocarriers, the findings from this dissertation suggest that the zein nanocarriers have to 
be customized based on the drug’s physicochemical properties, the functional properties of 
the shell and the disease type. To this end, depending on the physicochemical properties of 
the drug, one or more of the functional characteristics of the zein-based nanocarriers 
contributes to the enhanced oral bioavailability. In case of LPV, the inhibition of P-gp and 
CYP3A4 metabolism are the primary determinants of oral bioavailability. On the other 
hand, in case of fenertinide, the enhanced memberane permeability and sustained release 
characteristics are important determinants for enhanced oral bioavailbility. Overall, the 
results from this dissertation provides a roadmap for rational development of zein-based 
nanocarriers in particular and protein based nanocarrier in general for oral drug delivery 
applications.  
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Table 32: Comparison of zein-based nanocarriers for the feasibility of using for oral drug 
delivery applications.  
Characteristics ZC ZLF ZPEG ZPL ZLG ZWP 
Sustained release +++ + ++ +++ ++ ++ 
Inhibition of P-gp efflux + ++ +++ +++ + + 
Sequential release (Food matrix, SGF 
and SIF) 
++ +++ +++ ++ +++ +++ 
Transepithelial permeability (Caco-2 
monolayer) 
++ ++ +++ +++ +++ ++ 
Gastrointestinal Retention ++ + + ++ +++ +++ 
Bioadhesive/mucoadhesive property ++ ++ ++ ++ +++ +++ 
Oral Immunogenicity +++ +++ +++ +++ +++ +++ 
Oral bioavailability of lopinavir  ND ND +++ ND ++ ++ 
Oral bioavailability of fenretinide + ND ND +++ +++ +++ 
(+++) Excellent; (++) good; (+) fair. ZC: Zein-β-casein nanoparticles; ZLF: Zein-
lactoferrin nanoparticles; ZPEG: PEGylated zein micelle; ZPL: Zein-pluronic-lecithin 
nanoparticles; ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein isolate 
nanoparticles. ND: Not done. 
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6. FUTURE STUDIES 
 Findings from this dissertation open several new opportunities to expand the 
application of these nanocarriers for the delivery of other drugs. Future studies should 
include the following: 
• The findings from this study should be extended to BCS class II drugs (low 
solubility and high permeability) and BCS class III drugs (highly soluble and low 
permeability). 
• To understand the role of zein in core-shell nanocarriers, future studies should 
include zein nanoparticles as a control.   
• Studies should evaluate the taste masking ability of these nanocarriers by 
encapsulating drugs with a bitter taste. Future studies should also focus testing the 
compatibility with additional food matrices based on preferences for different age 
group of pediatric patients.  
•  Mechanistic studies should be performed to understand the segmental absorption 
in the gastrointestinal tract. Further studies should be performed to understand the 
mechanism involved and identifying the major site of absorption. 
• The ability of the nanocarriers to target M-cells or mesenteric lymph nodes should 
be explored to understand the potential of these nanocarriers for the treatment of 
metastatic cancer and HIV infection. 
• Future studies should confirm the findings from this dissertation by testing the 
formulations in appropriate pediatric animal models such as a juvenile pig model.  
• Future studies should also focus on testing the efficacy of these formulations in 
suitable animal models.  
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